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Abstract 
 
Clinical response to B cell depletion therapy (BCDT) is highly variable in patients with 
systemic lupus erythematosus (SLE). Reductions in anti-dsDNA antibody levels also vary. It 
has been shown that early relapse is more likely if anti-dsDNA antibody levels remain high 
after BCDT. The cellular factors that determine how anti-dsDNA antibodies are produced and 
whether they are likely to fall after BCDT have not been clarified. This thesis describes two 
different immunological processes that might explain why anti-dsDNA antibody levels either 
fall or remain high after BCDT. (1) In patients whose anti-dsDNA antibody levels fall, it was 
hypothesized that short-lived plasma cells arise from ectopic lymphoid tissue (ELT). They 
had higher percentages of CD4+ T cells expressing chemokine receptors CXCR3, CCR5 and 
the integrin CD49d, which are associated with migration into non-lymphoid tissue. Clinical 
relapse in this group starts with the expansion of B cells in the blood, in particular the IgD–
CD27– subset, and is followed by a fall in circulating lymphocyte numbers before anti-
dsDNA antibody levels rise. CD4+ T cell numbers are inversely related to HLA-DR 
expression by CD4+ T cells and CD4+CD49dhi T cells express HLA-DR, suggesting that 
HLA-DR induces T cell migration. Activated B cells can induce HLA-DR expression by T 
cells, suggesting that they initiate T cell migration. Taken together, the data suggest that B 
cells induce the formation of ELT. (2) Patients with anti-dsDNA antibody levels that do not 
fall after BCDT had higher percentages of CD4+ T cells that express CCR7 and CD62L, 
which are associated with migration to secondary lymphoid organs (SLO), supporting data 
that show long-lived plasma cells are produced in SLOs. In conclusion, T cell surface markers 
might be useful for predicting the clinical outcomes and serological changes following BCDT 
and designing therapeutic trials in SLE. 
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1 INTRODUCTION 
1.1.1 The immune system 
All living organisms have evolved an immune system, which has mechanisms that can detect, 
neutralize and clear unwanted substances to protect them from the environment. The immune 
system is broadly divided into the innate immune system, which can be found in all 
organisms including single cell organisms, such as protozoa, and the adaptive immune 
system, which is found only in vertebrates (1). 
The central function of the immune system is to prevent infection or invasion, whether by 
other living organisms, such as bacteria, fungi and helminths, by non-living replicating 
agents, such as viruses, or by proteins, such as clostridial toxins (2, 3). A number of 
mechanisms are required, including creating barriers to prevent invasion and clearance (4). 
However, in higher vertebrates the immune system has at least 3 additional functions. One of 
these functions is to clear the body of unwanted by-products of cell metabolism, such as 
oxidized lipoproteins (5). A second is to clear the body of by-products of cell death, which are 
either released spontaneously, due to necrosis, or by an organized process called apoptosis (6-
8). A third important function is the control of excessive cell growth and division 
(malignancy) (9).  
In vertebrates innate immunity provides the initial immune response followed by the adaptive 
immune response. These responses are mediated by white blood cells, called leukocytes. 
Leukocytes respond to molecules, which are termed antigens. They can originate from the 
host (self or auto-antigen) or from the external environment (foreign or non-self antigen). 
These antigens can be in various different forms of protein, lipid, carbohydrate or nucleic 
acid. Leukocytes also vary in their ability to detect these different forms (1). 
1.1.2 Anatomy of the immune system 
The immune system of vertebrate animals is composed of multiple different structures, of 
which five interface with the environment; the skin, gastrointestinal tract, genitourinary tract, 
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eyes and lungs. Each of these interfaces are covered by a layer of epithelial cells which 
differentiate to allow (or actively transport) entry of substances that are necessary for the 
body but prevent and contain invasion by microorganisms, sometimes by secreting 
antimicrobial peptides (10, 11). 
White blood cells (or leukocytes) that circulate within the body are made in the bone marrow 
and then, in the case of a specialized group of leukocytes called T cells, undergo further 
differentiation and selection in the thymus. These 2 anatomical structures are referred to as 
the primary lymphoid organs. From these organs the leukocytes then enter the blood and 
lymphatic vessels where they subsequently migrate to the spleen or lymph nodes, which are 
referred to as the secondary lymphoid organs (SLO) (12). The liver also forms a critical part 
of the immune system both by producing important proteins and lipids (13) and providing a 
place for leukocytes to survey the blood for pathogens (14). 
The leukocyte populations and immune responses differ in the non-lymphoid tissue 
depending on the tissue function and its environment. The gastrointestinal tract, for example, 
has highly specialized lymphoid tissue to manage the higher exposure of the cells to 
microorganisms and ingested food (15). The brain on the other hand has no lymphoid tissue 
and limits the infiltration of leukocytes from the circulation in order to prevent excessive 
immune responses within it. It instead relies mostly on a number of brain-specific innate 
immune cells to protect it from infection and clear products of tissue damage (16).   
1.1.3 The innate immune system 
Innate immunity provides the first line of defense against microbial invasion and detection of 
cellular damage or dysfunction (stress). The response is generally rapid but of limited 
specificity and self-regulation, being mainly dependent on clearance of the stimulating 
proteins or organisms before the response subsides. The innate immune system is composed 
of epithelial barriers, soluble proteins, circulating effector cells and cytokines. Stimulation 
and inhibition of the innate immune system is dependent on a limited number of pattern 
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recognition receptors (PRR) that are encoded in the germline deoxyribonucleic acid (DNA) 
and detect structures that are commonly seen on a wide variety of microbes but not in the 
host. These receptors include toll-like receptors (TLR), Nod-like receptors (NLR), C-type 
lectins and scavenger receptors (17, 18). 
The cells of the innate immune system include mononcuclear phagocytes, such as 
macrophages and dendritic cells (DC), polymorphonuclear phagocytes, such as neutrophils, 
and natural killer (NK) cells. Their primary function is to clear the tissue of the invading 
pathogen by killing it or the cell it has invaded. However, the cells also secrete messenger 
molecules, called cytokines, to recruit other cells to the infected tissue or activate cells, such 
as B cells. Macrophages and DCs can also process the antigen that it has captured from the 
tissue and present it in the form of peptide with the major histocompatibility complex (MHC) 
on its cell surface to T cells. If these antigen-presenting cells (APCs) have received an 
additional signal via one of its PRRs then it will be activated to provide additional stimulation 
to the T cell, by co-stimulation and/or cytokine secretion, resulting in the activation and 
differentiation of the T cell. Therefore, innate cells and their PRRs also have an important 
role in directing the adaptive immune response. However, both B and T also have functional 
PRRs that can directly influence their differentiation, which shows that there is not a clear 
boundary between innate and adaptive immunity (19-21). 
1.1.4 The adaptive immune system 
The evolutionary origins of the adaptive immune system can be traced to the vertebrates (22). 
A number of potential environmental pressures may have contributed to its development but 
it is probably not a coincidence that animals with adaptive immunity are significantly bigger 
than those without and are characterized by more compartmentalized internal organs, in 
particular the brain. Adaptive immunity supports these physical differences by having 
mechanisms that are able to react to a wide range of pathogens, localize to an infected 
compartment, expand and then contract when the threat is cleared. It can then form a memory 
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for the pathogen to allow it to respond more rapidly if reinfected whilst occupying only a 
small area within the body and using a minimal amount of energy (1).  
The formation of memory cells following initial exposure to an antigen is called the primary 
immune response. The process starts with antigen recognition, followed by clonal expansion 
and differentiation. Once the antigen is cleared most of the cells die by apoptosis, a process 
termed contraction, but a few survive to become memory cells. With re-stimulation, a 
secondary immune response can expand more rapidly and migrate to the invaded or stressed 
tissue. It contracts again via cell apoptosis once the pathogen has been removed (23-26).  
There are two different types of adaptive immune response, humoral and cell-mediated, 
which are both controlled by a specialized group of cells called lymphocytes. Humoral 
immunity is mediated by small molecules called antibodies that are secreted into the blood or 
mucosa by B lymphocytes (or B cells). Cell mediated immunity involves the recruitment of a 
variety of different leukocytes, depending on the pathogen, under the control of T 
lymphocytes (T cells). Each B and T cell in the body has a receptor that is specific to a 
particular antigen. However, these cells might share the same receptor if they arise from the 
same clone (27). 
The immune response that results from a stimulus is highly specific to the invading 
microorganism. In order to be able to respond to the multiple different types of 
microorganisms the adaptive immune system requires very high receptor diversity, which is 
achieved via gene rearrangement. However, the process can produce receptors that recognize 
self-antigens. To prevent inappropriate immune responses against the cells of the host 
lymphocytes that recognize self-antigen are either removed, made unresponsive (anergic) or 
induced to become regulatory cells. This process occurs either in the bone marrow or the 
thymus (central tolerance) or in the non-lymphoid tissue (peripheral tolerance) (27-29). 
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1.1.5 Lymphocytes 
Mediated by the cytokine interleukin 7 (IL-7), which is produced locally by stromal cells in 
the bone marrow, B cells, T cells and NK cells originate from a common lymphoid progenitor 
cell (CLP) (30). Unlike B and T cells, NK cells have only a limited range of receptors and 
therefore are considered part of the innate immune system.  However, B and T cells differ in 
the nature of their receptors and their specific function, which is discussed below. 
B cells 
There are three important subsets of mature B cells; follicular B cells, marginal zone (MZ) B 
cells and B-1 B cells. The primary and unique function of B cells is to produce antibodies by 
differentiating into antibody secreting plasma cells, but plasma cells can be short or long-
lived, migrate to different locations and the antibodies that they produce can vary in isotype 
and function. B cells also have additional functions, such as antigen-presentation and cytokine 
production, which can vary between cells (31). However, the precise factors that determine 
their differentiation and activation, particularly in humans, remain unclear. 
Both MZ and follicular B cells arise from the CLP, which commits itself to the B cell lineage 
following expression of specific transcription factors, in particular Pax-5, that regulate the 
expression of genes specifically involved in B cell signaling and gene recombination (30). 
With the expression of these genes B cells go through a number of stages of maturation from 
pro-B cell, to pre-B cell, to immature B cell and then to the mature B cell. Each stage is 
characterized by the expression of a specific combination of surface markers (Table 1.1.1) 
and immunoglobulin (Ig) genes. The Ig gene rearrangement eventually forms an intact IgM 
molecule (the B cell receptor (BCR)) on the surface of the immature B cell (32, 33). The 
rearrangement is an important process that contributes to the BCR diversity. During this stage 
B cells will be exposed to a number of antigens, primarily in the bone marrow. If the BCR 
binds to an antigen with high affinity it will be induced to edit the BCR or eliminated. If no 
antigen is detected the B cell survives. Immature B cells leave the bone marrow and then 
enter the peripheral lymphoid tissue where they undergo further selection and maturation, 
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controlled by B cell activating factor (BAFF), by first differentiating into transitional B cells 
and then either follicular B cells, which recirculate through the blood and follicles in the 
SLOs and bone marrow or marginal zone B cells, which reside mostly near the marginal sinus 
of the spleen (i.e. outside the follicle) (31, 34).  
Follicular B cells go through several further rounds of selection and activation, but this time 
with the help of T cells, in particular the T follicular helper (TFH) cell. These T cells interact 
with mature B cells at the B:T interface of the follicular niche in the SLO where B cells will 
present antigen to the T cell (35). Using a combination of signals, including cytokines, such 
as IL-4 and IL-21, and co-stimulatory molecules, such as CD40 ligand, TFH cells instruct the 
B cells to differentiate into either short-lived extrafollicular plasma cells, which appear to be 
important for the primary immune response (36), early memory B cells or germinal centre 
(GC) B cells. To enter the centre of the follicle GC B cells downregulate the chemokine 
receptor EBV-induced molecule 2 (EBI2) where they encounter antigen-bearing follicular 
DCs (FDC) and more TFH cells (37). GC B cells undergo somatic hypermutation, which 
changes the affinity of the BCR. Those cells with the BCR of highest affinity will out 
compete GC B cells with BCRs of lower affinity for antigen from the FDC and receive the 
most survival signals from the surrounding TFH cells after presenting antigen to them. 
Therefore, the GC B cells with high affinity BCRs are more likely to clonally expand and 
differentiate into plasmablasts. TFH cells provide additional co-stimulatory and cytokine 
signals to induce GC B cells to either become long-lived memory B cells, long-lived plasma 
cells or re-enter the cell cycle. 
Marginal zone and B-1 B cells can produce some antibodies without conventional help from 
T cells, i.e. via T cell receptor (TCR) and MHC class II interaction. The antigens that these 
antibodies bind to are not proteins and are often multivalent with repeating determinants, such 
as polysaccharides and nucleic acids. They are called thymus independent (TI) antigens. 
There are three types of TI-antigens. Each of these antigens requires help from a different 
signal to induce an antibody response; TI-1 antigens, which are typically lipopeptides, 
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lipopolysaccharides or nucleic acids, require TLR stimulation, TI-2 antigens, which are 
polysaccharides, require crosslinking of several BCRs leading to a prolonged signal to the B 
cell, and TI-3 antigens, which are microbial genetic material, require myeloid cells to provide 
additional signals, such as BAFF and IL-21. T cell-derived CD40L and IL-21 can enhance the 
TI-1 antibody response. The humoral response can be rapid, suggesting that they have an 
important role in the initial immune response. However, memory B cells and long-lived 
plasma cells can be formed, even though they do not arise from the germinal centres in SLOs 
(38).  
The secreted antibody is formed by means of class-switch recombination (CSR), which 
involves switching the component of the receptor attached to the cell membrane, known as 
the heavy chain, into one of several secretory forms. Change to the heavy chain is known as 
isotype switching. Each antibody isotype differs in their ability to bind to Fc receptors, which 
are expressed on leukocytes, and induce complement activation. They also differ for half-life 
and tissue distribution. Therefore, they are utilized for different immune responses. IgE, for 
example, elicits a mast cell response that is good at clearing helminths (39, 40), whilst IgG 
forms immune complexes that activate complement, which opsonize bacteria (41). CSR can 
occur at various stages after B cell maturation. T cells can induce CSR, using cytokines and 
co-stimulation, but are not always necessary, because other cells, such as DCs and even TLR-
stimulated epithelial cells can also provide the necessary signals (42, 43). 
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 Pro-B Pre-B Immature Transitional Mature 
Naïve 
Mature 
Pre-
GC 
GC Memory Plasma 
Cell 
CD19 + + + + + + + + low 
CD20 – + + + + + + + – 
CD38 high high high high –/low high high –/low high 
CD10 high high int – – + +   
CD24 high high high high int     
IgM   + high + +    
IgD    –/low + + – – – 
CD27       + + + 
Table 1.1.1 – Surface markers of human B cell subsets  
(33). GC; Germinal centre. 
 
Antibody-independent roles of B cells 
Although the primary function of B cells is to differentiate into antibody secreting plasma 
cells, it has also been known that they can present antigen, express co-stimulatory molecules 
and secrete cytokines. Studies have shown that these different functions can prime CD4+ T 
cells (44, 45), generate CD4+ memory T cells (46) and they can directly influence the 
differentiation and polarization of T cells (47). They might also play a role in preventing or 
suppressing an immune response by inducing a population of regulatory T cells (47). They 
have also been shown to express a range of different chemokines, suggesting that they can 
recruit other immune cells to SLOs or non-lymphoid tissue (48-50).  
It is not clear which B cell subsets are involved in these non-antibody producing roles and 
what stage of the immune response they are important for mediating. B1 and MZ B cells 
produce more IL-10, which induces regulatory T cells, while follicular B cells possibly 
produce more IFN-γ (47), suggesting that they have a different effect on the polarization and 
regulation of T cells. Some of the B cells, for example those that induce IL-4 secretion by T 
cells via OX40L, require stimulation with protein antigen (51), but some functions, such as 
the production of chemokines, only appear to require the stimulation of PRRs (50). 
 27 
B cells are important for generating T-helper 1 and T-helper 2 cells in both the primary and 
secondary immune responses to infectious organisms (52, 53). However, it appears that 
different B cell signals are required for the primary and secondary response. The primary 
immune response requires only signals via TLR-induced secretion of cytokines by B cells, but 
the secondary immune response requires BCR-mediated antigen presentation (52).  
The studies illustrate that B cells are a diverse group of cells with multiple different functions, 
antibody-dependent and antibody-independent, that are important for the primary and/or 
secondary immune response. 
T cells 
T cells are a group of lymphocytes that recognize MHC-bound peptide. CD4+ T cells are only 
able to recognize peptides bound to MHC class II molecules, which are expressed by APCs, 
such as macrophages, DCs or B cells, whilst CD8+ T cells are only able to recognize peptides 
bound to MHC class I molecules, which are expressed by most nucleated cells (54). They can 
induce an immune response by activating and recruiting other leukocytes, induce B cell 
differentiation and antibody synthesis (55, 56) or induce cell lysis (57). They can also 
suppress the immune response (58). 
On expressing GATA-3 and Notch-1, the CLP becomes committed to the T cell lineage (30). 
The pro-T cell migrates to the thymus to undergo maturation. There are a number of stages to 
the maturation process. The first stage involves the rearrangement of the TCR and the 
expression of the CD4 and CD8 co-stimulatory molecules followed by positive selection of T 
cells that are able to recognize self-MHC molecules with low avidity but deletion of cells that 
recognize antigens with high avidity. Finally the T cells lose either CD4 or CD8 to commit 
them to becoming either part of the CD4+ helper or regulatory T cell subset (that recognize 
peptide on MHC class II molecules) or the CD8+ cytotoxic T cell subset (that recognize 
peptide on MHC class I molecules), before they then migrate into the periphery. At this stage, 
when the T cells have not yet encountered antigen presented by an APC in the periphery, the 
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T cells are considered naïve. When antigen is presented with appropriate co-stimulation the T 
cell then differentiates into an effector or regulatory cell. 
CD4+ T helper cells 
To date a number of different CD4+ effector (or helper) T cell subsets have been described. 
They are all defined by the expression of the IL-7 receptor (CD127) but they express different 
chemokine receptors (Table 1.1.2) (59). Each subset has a different cytokine profile; T helper 
1 (TH1) cells are characterized by the expression of IFN-γ and IL-2, TH2 cells by IL-4, 5 and 
13 and TH17 by IL-17, 21 and 22 (60). During infection these cytokines recruit and stimulate 
other cells, including B cells, neutrophils and macrophages to mount an appropriate immune 
response. TH1 cells act against intracellular pathogens by recruiting macrophages, neutrophils 
and stimulating B cells to produce opsonizing and complement-fixing IgG antibodies. TH2 
cells respond to helminthic infections by activating eosinophils and stimulating B cells to 
produce IgE. Less is known about TH17 cells but they are thought to induce immune 
responses to extracellular pathogens by recruiting neutrophils. There is also a subset of T 
cells, called T follicular helper cells (TFH), which reside in the germinal centres in SLOs. 
These cells provide signals to germinal centre B cells, which induce their differentiation into 
long-lived memory B cells and antibody secreting plasma cells (61) that then home to 
survival niches in the bone marrow (62). The large number of different subsets illustrates the 
wide range of responses that the immune system can mount to different pathogens. 
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  Naïve Central memory Effector/ Revertant memory 
Non-polarized Pre- TH1 Pre-TH2 TH1 TH2 TH17 
 CD27 + + + + – – – 
 CD28 + + + + +/– +/– +/– 
 CCR7 + + + + – – – 
 CD45RA + – – – –/+ –/+ –/+ 
 CD57 – – – – –/+ –/+ –/+ 
 CD11a low high high high high high high 
 CXCR3   +  +   
 CXCR5  +      
 CCR3      +  
 CCR4    +  + + 
 CCR5     +   
 CCR6       + 
Table 1.1.2 – Surface markers of human CD4+ T cells  
(59) 
 
Regulatory T cells 
Regulatory T cells play a key role in maintaining tolerance to self-antigen and preventing 
autoimmunity. They work through a variety of mechanisms, including suppressing or 
inducing cell death of effector T cells and APCs. They may also suppress differentiation of B 
cells into plasma cells and the production of antibodies. They are characterized by the 
expression of the intracellular signaling molecule forkhead box-P3 (FoxP3), and several 
surface markers, including the IL-2 receptor (CD25), cytotoxic T-lymphocyte antigen 4 
(CTLA-4) and the glucocorticoid-induced TNFR-related (GITR) protein (63).  
T helper cell differentiation 
The polarization of TH cells toward one or other subset is determined by a number of different 
factors, including the duration of antigen presentation (64), co-stimulatory factors (51, 65), 
and exposure to specific combinations of cytokines (60). TH1 cells require IFN-γ and IL-12, 
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TH2 cells require IL-4 and IL-2, TH17 cells require transforming growth factor beta (TGF-β) 
and IL-6 and regulatory T cells require TGF-β and IL-2. Although it is thought that DCs are 
the main source of these signals, and therefore the cell that mediates T cell activation and 
differentiation (66), other cells, such as B cells, might also play an important role (44, 45, 47, 
52, 53, 67). 
1.1.6 Lymphocyte migration 
The diverse nature of the adaptive immune system requires lymphocytes to survey both the 
lymphoid and non-lymphoid tissue and induce an effector response, either by recruiting more 
cells to an infected site or producing antibody, when a pathogen is detected. The process of 
migration between lymphoid organs and from lymphoid organs to non-lymphoid tissue is 
called lymphocyte recirculation. Both B and T cells recirculate, although there are 
differences. T cells, for example, appear to be more efficient at migrating to peripheral 
lymphoid tissue, whilst B cells preferentially migrate to the spleen and to Peyer’s patches in 
the intestines (68, 69).  
Naïve T cells continuously migrate through the blood stream into secondary lymphoid tissue 
and back into the blood stream until they encounter antigen on an APC. If presented with an 
antigen in a lymph node, the T cells differentiate into effector memory T cells and then 
migrate back into the blood stream. From the blood stream the effector T cells are then 
directed towards the infected or inflamed tissue (called lymphocyte homing). The blood 
vessels are therefore the main point of origin from which effector T cells enter infected or 
inflamed tissue.  
To move within the lymph nodes, naïve T cells express high levels of L-selectin (CD62L) and 
CCR7, which are recruited by CCL19 and CCL21. After encountering antigen these receptors 
are downregulated. In order to be guided towards the infected area, the T cells express 
chemokine receptors specific for the infected tissue and the cells in the infected tissue express 
the corresponding recruiting chemokine. The skin, for example, recruits cutaneous memory T 
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cells by expressing the thymus and activation chemokine (TARC) that binds to CCR4, which 
is expressed on the T cells. However, once the T cell reaches the infected or inflamed tissue it 
needs to attach itself to the blood vessel and pass between the endothelial cells in order to 
enter the tissue parenchyma. This is a complicated process that requires the expression of a 
number of different adhesion molecules (integrins), mainly lymphocyte function-associated 
antigen 1 (LFA-1) or very late antigen 4 (VLA-4), by the T cell and corresponding ligands by 
the endothelial cells (12). 
It is common to see CD4+ and CD8+ T cells in the non-lymphoid tissue of healthy individuals, 
predominantly surrounding the blood vessels, with macrophages scattered within the tissue. 
The T cells are phenotypically memory cells and show evidence of activation. However it is 
not certain whether these T cells reside within the tissue or actively circulate through the 
tissue and return to the SLOs. Studies suggest that CD4+ T cells move quickly through the 
tissue, whilst CD8+ T cells move more slowly and possibly reside for long periods (70, 71). 
However, evidence suggests that CD4+ T cells initiate the formation of ectopic lymphoid 
tissue (ELT), showing that with the appropriate signals some CD4+ T cells will remain in the 
non-lymphoid tissue (72). How frequently CD4+ T cells recirculate and what signals are 
necessary before they commit themselves to stay in the tissue remain uncertain. 
Less is known about the mechanisms that control mature B cell migration. Naïve B cells 
recirculate through non-lymphoid tissue like T cells (73), but unlike naïve T cells they need to 
undergo a second round of antigen receptor editing, which requires help from additional 
leukocytes. Therefore, B cells preferentially migrate to specialized microenvironments within 
SLOs, which is partly mediated by the binding of CXCR4, expressed on B cells, to the 
chemoattractant, stromal cell derived factor one-alpha (SDF-1α) (74). When B cells encounter 
antigen, they then differentiate into antibody-secreting cells (ASC) or memory B cells. Both 
IgA and IgG secreting cells migrate to the bone marrow, but IgA secreting cells also migrate 
to mucosal surfaces, whilst IgG secreting cells migrate to sites of tissue inflammation (75). 
Memory B cells appear to migrate to and/or remain in the spleen. However, the presence of a 
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small number of memory B cells in people who have had splenectomies suggests that there 
are additional minor storage sites (76). During infection, memory B cells are recruited by the 
chemokine CXCL13, which is secreted by monocytes (77), and produce IgG locally in ELT 
(78). The studies therefore suggest that antibodies can get into the non-lymphoid tissue via 
three sources; from ASCs in the bone marrow that secrete antibodies into the circulation, via 
infiltrating ASCs that migrate from SLOs or from ASCs that arise from memory B cells in 
ELT. 
Each organ is likely to have differences in how lymphocytes recirculate. The lungs of mice, 
for example, have developed specialized lymphoid tissue that utilizes a distinctive 
combination of adhesion molecules to retain lymphocytes and provides a microenvironment 
where lung-specific cells can present antigen to naïve T cells (79). The brain, however, does 
not have any lymphoid tissue or lymphatic vessels. Therefore, the only entry and exit points 
for lymphocytes are via blood vessels. Antibody is also present at much lower levels in the 
cerebrospinal fluid than in the circulation suggesting that it does not pass through the barriers 
of the central nervous system easily. There is tight control of the migration of lymphocytes 
through the brain but the mechanisms are not fully understood. Expression of specific 
adhesion molecules, chemokines and chemokine receptors by both endothelial cells and 
lymphocytes have been shown to be important (80, 81). Whether cell migration depends on 
antigen specificity is less clear. One study has shown that T cell entry into the brain is not 
antigen specific but the cells are retained in the tissue if they recognize brain antigen, 
suggesting that there is careful selection of antigen specific T cells inside the brain (82). Other 
studies show that T cells require an antigen-specific signal to cross the blood brain barrier 
(83, 84).  
B cell migration into the brain has not been studied as extensively as T cells. One study has 
shown that murine memory B cells from SLOs can locate antigen in the brain and generate an 
intrathecal humoral immune response (85). This local production of antibody by infiltrating B 
cells appears to be important for the clearance of acute infections (78, 86). It is difficult to 
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investigate the migration of B cells in human brains but one study has shown that they 
migrate across brain endothelium more rapidly than T cells, possibly due to differences in 
their responsiveness to specific chemokines (87).  
1.1.7 Summary 
This section has described the development of B and T cells, their multiple functions and 
interactions with each other, and how they both mount effector responses to pathogens, by 
secreting antibodies and/or differentiating into tissue infiltrating effector cells. The immune 
response starts with the primary adaptive immune response, which consists of distinct phases; 
formation of a naïve lymphocyte pool (lymphopoiesis), antigen recognition, clonal expansion 
and differentiation (activation), antigen elimination, contraction (homeostasis) and then 
finally memory (1). The secondary (recall) immune response following re-exposure to antigen 
is similar but more rapid and larger. They have another important difference, which is that in 
the primary immune response naïve lymphocytes mostly recirculate within the SLOs, whilst 
in the secondary immune response memory lymphocytes mostly recirculate within the non-
lymphoid tissue, although a subset of memory lymphocytes can remain resident in niches 
within SLOs (88).  
Immune surveillance by recirculation is an important part of the adaptive immune response 
and therefore should be recognized as one of the phases, before antigen recognition. By 
including it the two immune responses it becomes easier to appreciate that the adaptive 
immune responses are dynamic, cyclical, interacting processes in 2 separate physical 
compartments (Figure 1.1.1). This model proposes that in the primary immune response naïve 
lymphocytes survey the SLOs and after recognizing antigen and clearing it, then provide a 
pool of memory lymphocytes, which survey the non-lymphoid tissue. In the secondary 
immune response if antigen is recognized in the non-lymphoid tissue the memory 
lymphocytes become activated and mount a more rapid immune response to clear the antigen. 
When the immune response contracts, the cells either die (26) or return to the memory 
lymphocyte pool (88). 
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The secondary immune response varies within the different types of non-lymphoid tissue 
because of their structural and functional differences and to protect them from specific 
environmental pressures. Understanding the mechanisms that control and regulate this 
process and how it differs within each tissue will help to understand how the immune system 
protects the body and also how immunological diseases occur. 
 
 
 
 
Figure 1.1.1 – Primary and secondary immune response 
The secondary immune response is characterized by a pool of memory lymphocytes that are 
supplied by naïve lymphocytes that have been activated in the SLOs during the primary 
immune response. The memory lymphocytes mostly recirculate within the non-lymphoid 
tissue. After recognizing antigen they become activated (clonally expand) and eliminate the 
antigen. The immune response then contracts, either by the lymphocytes dying or returning to 
the memory lymphocyte pool where they continue to recirculate within the non-lymphoid 
tissue. 
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1.2.1 Diseases of the immune system 
Diseases of the immune system can be due to either an insufficient immune response 
(immunodeficiency), self-directed damage due to an inappropriate innate immune response 
(autoinflammation) or an inappropriate adaptive immune response (hypersensitivity). Five 
types of hypersensitivity reactions have been described; type 1 (atopy) is due to IgE 
antibodies directed against common and normally harmless antigens (allergen), type 2 
(cytotoxicity) is due to IgG or IgM antibodies directed against proteins on the cell surface, 
type 3 (immune-complex mediated) is due to IgG or IgM antibodies directed against soluble 
antigens, type 4 (delayed-type) is due to CD4+ or CD8+ T cells directed against an 
intracellular antigen and type 5 (receptor mediated) is due to antibodies that can either 
stimulate or inhibit cell receptors (89). 
In some inflammatory diseases the pathological mechanisms can be explained by either 
autoinflammation or one of the hypersensitivity disorders. However, some inflammatory 
diseases appear to be due to a combination of these disorders. Crohns’ disease, for example, 
has been shown to have features of both autoinflammation and Type 4 hypersensitivity (90). 
It has been proposed that these diseases are part of an immunologic disease continuum (91). 
These combinations might provide an explanation for the heterogeneous manifestations that 
are seen in some inflammatory diseases.  
1.2.2 Autoimmunity and autoimmune disease 
An immune response directed against self-antigen is referred to as autoimmunity. This 
process can be due to either autoantibodies or autoreactive T cells. It has been suggested that 
self-reactivity might be an important part of the normal immune response, in order to protect 
the body from malignancy (92), atherosclerosis (93) and infection (94). Some autoreactive 
CD4+ T cells have been shown to protect the tissue from trauma induced-damage, i.e. they are 
important for repair and tissue homeostasis (95). However, autoantibodies and autoreactive T 
cells can induce hypersensitivity reactions (types 2 to 5). The point at which the recognition 
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of autoantigen leads to tissue damage and becomes detrimental to the host rather than 
protective is called autoimmune disease. There are two types of autoimmune disease; organ-
specific, which are usually associated with autoantibodies that are directed against tissue 
specific antigen, and systemic, which are usually associated with autoantibodies that are 
directed against soluble antigens. 
For autoreactive cells and antibodies to cause autoimmune disease additional events need to 
occur, either in sequence or in parallel. Sequential events that might need to occur include 
increased affinity of antibodies or the T cell receptor to antigen, immunoglobulin class-
switching, complement activation and/or recruitment of other immune cells. Parallel events 
might include activation of other immune cells, such as macrophages and/or neutrophils, or 
changes within the target cell or tissue. A breakdown in tolerance, therefore, first occurs 
centrally, by failing to eliminate autoreactive B and T lymphocytes, and then peripherally, by 
failing to inhibit the autoreactive lymphocytes, recruitment of additional activated leukocytes 
and changes to the target cells, resulting in an immune response that causes a hypersensitivity 
reaction.  
Interestingly, patients with immunodeficiency syndromes associated with B and/or T cell 
deficiency, such as X-linked aggammaglobulinaemia, combined variable immunodeficiency 
(CVID) (96) and acquired immune deficiency syndrome (AIDS) (97) are more susceptible to 
autoimmune disorders. This observation might suggest a causal link between infection and 
autoimmune disorders, but patients with immunodeficiency might also have reduced 
regulatory cells to maintain peripheral tolerance.  
Most autoimmune diseases are characterized by the autoantibodies present in the blood rather 
than the T cell specificities, partly because of the relative ease with which the antibodies can 
be identified (typically by enzyme-linked immunosorbent assay (ELISA)). However, 
consideration also needs to be given to the T cell in the inflammatory process and research is 
needed to understand how it might contribute to the development of autoimmune disease. 
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1.3.1 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease with a 
prevalence of 40 to 200 per 100,000. It has a female:male ratio of 6-12:1, mainly affecting 
women of child-bearing age. The prevalence varies in different ethnic and socioeconomic 
groups, being more common in Afro-Caribbean and Asian populations (98). It is 
characterized by the presence of antibodies directed against nuclear antigen, in particular 
against double-stranded DNA (dsDNA), histone complexes and ribonucleic acid (RNA)-
binding proteins. All organs or systems can be affected, although the clinical manifestations 
vary markedly between patients. The disease course is variable and unpredictable with 
patients experiencing episodes of remission followed by relapse. There are certain 
environmental factors that are known to exacerbate the disease, such as exposure to ultra-
violet light, but in most cases a precipitant cannot be established. The survival rates have 
improved considerably in the past 40 years as a result of the introduction of corticosteroids 
and other immunosuppressants, dialysis and renal transplantation but the disease still causes 
significant morbidity and increased mortality. 
1.3.2 Clinical manifestations of SLE 
Patients can present with a wide variety of different symptoms. Constitutional symptoms such 
as fever, weight loss and fatigue are common, but not specific to the disease. Likewise joint 
and muscle pain (with or without inflammation) and sicca symptoms are also common, but 
these symptoms can occur in several other autoimmune diseases. The organs that are most 
frequently affected in SLE are the kidneys, skin and joints, but no organ is protected. Most 
organ-affected manifestations are due to inflammation (or hypersensitivity) but they can also 
be due to vascular occlusion by thrombi (99) or atherosclerosis (100). 
The diverse nature of the disease and non-specificity of some of the abnormalities seen in the 
disease means that there is no single symptom, sign or serological factor that is seen in all 
patients that can alone be used to diagnose SLE. However, classification criteria for SLE have 
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been devised to ensure that there is a consistent definition of the disease for the purposes of 
research and surveillance. These classification criteria require a combination of objective 
clinical signs from commonly affected organs and/or serological or haematological 
abnormalities to be present. The American College of Rheumatology (ACR) revised criteria 
for the classification of SLE was the most widely used until the Systemic Lupus International 
Collaborating Clinics (SLICC) classification criteria for SLE replaced it in 2012 (101, 102). 
For a person to be defined as having SLE the ACR revised classification criteria required at 
least four out of 11 criteria to be present (Table 1.3.1) (101), whereas the SLICC 
classification criteria requires fulfillment of at least four out of 17 criteria, with at least one 
clinical criterion and one immunologic criterion, or lupus nephritis in the presence of ANA or 
anti-dsDNA antibodies (Table 1.3.2) (102). 
Whilst it is a disease that can affect all organ systems it has certain symptoms which make it 
more distinguishable from other systemic autoimmune diseases, such as rheumatoid arthritis, 
primary Sjögren’s syndrome and sytemic sclerosis, even though they share some of the 
serological abnormalities (103). These symptoms include malar rashes, mouth ulcers, cerebral 
involvement and glomerulonephritis. Most studies have focused on understanding the 
pathogenesis of glomerulonephritis because it is one of the more common disease 
manifestations and it is associated with higher mortality and morbidity, particularly if it is 
untreated, making it more of a priority for research (104). It is also easier to get histological 
samples from the kidneys for analysis compared to other sites of inflammation, such as the 
mucous membranes and brain. However, cluster analyses suggest that certain symptoms are 
less likely to be associated with glomerulonephritis (105, 106) and therefore it cannot be 
assumed that the factors that cause glomerulonephritis are the same as those that cause other 
symptoms. 
Incomplete lupus erythematosus 
Multiple symptoms and serological abnormalities are considered a defining feature of the 
disease as illustrated by the ACR and SLICC classification criteria. However, disease usually 
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starts with the stepwise accumulation of autoantibodies that are typically seen in the disease 
and then with the development of one of the ACR criteria symptoms before the diagnosis is 
made (107). 
Some patients do not develop enough clinical manifestations and serological abnormalities to 
fulfill the ACR or SLICC classification criteria for SLE. These patients are sometimes 
diagnosed as having an undifferentiated autoimmune rheumatic disease (or connective tissue 
disease) or incomplete lupus erythematosus (ILE). Studies show that the percentage of 
patients with ILE that eventually develop SLE ranges from 3 to 57% over a mean follow-up 
time of 1.6 to 13 years (108-112). The large differences in the percentage of patients with ILE 
that transformed into SLE between studies is likely to be partly due to the differences in the 
duration of follow-up, suggested by an 8 year prospective study in a Danish community that 
found an estimated progression rate of SLE from ILE to be 3.64 per 100 person-years at risk 
(113).  
The most common symptoms in patients with ILE were photosensitivity (23-42%), arthritis 
(10-47%), malar rash (4-21%) and serositis (1-35%). Two out of five studies showed that 
malar rash is a risk factor for SLE progression. One of these two studies also showed that 
mouth ulcers to be a risk factor. The other three studies did not identify any risk factors for 
SLE progression from the baseline symptoms. 
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Criterion Definition 
Malar rash Fixed erythema over the malar eminences, tending to spare the nasolabial folds 
Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging; 
atrophic scarring may occur in older lesions 
Photosensitivity Skin rash that occurs following exposure to sunlight 
Oral ulcers Oral or nasopharyngeal ulceration 
Arthritis Non-erosive arthritis involving two or more peripheral joints, characterized by tenderness, 
swelling or effusion 
Serositis a) Pleuritis – history of pleuritic pain or rub heard by physician or evidence of pleural 
effusion 
or 
b) Pericarditis – documented by ECG or rub or evidence of pericardial effusion 
Renal disorder a) Persistent proteinuria greater than 0.5g/day or greater than 3+ on urine dipstick 
or 
b) Cellular casts – may be red cell, haemoglobin, granular, tubular or mixed 
Neurologic disorder a) Seizures – in the absence of offending drugs or metabolic derangement 
or 
b) Psychosis – in the absence of offending drugs or metabolic derangement 
Haematologic disorder a) Haemolytic anaemia – with reticulocytosis 
or 
b) Leukopaenia – less than 4 x 109/L on two or more occasions 
or 
c) Lymphopaenia – less than 1.5 x 109/L on two or more occasions 
Immunologic disorder a) Anti-DNA – antibody to native DNA in abnormal titre 
or 
b) Anti-Sm – presence of antibody to Sm nuclear antigen 
or 
c) Antiphospholipid antibody – either an abnormal serum level of IgG or IgM 
anticardiolipin antibodies, a positive test result for lupus anticoagulant using a 
standard method, or a false serologic test result for syphilis known to be positive for at 
least 6 months and confirmed by Treponema pallidum immobilization or fluorescent 
treponemal antibody absorption test 
Antinuclear antibody An abnormal titre of antinuclear antibody by immunofluorescence or an equivalent assay at 
any point in time and in the absence of drugs known to be associated with “drug-induced 
lupus” syndrome 
For the purpose of identifying patients in clinical studies, a person is defined as having SLE if any 4 or more of the 11 criteria are 
present, serially or simultaneously, during any interval of observation 
Table 1.3.1 – American College for Rheumatology revised criteria for the classification 
of SLE 
(101) 
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Clinical Criteria Immunologic Criteria 
 
Acute Cutaneous Lupus 
Chronic Cutaneous Lupus 
Oral or Nasal ulcers 
Non-scarring alopecia 
Arthritis 
Serositis 
Renal 
Neurologic 
Haemolytic anaemia 
Leukopaenia 
Thrombocytopaenia 
 
 
ANA 
Anti-DNA 
Anti-Sm 
Antiphospholipid antibodies 
Low complement (C3, C4, CH50) 
Direct Coombs’ test (do not count in the 
presence of haemolytic anaemia) 
 
 
 
 
Requirements: >4 criteria (at least 1 clinical and 1 laboratory criteria) OR biopsy-proven 
lupus nephritis with positive ANA or Anti-DNA 
 
Table 1.3.2 – Systemic Lupus International Collaborating Clinics classification criteria 
for SLE 
(102) 
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1.3.3 Genetics and aetiology of SLE 
Consistent with the heterogeneous nature of the disease, more than 50 genes, with a diverse 
range of functions, have also been associated with the disease (114). In a few cases patients 
have been found to have highly penetrant genetic mutations causing deficiency in 
complement proteins (115). However, the majority of cases of disease are due to genetic 
polymorphisms, some of which are still to be identified, that confer a susceptibility to disease 
(116, 117). The development of disease most likely requires a combination of these genetic 
polymorphisms.  
All of the genetic associations that have been identified from the genome-wide analyses relate 
to immunological function or control of apoptosis. As is seen in other autoimmune diseases 
the strongest associations were found with the MHC class II molecules. Some additional 
genes that have been identified are linked to B and T cell function (Table 1.3.3).  These 
genetic associations point at potential mechanisms that may be involved in the development 
and progression of the disease. 
Genes are not the only factors that influence the development of SLE. Sex hormones are also 
likely to be important, because it is more prevalent in women, particularly during the second 
decade (118), and some studies have shown that there is an increase in disease flares during 
pregnancy (119). Environmental factors, such as infectious organisms (120), smoking (121), 
exposure to chemicals, such as silica and pesticides (121), and ultraviolet light (122), have 
also been implicated in the aetiopathogenesis of SLE. Drugs have also been shown to cause 
lupus-like diseases (123). The disease is, therefore, probably caused by a combination of 
genetic polymorphisms, hormones and environmental stimuli. 
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Gene Odds Ratio Function 
The MHC 2.36, 2.01* 
2.35† 
Antigen presentation to T 
cells 
BLK 1.39, 1.22* 
0.69† 
BCR signaling 
BANK1 1.38* 
1.31† 
BCR signaling 
LYN 1.30* 
0.77† 
BCR signaling 
FCGR2B 1.21, 1.33* 
- † 
Inhibits B cell activation  
CD40 - * 
0.63† 
Synergizes with BCR 
signaling pathway 
IL10 - * 
1.19† 
B cell stimulant 
STAT4 1.53, 1.50* 
1.55† 
T cell differentiation 
PTPN22 1.53, 1.49* 
1.4† 
TCR signaling 
ITGAM 1.62, 1.33* 
1.62† 
Leukocyte adhesion 
TNFSF4 - * 
1.46† 
Co-stimulatory signal by 
APCs to CD4+ T cells 
Table 1.3.3 – Genetic polymorphisms associated with lymphocyte function in SLE  
*(116), †(117) 
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1.3.4 Clinical assessment  
One of the many difficulties of treating patients with SLE is determining whether the 
symptoms that the patient is experiencing is due to an active inflammatory process, damage 
(i.e. scarring) from past inflammation or due to a pathology unrelated to SLE. An objective 
measure of active disease is important for deciding when to initiate or increase therapy, for 
establishing the efficacy of a therapy, both for the individual patient in the clinic and in 
clinical trials, and also for understanding whether an immunological abnormality has a role in 
the inflammatory process or is secondary to tissue damage. However, as yet there is no single, 
commercially available assay that can detect active inflammation with 100% sensitivity and 
specificity. Nevertheless the appearance or worsening of a number of symptoms and signs has 
been consistently shown to suggest an active inflammatory process that, if left untreated, 
would ultimately cause damage to the tissue and increase mortality or morbidity for the 
patient. Several different clinical assessment tools have therefore been designed, each by 
consensus between investigators, to agree on criteria for active disease using a combination of 
these symptoms and signs. These assessment tools, which include the European Consensus 
Lupus Activity Measure (ECLAM), the Systemic Lupus Activity Measure (SLAM), the 
Systemic Lupus Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment 
Group (BILAG) index, have been validated and found to be reliable and sensitive, but they all 
differ between each other, both in terms of the logistics of the assessment process and in 
terms of their strengths and limitations. The BILAG index, for example, provides a global 
score for disease activity and organ-specific scores, to allow for differences in drug efficacy, 
and possibly pathology, between organ systems. Other indices incorporate scores for 
treatment and immunological variables, such as complement levels (Table 1.3.4) (124). 
The role of histological analysis in assessing disease activity is controversial. In animal 
studies of SLE, histological assessment of the kidneys, skin or joints is usually performed to 
show the presence of inflammation. However, human disease is more heterogeneous, which is 
demonstrated by the wide variation in histological abnormalities that have been reported in 
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the biopsies of both kidneys and skin (125, 126). This variation can be due to differences in 
the stage of the disease, the disease duration, the cause of the inflammation and the presence 
of tissue damage. Certain abnormalities are considered markers of disease activity, which in 
renal disease can be used to form an activity index. However, using histology as a regular 
disease assessment tool is impractical, and therefore serological factors and disease 
assessment indices using symptoms, signs and laboratory data remain the most widely used in 
clinical studies. Nevertheless, the information that tissue histology provides is extremely 
useful for making a diagnosis, staging, predicting outcomes and guiding treatment, especially 
in kidney disease. It is also very useful for understanding the pathogenesis of the disease. 
 No. of items/ 
Content (organ 
systems) 
Recall 
period 
(days) 
Strengths Limitations 
BILAG 101 items  
+ 5 items for GFR/ 
9 organ systems 
 
28 Can detect change in 
disease activity over time 
Can show activity in each 
system 
Records flare and response 
Based on physician’s 
intention to treat 
Formal training of raters 
needed 
Computer required to 
calculate the score 
Higher respondent and 
administrative burden 
SLEDAI-
2K 
24 items/ 
9 organ systems 
 
30 Easy to use 
Scoring is simple additive 
 
  
Does not record improving 
or worsening disease 
Does not assess severity of 
each organ system 
SLAM-R 9 items/ 
9 organ systems + 7 
laboratory features 
30 Includes both disease 
activity and disease 
severity 
Scoring can be subjective 
Difficulty in distinguishing 
changes 
ECLAM 33 items/ 
10 organ systems + 
ESR and complement 
levels 
 
30 Easy to use 
Scoring is simple additive 
Formal training of raters 
needed 
Global score only – will 
miss changes in severity 
over time 
Table 1.3.4 – Comparison of physician completed disease activity indices in SLE 
(124) 
 
1.3.5 Biomarkers for SLE disease activity 
A biomarker is a gene or biological molecule whose quantifiable change correlates with the 
disease process and/or its manifestations. Given the abnormalities that are seen in the tissue of 
patients with SLE, disease biomarkers can be divided into four different types; those 
associated with humoral dysfunction, immune complex deposition, cell migration and tissue 
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damage. These biomarkers vary in their specificity and sensitivity to active disease. In general 
the humoral biomarkers, such as anti-dsDNA and Sm antibodies are the most specific for SLE 
but are not very sensitive to changes in disease activity (127). An alternative biomarker of 
humoral dysfunction is the plasma cell count, which has been shown to correlate with disease 
activity, and was independent of changes in anti-dsDNA antibody levels (128). Direct 
measurement of immune complexes has proved challenging due to high false positive results 
in patients with SLE (129). Decreases in complement levels, notably C3 and C4, are often 
used as an indirect measure of immune complex formation (and subsequent clearance), 
although they might also reflect direct complement deposition in the tissue. However, 
complement levels vary between individuals, sometimes rising during active disease or before 
a clinical flare (130), and sometimes being low due to a hereditary deficiency (131). A 
decrease in complement proteins has been shown to correlate with disease activity in patients 
with moderate to severe disease but not mild disease, particularly patients without renal 
disease (130). Patients with active disease but normal complement levels might also have 
normal anti-dsDNA antibody levels but follow-up of these patients show that the markers 
might appear at a later stage of the disease (132).  
Various cytokines, soluble cytokine receptors, cell surface markers and adhesion molecules 
have also been studied as candidate biomarkers of active disease. The percentage of HLA-
DR+ T cells in the circulation might also be useful for predicting flares (130). Levels of 
adhesion molecules, chemokines and T cells in the urine have been correlated with active 
nephritis and therefore might be useful biomarkers for renal disease (130, 133, 134).   
Circulating endothelial microparticles have been detected in patients with persistent 
endothelial damage despite the disease appearing to be under control (135) and have also 
been detected in patients with atherosclerotic disease (136), which patients with SLE are 
predisposed to. They might therefore be useful for detecting sub-clinical inflammation in 
SLE. 
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Studies have also tried to find biomarkers that might predict specific clinical manifestations. 
Most studies have focused on the predictive value of autoantibodies. There is agreement that 
antibodies against nucleosomes and C1q are useful for predicting renal disease (137). Some 
autoantibodies might predict thrombosis (138), cytopaenias (139), cerebral disease (137) and 
xerostomia (140). However, there are several symptoms that do not appear to have strong 
associations with autoantibodies. Correlations between abnormalities of peripheral blood 
leukocytes and clinical symptoms have not been studied as extensively as autoantibodies and 
are therefore not currently considered useful biomarkers for predicting disease symptoms. 
One of the problems with developing disease biomarkers for SLE has been that the 
pathogenesis is likely to be due to a combination of factors, with the contribution of each 
factor varying between individuals. Therefore, the ideal biomarker is most likely going to be a 
composite of several factors that are part of all or most of the pathological processes causing 
the disease in that individual. 
The most likely reason for the difficulty in developing reliable clinical assessment tools and 
finding biomarkers that could be used in SLE is that clinicians assume that the pathogenesis is 
identical in all patients. However, the heterogeneity of the disease suggests that the 
underlying pathology differs between patients. A better understanding of the pathogenesis of 
the disease is likely to lead to improvements in the reliability of clinical assessment tools and 
biomarkers. 
1.3.6 Therapeutic management of SLE 
The main treatment options for patients with SLE include corticosteroids, anti-malarial and 
cytotoxic agents, which include azathioprine, methotrexate, mycophenolate mofetil and 
cyclophophosphamide (141). Corticosteroids and cytotoxic agents are associated with more 
side effect and long-term complications, in particular a higher risk of infection and 
malignancy. Therefore, the choice of medication depends on the severity of the disease, 
which is usually determined by the degree of internal organ involvement. For musculoskeletal 
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and cutaneous symptoms, the treatment would typically start with anti-malarial agents and 
low-dose corticosteroids when needed. For internal organ disease, in particular 
glomerulonephritis, vasculitis and cerebral disease, the treatment would usually require the 
addition of cytotoxic agents and high-dose corticosteroids. The side effects of cytotoxic drugs 
are a result of their broad range of action. Therefore, more targeted therapies have been 
developed, which have fewer side effects (Table 1.3.5). These drugs target surface molecules 
on B and T cells, either to deplete them from the circulation or to modify their function, and 
cytokines, such as BAFF and IFN-α. However, despite positive results in open-labeled 
studies, the efficacy of these targeted therapies have shown disappointing results in 
randomized controlled trials, with the possible exception of Belimumab, a drug that inhibits 
BAFF, which showed statistically significant benefits, although only in one of the two time-
points (142). 
The treatment of moderate to severe disease is often divided into induction and maintenance 
therapy (143). Induction therapy typically involves giving intensive immunosuppression in 
order to stop the inflammatory process as rapidly as possible with the aim of preventing 
further damage to the affected organ. During maintenance therapy the immunosuppression is 
reduced in order to prevent long-term complications from the drugs. Whilst the treatment 
regimen is usually guided by clinical trials, it might need to be tailored to the individual 
patient depending on other factors, such as the severity of the disease or co-morbidities that 
the patient might have.  
There have been significant improvements in the mortality rates over the last 40 years (144), 
but only anti-malarial agents have been shown to improve the long-term survival of patients 
with SLE (145). In addition, whilst several new drugs have been trialled in SLE only one has 
been licensed for the treatment of SLE in the last 30 years. The failure of trials to show 
convincing efficacy is likely to be due to a combination of factors, including the design of the 
trials, such as inclusion criteria, excessive concomitant therapy, notably corticosteroids, the 
use of therapy in the comparator arm, defined end-points, the choice of assessment tool and 
 49 
the length of follow-up (146). However, in a disease with diverse clinical manifestations due 
to a complex pathological process, a drug might be effective with one manifestation of the 
disease but not another. This possible explanation becomes more important as the therapeutic 
target increases in specificity. To illustrate this point, a secondary analysis of a recent clinical 
trial with a drug targeting CTLA-4 co-stimulation showed statistically significant 
improvements in arthritis despite not demonstrating an improvement in the disease overall 
(147). Likewise, certain drugs have been shown to only lead to significant benefits in patients 
with specific antibody profiles (148, 149). It could therefore be argued that until the 
pathogenesis of the disease and in particular the reasons for the heterogeneous manifestations 
of the disease are understood, the drugs that have the broadest mechanism of action will be 
the most likely to demonstrate efficacy in SLE. In other words as the targets become more 
specific, the clinical trials will need either greater numbers of patients or selection of patients 
with specific clinical or immunological characteristics in order to demonstrate therapeutic 
efficacy.  
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Drug Mechanism of action Targets Efficacy 
Prednisolone 
 
Inhibition of NF-κB All leukocytes Effective for most SLE 
manifestations. 
Licensed for SLE 
Hydroxychloroquine 
 
Inhibits TLR signaling Monocytes 
Dendritic cells 
B cells 
Effective for cutaneous 
LE, arthritis and 
constitutional symptoms. 
Licensed for SLE 
Cyclophosphamide 
 
DNA alkylation leading 
to cell death 
Bone marrow 
(leukopoiesis) 
All leukocytes 
Effective for most severe 
SLE manifestations, 
particularly nephritis 
Azathioprine Inhibits DNA synthesis Bone marrow 
(leukopoiesis) 
All leukocytes 
Effective for lupus 
nephritis. Less effective 
than cyclophosphamide 
Mycophenolate 
Mofetil (MMF) 
 
Inhibits purine 
biosynthesis by 
lymphocytes 
B cells 
T cells 
Effective in lupus 
nephritis. Comparable 
with cyclophosphamide. 
Rituximab 
 
B cell depletion via 
ADCC/apoptosis 
B cells Efficacy not 
demonstrated in RCT 
Belimumab 
 
BAFF blockade B cell activation Efficacy demonstrated in 
RCT at 52 weeks only 
Abatacept 
 
Binds to B7 on APCs T cell activation Only effective for 
arthritis 
Abetimus Sodium Binds to anti-dsDNA 
antibodies 
Anti-dsDNA 
antibodies 
Efficacy not 
demonstrated in RCT 
Table 1.3.5 – Therapeutic options in SLE  
(141, 147, 149, 150) 
 
1.4.1 Pathogenesis of SLE 
There is evidence of at least two hypersensitivity reactions in patients with SLE. Firstly, type 
2 hypersensitivity reactions are seen in a group of patients who develop autoimmune 
haemolysis and thrombocytopaenia. However, this possibly accounts for only a small 
proportion of the disease manifestations. Most patients develop some organ involvement, 
which has been commonly attributed to immune complex mediated disease, i.e. type 3 
hypersensitivity reactions, particularly in lupus nephritis. Antibodies to dsDNA are thought to 
be an important cause of this immune complex deposition (151). However, many of these 
manifestations are also associated with the cellular infiltrates, most commonly T and B cells, 
macrophages and, occasionally, neutrophils (126, 134, 152-155). The presence of these cells, 
particularly T and B cells, do not fit into the classical type 3 hypersensitivity reaction, and 
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their exact role in the pathogenesis of the disease is not very well understood. However, they 
are associated with poor outcomes suggesting that they are contributing to the damage that 
occurs in the tissue. 
Vasculitis in SLE – Arthus or Schwartzman reaction? 
Two studies have shown that the incidence of vasculitis in patients with SLE is between 11 
and 33% (156, 157). The vasculitis was cutaneous in over 80% of cases. Internal organs that 
were affected included nerves, digits, retina and mesentery. One study showed that the 
vasculitis involved small vessels in 86% of cases and medium-sized vessels in 14% of cases 
(157). Both studies found an association with lymphopaenia and anti-phospholipid syndrome 
or the presence of antiphospholipid antibodies. Hypocomplementaemia was associated with 
vasculitis in one of the studies (157). Neither study found an association with 
glomerulonephritis. 
Immune complex deposition leading to activation of complement (Arthus reaction) is one of 
the possible causes of vasculitis, but circulating or deposited immune complexes are not 
always detected in patients with vasculitis. It is also possible that autoantibodies directly 
induce endothelial cell death, although they have only been shown to induce death by 
apoptosis rather than cell lysis (158). A third explanation for lupus vasculitis has arisen from 
studies that have shown that several autoantibodies that have been found in patients with SLE 
can induce endothelial cells to express adhesion molecules, such as intercellular adhesion 
molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) (159-161). Rather 
than causing a type 2 or type 3 hypersensitivity reaction, the autoantibodies might instead be 
priming endothelial cells to bind and recruit activated leukocytes, causing a cell mediated 
immune response (Schwartzman reaction) (162, 163). Proteolytic enzymes released by 
neutrophils and CD8+ T cells would be the likely cause of endothelial cell necrosis in this 
process. Observations that T cells and neutrophils from patients with vasculitis express 
increased levels of the adhesion molecules that bind to ICAM-1 and VCAM-1 support this 
hypothesis (164, 165).  
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1.4.2 Histological studies 
Although the disease does not start in the peripheral tissue, this is nevertheless where the 
autoimmune response exerts its effect and ultimately induces damage. A large amount of 
information can therefore be obtained from careful analysis of the tissue. The difficulty with 
histological analyses is that the disease can affect different organs in each patient and have 
multiple different effects within each organ. However, there are a number of similarities, 
which provide important information about the inflammatory process that causes the disease. 
The most commonly studied tissues from patients with SLE are those from the skin and 
kidneys. Immunofluorescence studies have identified deposits of IgM, IgG, IgA, complement 
factors, such as C3, and DNA in the tissue (166, 167). Deposition is mostly seen in areas 
where there is a basement membrane, such as blood vessel walls (168, 169), the dermal-
epidermal junction (167), renal tubules and glomeruli (166, 169, 170), possibly because the 
basement membrane can trap nucleic acid (171). In glomerular lesions IgG is the most 
common class of antibody present (170), but in skin lesions the most common class present is 
IgM, although disease severity is greater when IgM is present with IgG and/or IgA (167). 
Immune depositis with IgM, IgG and/or IgA are also seen in non-lesional skin (168), which 
raises questions about their relevance in the disease process and the value of using 
immunofluorescence as a prognostic tool in SLE.     
Lymphocytes, particularly T cells, are the most common leukocyte to be seen in renal and 
skin lesions, either in a perivascular distribution or in the interstitium. Granulocytes, in 
particular macrophages and neutrophils, are also commonly seen in the tissue (126, 172). T 
cells, either in the renal tissue or urine, correlate with active nephritis, increased renal damage 
and impairment (134, 154, 155, 173). The lungs and heart have been less well studied due to 
fewer biopsies being taken from patients but similar results have been seen with immune 
deposits along the blood vessel wall and perivascular and interstitial leukocytic infiltrates 
(174, 175).  
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In addition to the inflammatory changes, abnormalities in the tissue parenchyma also provide 
some information about the disease process. In the skin and glomeruli, characteristic changes 
of the epithelial and endothelial cells can be seen, but changes can also be seen in tissue 
specific cells, such as the mesangial cells in the glomerulus and the dermal cells in the skin.  
Active disease is often characterized by cell necrosis, but might show other features that are 
specific for that tissue, such as crescents in the glomeruli, whilst chronic disease is indicated 
by fibrotic or sclerotic changes and tissue atrophy (126, 176).  
Characteristic signs can be absent from affected tissue (126). Likewise, abnormalities, such as 
immune deposits, can be found in non-lesional skin, although might still correlate with active 
non-cutaneous disease (177). It is, therefore, difficult to make a clear causal link between the 
inflammation and damage that occurs in the tissue, which then makes it difficult to identify 
biomarkers and formulate effective treatment strategies for patients. 
1.4.3 Humoral abnormalities in SLE 
The presence of autoantibodies is considered the central immunological abnormality in SLE. 
They are produced by plasma cells, which differentiate from autoreactive B cells. Anti-
nuclear antibodies (ANA) are the most common antibodies, found in over 95% of patients. In 
SLE, these antibodies most commonly bind dsDNA, histone complexes, which bind to DNA 
and RNA-binding proteins. In addition, antibodies can also be found that bind soluble 
molecules, such as those that regulate the complement and coagulation cascades, rheumatoid 
factor and phospholipids, as well as antigens found on the surface of cells. Several of these 
autoantibodies can also be found in other systemic and organ-specific autoimmune diseases 
but certain antibodies, such as those that bind dsDNA and the RNA-binding protein, Sm, are 
highly specific for SLE (178). 
Most studies have focused on the direct pathogenic effects that autoantibodies have on the 
tissue parenchyma, in particular their deposition as immune complexes within the tissue. 
However, antinuclear and antiphospholipid antibodies appear in the blood of patients many 
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years before diagnosis or the first symptom. Typically, antibodies to the RNA-binding 
proteins, Ro and La, appear the earliest, followed by antiphospholipid antibodies, then anti-
dsDNA antibodies and then anti-Sm antibodies (107). In addition, with the possible exception 
of a few autoantibodies, most do not perform very well as biomarkers (127). Many 
explanations have been provided for the poor correlation between autoantibodies and active 
disease, but the most likely explanations are that either certain factors are required in addition 
to the immune complexes and/or that the autoantibodies exert an effect upstream of the 
inflammatory cascade, which would mean that it might take many months or years for the 
subsequent tissue inflammation and damage to become clinically apparent. 
Role of autoantibodies in SLE 
As previously mentioned, antibodies can exert multiple effects. Autoantibodies in SLE, have 
shown that they are able to induce antibody-dependent cell mediated cytotoxicity (type 2 
hypersensitivity) and immune complex mediated cytotoxicity (type 3 hypersensitivity), but 
have also been shown to directly stimulate APCs and upregulate adhesion molecules on 
endothelial cells, suggesting that they might also have a role in cell mediated cytotoxicity 
(type 4 hypersensitivity). They also remove molecules important for the normal clearance of 
apoptotic bodies. 
Several autoantibodies that are seen in SLE have been shown to have multiple pathogenic 
effects. For example, anti-C1q antibodies can bind to and inhibit important molecules that 
regulate the clearance of apoptotic bodies, but have also been shown to form immune 
complexes and deposit in the glomerular basement membrane (179). Likewise, immune 
complexes containing dsDNA or nucleosomes can deposit in the glomerulus (180) and have 
also been shown to stimulate DCs, via the ligation of Fc receptors and TLR-9, to produce 
high levels of the cytokine, interferon alpha (IFN-α) (181-184), which is thought to have an 
important role in systemic autoimmunity. They can also induce the production of other 
important inflammatory cytokines by both plasmacytoid DCs (PDC) and B cells (183, 185) 
and induce B cell proliferation and IgM synthesis in mice (186). These multiple functions 
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might explain why it is difficult to draw a clear connection between the autoantibody and the 
inflammatory lesions of active disease. Also, these autoantibodies need additional factors, 
such as antigen and leukocytes in order to exert their pathogenic effect, which might provide 
another explanation for why they do not correlate very well with active disease. 
Anti-dsDNA antibodies 
Antibodies directed against dsDNA can be found in healthy individuals, but these antibodies 
are typically specific for DNA from a given bacteria. In SLE, anti-dsDNA antibodies 
typically bind to a conserved DNA sequence (either the B or Z conformation) and cross-react 
with both bacterial and mammalian DNA (151, 187). These antibodies appear in the sera of 
approximately 60 to 83% of patients at some point during the course of the illness. The titres 
of anti-dsDNA antibodies correlate variably with disease activity but high titres have been 
shown to indicate an increased likelihood of clinical relapse (188). Furthermore the presence 
of anti-dsDNA antibodies has been shown to correlate well with glomerulonephritis (189). 
Several studies have shown the presence of anti-dsDNA antibodies in the glomerular eluates 
of patients with active nephritis (180). They have also been shown to deposit in the kidneys of 
experimental models of SLE (190-192) 
It is unclear why anti-dsDNA antibodies are closely associated with glomerulonephritis but 
less clearly associated with other manifestations of SLE. There might be unique features of 
the glomerulus that encourages anti-dsDNA binding or immune complex formation. For 
example, it has been suggested that the specific localization of DNA-anti-dsDNA immune 
complexes in the glomerulus is due to a mechanism termed in situ immune complex 
formation. According to this mechanism the charge of the basement membrane of the 
glomerulus traps circulating nucleosomes with DNA, which then cause binding and 
accumulation of anti-dsDNA antibodies and subsequent complement deposition (193). Other 
possible explanations for anti-dsDNA induced glomerular damage include cross-reactive 
binding to a non-DNA glomerular antigen or direct penetration of glomerular cells by the 
antibodies (151).  
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It is possible that antibodies with different specificities induce similar mechanisms of 
inflammation in other organs but the unique function and structure of the glomerulus suggests 
that glomerulonephritis is a distinct pathological entity in SLE and not representative of the 
systemic disease process. Two animal models support this view. The first showed that certain 
anti-dsDNA antibodies when injected into the peritoneum of severe combined 
immunodeficiency (SCID) mice deposit in the glomeruli but not in other organs (194). A 
second animal model showed that when B cells were genetically modified so that their B cells 
could not secrete autoantibodies the mice did not get glomerular lesions, but still died 
prematurely with interstitial lesions (195). Not all anti-dsDNA antibodies induce 
glomerulonephritis. The reasons for this might relate to differences in the structure of the 
bound DNA, the presence of associated DNA-binding proteins, such as nucleosomes and 
histones, and the affinity of the antibody (196). 
DNA has been shown to have another important immune property, which is the ability to 
stimulate leukocytes via TLR-9 stimulation. In doing so, DNA functions as a pathogen 
associated molecular protein (PAMP) to provide additional stimulation to cells during 
infection or stress (197). The DNA detected by TLR-9 is made up of unmethylated cytosine-
phosphate-guanine (CpG) motifs, which is prevalent in bacterial but not vertebrate genomic 
DNA (198). However, it has been found in the sera of patients with SLE, and can induce 
some of the immunological abnormalities that are seen in the disease, such as activating 
mononuclear cells and inducing the expression of IFN-α, suggesting that it has an important 
role in the pathogenesis of the disease (199, 200). The immunostimulatory effects of 
unmethylated DNA are enhanced when it is complexed with anti-dsDNA antibodies (181). A 
subsequent study found that these DNA containing immune complexes can stimulate several 
cells that act as APCs, including B cells, PDCs and monocytes (183). Therefore, anti-dsDNA 
antibodies, when complexed with unmethylated DNA, can act as early mediators of immune 
dysregulation, which might explain why the first symptoms of the disease typically occur at 
least one year after the antibodies are first detected in the serum (107).  
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Anti-ENA antibodies 
The role that antibodies to RNA-binding proteins (also known as extractable nuclear antigen 
(ENA)) have in the disease is less well understood. Immune complexes containing ENA 
antibodies are also found in the tissue of patients (201), but the presence of these antibodies in 
the sera do not correlate with active disease (202). Furthermore, whilst some symptoms, such 
as sicca symptoms and Raynaud’s phenomenon are consistently associated with certain ENA 
antibodies, most clinical manifestations have not been found to have a strong association with 
any specific ENA antibody (140).  
Immunization with SmD183-119, a peptide of the SmD1 ribonucleoprotein, has been shown to 
lead to the generation of SmD183-119-reactive T cells, which help B cells to produce anti-
dsDNA and then anti-SmD183-119 antibodies (203). RNA-containing immune complexes can 
then activate PDCs by causing the internalization of RNA, which activates TLR-7, to produce 
pro-inflammatory cytokines (184, 204). They might also be able to activate B cells via 
BCR/TLR-7 engagement (205). It could therefore be proposed that ENA antibodies are 
initially produced following antigenic stimulation and then amplify the disease process by 
stimulating other autoantibody producing B cells and other cells that might be important at 
later stages in the inflammatory pathway. 
Antiphospholipid antibodies 
Antiphospholipid antibodies are a heterogeneous group of antibodies that bind to anionic 
phospholipids (206). They have been associated with a range of manifestations, including 
recurrent venous or arterial thromboses, foetal loss, eclampsia, thrombocytopaenia, valvular 
heart disease, small renal artery vasculopathies, livedo reticularis and neurological 
manifestations, such as transverse myelopathy (207). They have also been associated with 
small vessel vasculitides, such as Henoch-Schönlein purpura (208). The dominant 
antiphospholipid antibodies target the proteins prothrombin and β2GPI, both of which are 
important in the control of the coagulation pathway. These antibodies have been shown to 
promote coagulation, but it has also been suggested that they can induce inflammation by 
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activating the complement pathway, upregulating adhesion molecules by endothelial cells and 
inducing the expression of cytokines by endothelial cells, monocytes and DCs (206, 209, 
210). 
Rheumatoid Factor 
Rheumatoid factors are a class of autoantibodies that bind to the Fc portion of IgG antibodies. 
They are present in healthy individuals but class switched rheumatoid factor is associated 
with systemic autoimmune diseases, including rheumatoid arthritis, primary Sjögren’s 
syndrome and SLE (211). Their role in SLE is unclear but in an animal model they have been 
shown to increase the internalization of DNA-containing immune complexes into B cells, and 
activation of B cells via the BCR and TLR signaling pathways (212).  
Anti-C1q antibodies 
C1q is a collagen-like molecule that binds to and clears apoptotic bodies and antibodies 
bound to antigen. In SLE antibodies directed agains C1q have been observed in 
approximately a third of patients. It is seen most commonly in patients with lupus nephritis, 
particularly proliferative lupus nephritis. It has also been associated with other forms of renal 
disease. Like anti-dsDNA antibodies they have been found in the glomeruli, where they can 
induce immune-complex mediated inflammation. They might also influence immunological 
tolerance to nuclear antigen by dysregulating the normal clearance of apoptotic cells (179).  
Cell specific antibodies 
In addition to the antibodies to nuclear antigen patients with SLE are also highly prone to 
developing autoantibodies that bind to proteins on the cell surface, in particular glycoproteins 
on the surface of red blood cells and platelets (178), or bind to proteins expressed in specific 
tissue that are associated with an increased predisposition to developing organ-specific 
autoimmune disease, such as hypothyroidism (213). The large variety of autoantibodies that 
have been found illustrates the general breakdown in immune tolerance in SLE. 
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Do autoantibodies cause disease heterogeneity? 
Seropositivity for one or more of the antibodies described above is one of the typical features 
of the disease, but it has been difficult to explain how a limited number of autoantibodies can 
account for the various different disease manifestations. Studies have tried to correlate these 
antibodies with the symptoms but whilst some of the antibodies do correlate with symptoms 
(140), none of them are 100% specific, with the possible exception of antibodies to red blood 
cells and platelets that are seen in haemolytic anaemia and thrombocytopaenia respectively. 
Although, antinuclear antibodies are seen in the tissue it is not understood why antibodies to a 
ubiquitous antigen should deposit in different tissue in each patient and over different periods 
of time. This has led to studies, which have tried to find whether there are additional 
antibodies that are more specific to tissue antigen. As a result over 100 autoantibodies have 
been identified (178), suggesting that the disease might be induced by polyclonal B cell 
activation. Other studies have examined whether there are differences in the binding of 
antibody to the antigen in the tissue (214). 
Production of pathogenic autoantibodies 
Autoantibodies are produced naturally in healthy individuals and are seen as important 
components of the early immune response to infection. They might also remove products of 
cell death and inhibit inflammation. However, in autoimmune disease it is suggested that 
these autoantibodies become more pathogenic as a result of increased affinity of the antibody 
for the antigen and class switching from the IgM to the IgG isotype (215). Several 
explanations have been provided for the antibody changes, including molecular mimicry by 
microbial antigens, protein modification, exposure to proteins that are not normally detectable 
by leukocytes (e.g. nuclear antigen) by failure of dying cells to be cleared appropriately and 
defects in the processes that regulate antibody production (216). Some of these processes are 
primary phenomenon, as a result of genetic polymorphisms or mutations, whilst others are 
secondary phenomenon due to external factors, such as infection, drugs and ultraviolet light. 
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Sequential appearance of autoantibodies 
It has been shown that several years prior to diagnosis, 88% of patients with SLE have at least 
one typical SLE antibody that is detectable in the serum (107). The mean interval between 
detection of the antibody in the serum and the onset of first ACR symptom and then diagnosis 
was greatest for anti-Ro antibodies (2.97 and 3.68 years respectively) and lowest for anti-
nRNP (0.20 and 0.88 years respectively). For anti-dsDNA antibodies the mean interval from 
first detection in the serum to onset of first ACR symptom and diagnosis was 1.24 and 2.24 
years respectively. The antibodies steadily accumulated from a mean of 1.47 out of seven 
antibodies at six years before diagnosis to 3.01 at the time of diagnosis but the accrual of 
antibodies halted after diagnosis. Similar observations have been seen in other autoimmune 
diseases. 
These results emphasize that autoantibodies are important in the pathogenesis of disease, but 
also show that there is not a clear temporal relationship between the appearance of 
autoantibodies and the onset of symptoms, suggesting that another pathological step or ‘hit’ is 
required. However, the authors suggest that there is a “crescendo of autoimmunity 
culminating in clinical illness” based on the fact that there is a steady accumulation of 
autoantibodies with different specificities, which has also been seen in another study (217), 
and supported by a study that showed rising concentrations of autoantibodies before diagnosis 
(218). The authors also conclude that there are four phases of disease. First there is a normal 
phase when there are no autoantibodies present and patients are asymptomatic. In the second 
phase, termed benign autoimmunity, autoantibodies are present without any symptoms. In the 
third phase, termed pathogenic autoimmunity, autoantibodies that are more specific for SLE, 
namely anti-dsDNA and anti-Sm appear. Finally, in the fourth phase patients develop clinical 
symptoms and illness. However, the studies of patients with ILE show that not all patients 
develop multi-systemic disease even when they have some of the pathogenic antibodies. 
Therefore, there is possibly an additional phase that accounts for the transition from the onset 
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of symptoms in just one organ to the development of symptoms in multiple organs (i.e. 
systemic disease that fulfills the ACR criteria). 
The period of benign autoimmunity is poorly understood. The mechanisms that induce the 
immune system to enter the clinical phase need to be determined to help us predict the onset 
of clinical disease. Examining changes in the immune system and correlating with changes in 
symptoms following therapy might shed light on these mechanisms. 
1.4.4 The role of toll-like receptors in SLE 
TLRs act as an important bridge between the innate and the acquired immune systems. The 
ligands are highly conserved molecular motifs consistently found in or on the cell surfaces of 
a range of different pathogens, called pathogen-associated molecular patterns (219). By 
binding to TLRs, of which there are known to be 10 in humans, they have been shown to 
induce a number of different functions depending on the cell-type and the TLR ligand 
involved. These include increasing antigen presentation (220), modulating the cytokine and 
chemokine secretion profiles (49, 50, 221) and inducing leukocyte differentiation and 
proliferation (222). By doing this, the immune system can be adapted to respond to infectious 
organisms or neoplastic cells. However, systemic autoimmune disease appears to be driven in 
part by inappropriate stimulation of TLRs. In the case of SLE, the TLRs 3, 7, 8 and 9 have 
been implicated as being important factors in the disease (223, 224). The reason for this 
association is because the ligands for these receptors are RNA, which bind to the TLRs-3, 7 
and 8, and hypomethylated DNA, which binds to TLR-9, and are also the autoantigens 
recognized by the autoantibodies in SLE. TLRs-7 and 9 are predominantly expressed in PDCs 
and B cells. TLR-8 is mainly expressed in monocytes (225). TLR-3 on the other hand is not 
highly expressed by peripheral blood mononuclear cells, but is expressed in renal mesangial 
cells. Stimulation of these cells with RNA homologues, in mice predisposed to an SLE-like 
illness, leads to the production of cytokines and chemokines capable of exacerbating the 
disease (223). These ligands can therefore activate an inflammatory response by stimulating 
both peripheral blood mononuclear cells (PBMC) and interstitial cells. 
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Stimulation of TLR-9 in B cells has been shown to induce a number of different responses, 
including cytokine production, proliferation, upregulation of costimulatory markers and T cell 
independent antibody production (226, 227). TLR-7 stimulation of B cells has been shown to 
induce similar responses to those seen following TLR-9 stimulation (228). However, despite 
the similar effects of TLR-7 and TLR-9 stimulation these receptors do not induce identical 
immune responses. In fact, one study showed that TLR-9 deficiency but not TLR-7 
deficiency in mice, lead to different outcomes in the mice with an unexpected worsening of 
disease in the TLR-9 deficient animal model for SLE (229). In addition, varying 
combinations of the TLR ligands can induce different immune responses by DCs when 
stimulated (230). Further signals are also provided by Fc receptor activation by immune 
complexes (183). Therefore, the precise effect that the multiple combinations of RNA and 
DNA antigen complexed with different subclasses of antibodies have on varying levels of B 
cells and APCs and their respective receptors remains unknown but they could possibly 
explain the heterogeneous nature of the disease. 
Positive feedback of autoantibodies 
It is possible that during this period of benign autoimmunity DNA and RNA-containing ICs 
cause further activation of T cells and/or B cells. The first mechanism, as mentioned above, is 
by the stimulation of DCs via TLR-7 and/or 9 to prime naïve T cells and produce B cell 
activating cytokines, in particular IFN-α and BAFF. Secondly, hypomethylated DNA and 
RNA are potent B-cell mitogens and have been shown in mice to directly activate B cells, in 
particular to induce secretion of anti-dsDNA and ENA antibodies (231). DNA containing 
immune complexes can activate human B cells (183) and, therefore, could theoretically also 
increase the production of autoantibodies. Thirdly, autoantibodies can induce cell death in the 
tissue, which might lead to the release of more nuclear antigen that can stimulate B cells and 
other leukocytes. 
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1.4.5 Cellular abnormalities in SLE 
Cellular dysfunction in SLE can be divided into three categories. Firstly, the development of 
autoantibodies requires a breakdown in B cell tolerance, with possible help from other cells, 
notably CD4+ T cells (203) and natural killer T (NKT) cells (232). Secondly, leukocytes are 
seen in the tissue of patients and their presence correlates with functional impairment 
suggesting a direct role in inducing tissue damage (155). Thirdly, dysfunctional regulatory 
cells have been described, which may influence the loss of tolerance and/or the immune 
response within the peripheral tissue (233).  
Phenotypic and functional abnormalities have been described in several leukocytes, both 
effector and regulatory cells, in the blood of patients with SLE. These abnormalities can 
correlate with disease activity (234-236), autoantibody levels (236-238) and disease 
manifestations (239, 240). However, correlations with cellular abnormalities do not 
necessarily imply a causal relationship and might be secondary to the inflammatory process 
and/or autoantibody stimulation of APCs. The challenge of studying leukocytes in SLE is 
trying to determine whether the specific cellular abnormalities that are seen in the blood cause 
humoral dysfunction, tissue or lymph node infiltration, or induce another disease process, and 
if they are primary or secondary phenomenon. 
Autoantibodies can induce cellular dysfunction in SLE 
Human in vitro studies have demonstrated that autoantibodies, when complexed with nuclear 
antigen, can stimulate PDCs to produce high levels of IFN-α (181, 182, 184, 241). An 
important study showed that the IFN-α in the serum of patients with SLE leads to the 
maturation and activation of monocytes (241). It has since been shown to also increase agrin 
signaling in T cells (242), whilst IFN-α producing APCs from patients with SLE inhibit the 
function of regulatory T cells (243) and activate CD8+ T cells (234). IFN-α also has effects on 
other cell types, such as B cells (244).  
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A number of other pro-inflammatory cytokines and chemokines can be produced by PDCs 
stimulated by DNA containing immune complexes from patients with SLE, including IL-1β, 
IL-8, IL-12, IFN-γ and tumour necrosis factor alpha (TNF-α) (183). Interestingly, B cells and 
monocytes can also be stimulated to produce IL-8, a chemokine that recruits neutrophils and 
in mice myeloid DCs can also be stimulated by immune complexes bound to nuclear antigen 
to produce BAFF and TNF-α (185).   
The cytokines IL-1β, IL-12 and TNF-α have been shown to have important effects on T cell 
differentiation, in particular towards the pro-inflammatory TH1 and TH17 subsets (245, 246). 
Therefore many of the abnormalities seen in the leukocytes of patients with SLE might be a 
secondary phenomenon due to the effects of autoantibodies stimulating the production of pro-
inflammatory cytokines. 
As antibodies can dysregulate the cellular arm of the immune system it is difficult to establish 
which cells are initially responsible for the loss of tolerance to autoantigens and stimulating 
the production of autoantibodies, particularly in human disease. There is evidence of 
increased effector memory B and T cells (247, 248) and impaired regulatory cells (249-251). 
The disease might develop as a result of an imbalance between effector and regulatory cells 
leading to loss of self-tolerance and the activation of B cells resulting in the production of 
pathogenic autoantibodies. This hypothesis is supported by several experimental models (203, 
252-254) and a study in humans that showed a negative correlation between autoantibody 
levels and regulatory T cells (255). However, as autoantibodies are present in the blood many 
years before the clinical features of SLE emerge (107) it is difficult to establish whether the 
primary event that leads to the loss of self-tolerance occurs first in the B cells, effector T cells 
or in the regulatory cells. One group has proposed a model that suggests that B cell tolerance 
is lost first leading to the subsequent dysregulation and accumulation of other leukocytes, 
supported by a number of studies involving animal models of the disease (256). 
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B cells 
The presence of autoantibodies in patients with SLE indicates a central role for autoreactive B 
cells in the disease. Natural autoantibodies are considered to be important to immune 
homeostasis, but these antibodies are normally of the IgM class and have low affinity for 
antigen (215). Autoreactive B cells that have high affinity to autoantigen are often anergized 
or deleted (257). In humans there appears to be at least three checkpoints; two during early B 
cell development in the bone marrow and periphery (258) and a third during the transition 
from naïve to IgM+ memory B cell (259). It has been suggested that receptor editing might 
also be an important mechanism of inducing B cell tolerance (260). 
Precisely where the tolerance checkpoints fail in SLE is unclear. There have been only a few 
studies of human anti-dsDNA antibodies and whilst there have been studies of peripheral B 
cell tolerance in autoimmune mouse models they might not be applicable to human disease. 
One study of adolescent patients with SLE showed a high fraction of naïve antigen-
inexperienced B cells that are capable of secreting autoantibody suggesting a failure of 
tolerance during early B cell development (261). Another study showed that three clonally 
unrelated, somatically mutated anti-dsDNA antibodies from a single SLE patient were due to 
a failure in at least 2 different tolerance checkpoints and were derived from both self-reactive 
and non self-reactive B cells (262). Impairment of B cell tolerance in multiple checkpoints 
(both early and late) is more common in patients with active disease (263). A study of 9G4+ B 
cells that produce autoantibodies that react to self glycoproteins and are increased in SLE 
showed that these cells fail to be excluded from the germinal centre, possibly due to an 
anergic response to BCR stimulation (264). Additional factors that might contribute to the 
checkpoint failures include IL-2, IL-10, BAFF and co-stimulation via CD40L, ICOS and 
CD70 (237, 265-267). It has been shown that a subset of B cells that produce anti-dsDNA 
antibodies do not express RP105 (268), which negatively regulates TLR-4 signaling (269). 
However, studies have not shown if increased TLR-4 signaling has an effect on B cell 
function.  
 66 
Disturbances have been reported in both the immature and mature B cell compartment of 
patients with SLE. There is an increased percentage of immature transitional 1 B cells (270), 
and in the mature B cell compartment there are reduced frequencies of non-switched memory 
B cells but increased frequencies of plasma cells and an atypical population of memory B 
cells that do not express IgD or CD27 but express CD95, particularly during active disease 
(238, 271, 272). Autoreactive clones that produce autoantibodies have been identified in the 
switched and non-switched memory B cell population. A population of CD19hi B cells has 
also been identified which appears to produce antibodies to Sm antigen (238, 271, 273). The 
role of IgD–CD27– B cells in disease is not known. One study has shown that these cells have 
gene rearrangement indicating that they are memory B cells that have encountered antigen 
(238). They also correlated with the presence of pathogenic antibodies, but their ability to 
produce antibodies or their autoreactivity has not been examined.  
B cells appear to have multiple signaling defects (274). These defects either cause 
upregulation of a signaling pathway that causes differentiation, antibody secretion and 
proliferation (e.g. PI-3 kinase), cause downregulation of a signaling pathway that causes cell 
cycle arrest and apoptosis (e.g. ATR) or cause upregulation of a pathway that induces cell 
migration (e.g. ATR). Some patients with SLE have genetic polymorphisms in the BCR and 
FcγRIIb signaling pathways (275, 276), suggesting that the defects are intrinsic. 
In addition to antibody production B cells are also known to have other functions, including 
antigen presentation and cytokine secretion (277). An animal model of SLE has shown that 
the antibody-independent functions of B cells can induce mild disease, although it is less 
severe than when autoantibodies are present. The precise mechanism by which B cells induce 
disease without secreting antibodies was not shown but the disease was characterized by the 
activation and migration of T cells into the renal parenchyma (195). In human studies, B cells 
from patients with SLE have been shown to produce high levels of cytokines, such as IL-6 
and IL-10, which can stimulate B cells in an autocrine manner to produce higher amounts of 
 67 
antibodies (278-280). IL-6 and IL-10 can also influence non-B cells but it has not been shown 
if these effects are important in SLE. 
There are a number of in vivo studies using animal models that suggest that B cells play a 
direct role in T cell homeostasis (45, 46, 281) and primary B cell defects might therefore be 
the cause of the abnormalities seen in the T cells of patients with SLE. Regulatory T cells, for 
example, appear to be expanded by primary resting B cells via TGF-β secretion and antigen 
presentation but B cell activation results in the death of regulatory T cells (282). Activated B 
cells have also been shown to induce CD4+ T cell anergy and apoptosis in a contact 
dependent mechanism (283). B cells might also play an important role in expanding the 
effector memory T cell pool via CD70 (284), although if this process is uncontrolled there can 
be continuous conversion of naïve T cells into effector memory cells, depleting naïve T cells 
from the lymph nodes and spleen, which can result in severe immunodeficiency (285). 
 The differentiation of B cells into plasma cells is often considered to be a central mechanism 
of disease, supported by a study that showed that the numbers and frequency of plasma cells 
positively correlate with active disease and the titre of anti-dsDNA antibodies (128). 
However, plasma cells can be either short or long-lived. Evidence from human studies 
suggests that plasma cells that produce antibodies to ENA are usually long-lived but 
antibodies to dsDNA are usually short-lived (286). Plasma cells are more likely to be long-
lived if they arise from a germinal centre rather than an extra-follicular locus and also if they 
can find a survival niche in the spleen or bone marrow. Interestingly, the plasma cells that 
correlate with high anti-dsDNA antibody titres have been identified to be HLA-DRhi 
plasmablasts (287), supporting the possibility that they are arising as a result of autoreactive 
B cells prematurely exiting the normal tolerance checkpoints. Another study showed that B 
cells produce anti-dsDNA antibodies after co-stimulation by ICOS on T cells (288). There is 
evidence that the interaction between B cells and ICOS+ T cells occurs in the kidney (265), 
suggesting that short-lived plasma cells are produced in non-lymphoid tissue. 
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There is also evidence to suggest that B cells induce disease via antibody independent 
mechanisms (195). These mechanisms have not been fully explored, but studies in animals 
and more recent studies from patients that have B cell depletion therapy show that phenotypic 
and functional changes occur in CD4+ T cells (289-294). Changes have also been observed in 
the natural killer (NK) and NKT cell populations (295). These studies suggest that B cells 
modulate other cells of the immune system either directly or indirectly. 
T cells 
T cells from the blood of patients with SLE appear activated (296, 297) (237), terminally 
differentiated (247) and express high levels of pro-inflammatory cytokines (236). They also 
exhibit a number of signaling defects (298). However, the precise effect that these 
abnormalities have on the T cells and how each of these abnormalities contribute to the 
disease remains unclear. Whilst some of the effects of T cell dysfunction in SLE have been 
shown to contribute to autoantibody production, more recently it has been suggested that T 
cells might also induce damage directly within the tissue (234). Similarly, although 
polymorphisms have been identified in the genes that control T cell function of patients with 
SLE suggesting that they have primary defects, it has also been shown that some of the 
abnormalities identified are secondary phenomenon (242), possibly as a result of the 
antibody-induced dysregulation of APCs.  
An important role for CD4+ T cells in the pathogenesis of SLE has been supported by the use 
of anti-CD4 therapy in a small open label clinical trial with five patients with cutaneous 
disease (299). Clinical improvements were seen in these patients, but a randomized controlled 
trial (RCT) has not been performed to confirm the result and larger RCTs selectively blocking 
T cell costimulatory molecules have also failed to confirm a clear role for T cells in SLE 
(147). 
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CD4+ T cells are phenotypically and functionally heterogeneous in SLE 
Whilst T cells have been shown to have a number of different physiological functions within 
the immune system, most functional studies in SLE have focused on their ability to help B 
cells and increase autoantibody production, particularly the pathogenic anti-dsDNA 
antibodies. In mice predisposed to lupus-like disease memory T cells specific to an Sm 
peptide have been shown to be critical for increasing anti-dsDNA antibody levels when the 
mice were injected with an Sm peptide (300). In vitro studies showed that the T cells that 
increased anti-dsDNA antibody production secreted both IFN-γ and IL-4 (203). In human 
disease T cells specific to an Sm peptide have also been identified and shown to express high 
levels of TNF-α and IFN-γ but low IL-10, a regulatory cytokine. Disease activity and anti-
dsDNA levels positively correlated with the TNF-α secreting memory T cells but negatively 
correlated with IL-10 secreting memory T cells suggesting that a balance toward pro-
inflammatory cytokines induced autoantibody production (236). CD4+ T cells that are specific 
to histone peptides and RNP have also been identified. Most of these T cells secrete IFN-γ (a 
TH1 cytokine) but some also secrete IL-4 (TH2) and IL-10 (TR1) (301, 302). The 
hyperexpression of CD40 ligand by CD4+ T cells might also enhance the production of anti-
dsDNA and antinucleosome antibodies (237). 
TFH cells are a subset of T cells that reside in the germinal centres and have been shown to 
induce the differentiation of B cells into long-lived plasma cells (35). In animal models of 
SLE they induce the synthesis of anti-dsDNA antibodies (303). Circulating levels of TFH cells 
are elevated in a subset of patients with severe SLE and they correlate with anti-dsDNA 
antibody titres (304). However, it is not yet known if they induce the synthesis of anti-dsDNA 
antibodies and/or long-lived plasma cells in the human disease. 
The influence of T cells on autoantibody production is supported by the observation that 
autoantibody-producing B cells are class-switched and have undergone affinity maturation, 
which requires T cell help. However, studies of animals that get a lupus-like disease have 
shown that B cell tolerance can be broken without T cell help (305, 306).  
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Phenotypic analyses show that the memory T cell compartment is substantially increased in 
SLE compared to healthy individuals (247, 248) but whilst autoreactive T cells specific to 
nuclear antigens have been found in the peripheral blood it is not known if they make up a 
significant proportion of this memory T cell population. Likewise, a study has shown that T 
cells in the peripheral blood and kidneys are clonally expanded in active disease but the 
clonotypes that accumulate in the kidney are different to the clonotypes that accumulate in the 
blood and were highly restricted (307). The T cells that migrate into the kidney also have an 
effector memory phenotype (308). Therefore, whilst a large proportion of CD4+ T cells are 
more differentiated and clonally expanded there is a suggestion that a large proportion of T 
cells, particularly the T cells in the non-lymphoid tissue, are not influencing the production of 
antinuclear antibodies and might have another role in the disease.  
TH1, TH2, TH17 and TH22 subsets have all been implicated as important mediators of disease 
(236, 309-312). Each subset has been associated with different disease manifestations. Most 
studies indicate that TH1 cells are associated with renal disease, although one study has 
demonstrated that the renal histology differs depending on the TH1/TH2 balance (239, 313). 
TH1 cytokine expression has been associated with arthritis, whilst TH2 cytokine expression 
has been associated with serositis and neurological disease (314). TH17 cells have been 
associated with diffuse proliferative lupus nephritis (315) and elevated intrathecal levels of 
IL-17 have been observed in patients with neuropsychiatric lupus suggesting that TH17 cells 
might also be involved in neurological disease (316). TH22 cells have been associated with 
skin disease (235).  
It is possible that the balance of T helper cell subsets changes during the course of the disease. 
An animal study has shown that TH1 type cytokines precede TH2 type cytokines (317). 
However, in human disease TH1 cytokine levels are low in patients with recent-onset disease 
(318). Instead, TH17 cells might important in the early stages of human disease (319). 
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Some studies have examined the expression of chemokine receptors by T cells in patients 
with SLE. One study showed that CCR4+ T cells, which are associated with TH2 cells, were 
low in the blood but elevated in the renal biopsies of patients with nephritis, suggesting that 
they preferentially migrate to the kidneys (320). Other studies have shown large numbers of 
CXCR3 and CCR5 expressing T cells in renal biopsies, although in one study they were 
mostly seen in the tubulointerstitium (134, 321). The T cells in lesional skin appear to express 
similar chemokine receptors to the T cells seen in the renal lesions (322-324), but in patients 
with scarring disease the T cells express higher levels of cutaneous lymphocyte antigen 
(CLA), a skin homing receptor (322). 
The costimulatory molecule, inducible T-cell costimulator (ICOS), which is seen on TFH cells 
and is associated with helping B cells to differentiate into plasma cells, is expressed on CD4+ 
T cells in inflamed renal tissue close to B cells and Ig deposits supporting the possibility that 
they induce antibody production in the non-lymphoid tissue (265). Another possibility is that 
CD4+ T cells recruit and activate other inflammatory cells, in particular neutrophils, 
monocytes and CD8+ T cells but this does not appear to have been examined yet. It is 
nevertheless tempting to consider the possibility that the diverse functions and phenotypes of 
T cells in SLE explain some of the heterogeneous manifestations of disease. 
CD4+ Regulatory T cells 
Regulatory T cells suppress effector cells from targeting self and harmless environmental 
antigen (325) and reduced numbers or function leads to either autoimmune or atopic disease 
(63, 245, 326). As would be expected, a number of defects in regulatory T cells from patients 
with SLE have been reported. Firstly, regulatory T cell numbers are low (249) and the 
CD4+CD25hi cells that are present have been shown to have reduced FoxP3 expression (250), 
although FoxP3 is unexpectedly increased in CD4+CD25– T cells (327, 328). Secondly, 
CD4+CD25+ T cells from patients with active SLE have been shown to suppress CD4+CD25– 
T cells inadequately (250), although it is not certain whether this is due to a defect in the 
functional ability of regulatory T cells or a defective response to regulatory signals in the 
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effector T cell population (329-331). Thirdly, unlike effector T cells, regulatory T cells are 
not seen in the tissue of patients with SLE (332), possibly because regulatory T cells from 
patients with active disease express reduced levels of CCR4 and have reduced migratory 
ability (333). 
Animal studies show that genetic defects in regulatory T cells can lead to lupus-like disease 
(334). It is possible that the dysregulation of regulatory T cells in human disease might be due 
to polymorphisms in the genes controlling regulatory T cell function (116), it has also been 
shown that the dysregulation is secondary to defects in other cells within the immune system 
(243).  
T cell differentiation 
Although the precise mechanisms that influence the differentiation of T cells in SLE are not 
known, they are likely to require antigen-presentation, co-stimulatory signals and cytokine 
stimulation being provided by APCs, such as DCs and/or B cells. The polarization of T cells 
towards a particular helper subset depends on the cytokine and co-stimulatory signals 
provided, which in turn is dependent on the danger signal provided by the pathogen (335). In 
the case of SLE T cell differentiation is likely to be influenced by the abnormal processing 
and clearance of apoptotic and necrotic cells. Whilst the clearance of dying cells normally 
promotes an anti-inflammatory response, in SLE the nucleic acid and nuclear proteins induce 
pro-inflammatory signals in APCs and B cells leading to release of cytokines such as IFN-α 
by PDCs, increased MHC expression and increased co-stimulatory molecules such as CD80 
and CD86.  
There are a number of possible reasons for dying cells causing a pro-inflammatory response 
in SLE. The apoptotic process appears to be defective with apoptotic bodies being shown to 
accumulate in the sites of inflammation due to a number of factors, including C1q deficiency 
and impaired phagocytosis. As a result of the impaired clearance of apoptotic bodies, the 
antigens undergo novel post-translational modification resulting in cryptic epitopes that can 
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be recognized by autoreactive T cells. Post-translational modification of DNA also increases 
the ligation of toll-like receptors in APCs and B cells. Further danger signals by stress-
proteins released by dying cells might also amplify the pro-inflammatory signals by APCs 
(336). However, more importantly the pro-inflammatory response is amplified by 
autoantibodies complexing with the autoantigen and activating APCs via Fcγ receptors. This 
is particularly important in SLE because immune-complexes are soluble and therefore it is 
possible that they can deliver pro-inflammatory signals to APCs and B cells in germinal 
centres distal from the original source of cell death. As a result, large numbers of T cells can, 
in theory, be activated and induced to differentiate in the SLOs, such as the spleen, from 
where they subsequently enter the blood to migrate to the non-lymphoid tissue. 
Monocytes and monocyte derived antigen presenting cells 
Myeloid cells provide an important bridge between the innate and adaptive immune systems 
via phagocytosis, toll-like receptor activation followed by cytokine production and antigen 
presentation to T cells. Circulating monocyte numbers are low in active disease (337), but 
they have increased expression of activating high affinity Fc receptors, particularly in patients 
with severe lupus nephritis (338, 339), and there is an increase in the frequency of cells 
expressing the co-stimulatory molecule CD40L (340). MDC numbers are also low (341) and 
the cells are also characterized by high expression of activating Fc receptors, co-stimulatory 
molecules and the pro-inflammatory cytokine IL-8 (342, 343).  
Studies in mice show that MDCs are activated by direct stimulation with nuclear antigen 
(344) and can be induced to produce BAFF or TNF-α when stimulated with either chromatin 
or nucleosome-containing immune complexes (185). In humans nuclear antigen complexed 
with the high mobility group box protein 1 induce the maturation of MDCs and can stimulate 
macrophages to produce pro-inflammatory cytokines (345). Healthy monocytes can be 
induced to produce IFN-α when stimulated with RNA transfected using lipofectin (184) and 
IL-8 when stimulated with DNA-containing immune complexes (183). However, DNA-
containing immune complexes cannot induce healthy MDCs to produce IL-8. 
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It is likely that myeloid cells have roles in both the dysregulation of immune tolerance in 
SLOs and in mediating or exacerbating inflammation in the non-lymphoid tissue. In vitro 
studies show that monocytes from SLE patients function as potent APCs (241) and healthy 
monocytes stimulated with SLE serum induce CD8+ T cells to become more cytotoxic, which 
causes them to generate soluble nuclear autoantigen (234) that can activate more myeloid 
cells. They also directly promote IgG plasmablast differentiation via BAFF and IL-10 
stimulation of B cells and IgA plasmablast differentiation via (a proliferation-inducing ligand) 
APRIL (346).  
Macrophages have been seen in the biopsies of the inflamed tissue and the amount of 
infiltration correlates with the expression of monocyte chemoattractant protein 1 (MCP-1) 
(347, 348). It is unclear how they contribute to the inflammatory process. It is likely that they 
are either directly damaging local cells or they are presenting antigen to T cells that are also 
present. However, MFG-E8-deficient mice have macrophages that cannot engulf apoptotic 
cells and develop a systemic autoimmune disease as a result (349), suggesting that there is a 
defect in the function of the monocytes and macrophages that infiltrate the tissue. Patients 
with SLE have also been shown to have similar defects of phagocytosis (350-352), which in 
small numbers of patients might be a result of mutations in the MFG-E8 gene (353). 
Plasmacytoid dendritic cells 
PDCs are derived from a different precursor to MDCs and can be identified by their 
expression of the surface marker CD123 and lack of expression of the surface markers CD11c 
(354). They are considered to be the main source of IFN-α, which has a wide range of effects, 
including the activation of lymphocytes, APCs, plasma cells and endothelial cells, and 
therefore have a central role in the disease. PDCs can also influence the polarization of 
healthy T helper cells, but it is unclear whether they influence the different cytokine profiles 
of T cells that have been seen in patients with SLE.   
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The production of IFN-α by PDCs can be induced by both DNA and RNA-containing 
immune complexes by stimulating TLR-9 and TLR-7 respectively (183, 184). This can be 
inhibited by hydroxychloroquine, one of the key therapies in SLE (355).  
It has been shown that PDCs migrate to inflamed lymph nodes (356), where the release of 
IFN-α could contribute to the local activation of autoreactive naïve B and T cells. Studies 
have shown that they are also found in the biopsies of active lesions from the skin and 
kidneys (357-360). One study showed that they can produce IFN-α in the skin, which inhibits 
the repair of damaged tissue by disrupting normal angiogenesis (361) and recruits CXCR3+ T 
cells (that are TH1 biased) by inducing the synthesis of the chemokine IP-10 in the epidermis 
(358). PDCs can also produce the molecule granzyme B, which can cause the death of local 
interstitial cells (360).  
Granulocytes 
Granulocytes have also been implicated in the pathogenesis of SLE. Neutrophils express 
higher levels of complement receptor-3 (362) and Fas (363). Immune complexes, 
complement, cell debris and/or cytokines that are present in the tissue can activate them but 
they are not seen frequently in inflamed tissue, except in the less common lesions (126, 364). 
It is, therefore, unlikely that they have a significant role in causing tissue damage. However, 
there is evidence that they are more apoptotic and that the clearance of apoptotic neutrophils 
by macrophages is impaired (350, 363), which would lead to increased availability of 
extracellular nuclear antigen to induce the production of antinuclear antibody. Dying 
neutrophils have also been shown to capture antigen in in extracellular traps, which 
externalize autoantigens, including dsDNA, and have been shown to be associated with 
increased anti-dsDNA antibodies, suggesting another mechanism for the breakdown in 
tolerance to nuclear antigen (365). In mice, basophils that have been activated by autoreactive 
IgE, promote TH2 cell differentiation and enhance the production of autoantibodies that cause 
glomerulonephritis (366). The numbers of basophils in the circulation are lower in patients 
 76 
with active disease (367), but it is unclear whether they have a significant role in human 
disease. 
 
In summary, multiple cells, of both the innate and acquired immune system, are associated 
with the pathogenesis of disease but it is not clear at what stage they each participate in the 
inflammatory pathway. Therapeutic targeting of individual cells, for example with rituximab, 
might allow identification of the sequence of cell involvement that eventually leads to 
disease. 
Leukopaenia in SLE 
Another central feature of SLE is that circulating leukocyte numbers are usually low in 
patients with active disease. Lymphopaenia is most common, seen in between 65 and 80% of 
adult patients at time of diagnosis (368, 369). It correlates to some extent with disease activity 
and anti-dsDNA antibody levels and has also been associated with anti-ENA antibodies (368, 
370-372). One study has demonstrated that the lymphopaenia in untreated SLE is 
predominantly due to decreases in the CD4+ subset, but reductions are also seen in the CD8+, 
CD16/56+ natural killer (NK) (297) and B cell subsets (373). In the cutaneous variant of the 
disease, discoid lupus erythematosus, CD4+ T cells are not decreased, unlike the CD8+ and 
NK subsets, which might provide some insight into the different mechanisms of disease in 
each organ manifestations. Neutropaenia is a well described feature of active disease although 
it is seen in fewer patients than lymphopaenia (369). DC numbers are low, although disease 
activity only correlates with reductions in the plasmacytoid subset, which is responsible for 
the production of IFN-α, and does not correlate with reductions in the myeloid subset (359, 
374). Circulating monocyte numbers are also low, but it is not clear if this correlates with 
disease activity (339).  
Given the importance of many of these cells in helping autoantibody production and tissue 
infiltration, the low number of these cells in the blood provides further confusion as to 
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precisely what their roles are in the disease. If, for example, CD4+ T cells are low in the body 
how do they then help B cells to differentiate into plasma cells or class-switch and where do 
the CD4+ T cells in the tissue come from if they are not in the blood?  
Several explanations have been given for the cytopaenias that are seen in SLE. The most 
common is antibody mediated cytotoxicity (type 2 hypersensitivity), either due to antibodies 
to DNA cross linking with the lymphocyte membrane (375) or to the presence of antibodies 
that bind to specific cell surface markers such as CD4 and CD45 (376). Other possible 
explanations include increased apoptosis via soluble factors present in the serum (377-379), 
Fc receptor ligation by immune complexes (380), cell activation or loss of survival signals 
(381), bone marrow suppression (382), impaired lymphocyte development due to IFN-α 
(383) and cell migration (359, 384). Drug toxicity is another possible explanation although 
this would not account for the leukopaenia that is seen at presentation. Cell migration from 
the blood into the tissue would be the most logical explanation as this would account for the 
disappearance from the blood and appearance in the tissue and explain the similar phenotypic 
abnormalities that are seen in both compartments (322, 359). This explanation is supported by 
a study that transient lymphopaenia can be induced in mice by IFN-α enhancing the adhesion 
of lymphocytes to the endothelium (385). It is difficult to explain how cell death would 
account for leukopaenia in active disease because there is no clear reason why cells in the 
blood would be more likely to die than cells in the inflamed tissue. 
1.4.6 Lymphocyte migration in SLE 
Lymphocytic interactions can occur in either SLOs or in the non-lymphoid tissue. The 
mechanisms that control B and T cell migration are not clear, but they might explain some of 
the differences that are seen in patients. T cells have been shown to express a number of 
different chemokine receptors including CCR4, CCR5 and CXCR3, which are expressed on 
terminally differentiated memory cells. In the skin CCR4+ T cells are seen (322) whereas in 
kidneys, T cells have been seen to express a variety of different chemokine receptors 
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including CCR4, CCR5 and CXCR3 (320, 321, 386). It can be assumed that many of these 
cells are effector cells, but it is possible that some of these T cells are regulatory T cells, 
which are also known to express CCR4 (387), although in patients with SLE regulatory T 
cells express reduced levels of CCR4 (333). 
The observation that lymphocyte levels are commonly low during active disease, whilst being 
found in sites of inflammation suggests that T and B cells could be migrating to these areas 
from the blood. The migration of cells will depend on them expressing chemokine receptors 
that respond to the specific ligands and chemokines produced in the target tissue. These 
ligands are produced in different organs to varying levels. RANTES, the ligand for CCR5, for 
example, is expressed in high levels in the kidney possibly explaining the high levels of 
CCR5+ T cells that are seen in the kidneys of patients with SLE (388). Just as cellular debris 
can activate leukocytes it can also induce a pro-inflammatory response in the tissue 
parenchyma, to recruit inflammatory cells. CpG-DNA, for example, enhances expression of 
ICAM-1 on endothelial cells (389), whilst RNA enhances the expression of chemokines 
(223). 
1.4.7 Cytokines and chemokines 
SLE is characterized by abnormal levels of various different cytokines and chemokines (278, 
390-392). Different cell-types produce different cytokines and chemokines under specific 
stimulation (393). In SLE cytokine dysfunction can be broadly categorized according to those 
that are derived from APCs and those derived from T cells. Whilst there is general agreement 
with regards to the abnormal expression of cytokines derived from APCs, there is less 
agreement with regards to the abnormal expression of cytokines derived from T cells.  
APC-derived cytokines 
IFN-α has been strongly linked to SLE based on studies that have shown a strong correlation 
between active disease and activation of genes linked to the IFN-α receptor pathway, called 
the interferon signature. It has also been observed that administration of recombinant IFN-α 
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can induce a lupus-like disease (394). PDCs are the main source of IFN-α (395), although one 
report has suggested that in patients with SLE neutrophils might also be a source (396). It is 
produced after stimulation of TLR-7 and/or TLR-9 by nucleic acids and Fc receptors by 
immunoglobulins that bind to nucleic acid as immune complexes. Its effects in the immune 
system are diverse, but include increasing antigen presentation (via both class I and class II 
MHC expression), co-stimulation and activation of the NK cells and lymphocytes in order to 
enhance the cytotoxic immune response to intracellular pathogens, in particular viruses. 
Studies have shown that the IFN-α in the serum of patients with SLE can induce the 
differentiation of monocytes to become potent APCs (241), which activate cytotoxic CD8+ T 
cells that can increase the amount of soluble nuclear antigen and further exacerbate the 
immune response as a result (234). IFN-α can also induce the differentiation of B cells to 
become plasma cells but possibly only when PDCs are present (346, 397). There are several 
different subtypes of IFN-α, which has complicated attempts to develop therapies to block it. 
Therapeutic strategies that have been attempted include the development of monoclonal 
antibodies that can neutralize most, if not all, of the IFN-α subtypes, a vaccine that leads to 
the production of autoantibodies that can neutralize IFN-α and an antibody that can block the 
IFN-α receptor. Only phase 1 or 2 studies have been completed so far but the results have 
shown only moderate clinical benefits (398-400).  
BAFF (also known as B Lymphocyte Stimulator (BLyS)) is mainly produced by monocytes 
and neutrophils. It has three receptors, BAFF-R, B cell maturation antigen (BCMA) and 
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), 
which can also bind a protein similar to BAFF, called APRIL. BAFF acts primarily on B 
cells, although the receptors are also found on T cells. High expression of BAFF in mice leads 
to B cell hyperplasia, hypergammaglobulinaemia and production of anti-dsDNA antibodies. 
In patients with SLE, high BAFF levels correlate with high levels of anti-dsDNA antibodies 
(401) and BAFF secreted by DCs stimulated with serum from SLE patients induce IgG 
plasmablast differentiation (346). The importance of BAFF in SLE has been confirmed by a 
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RCT, which showed clinical and serological improvements in patients treated with anti-BAFF 
therapy (402). 
Other cytokines that are elevated in SLE include IL-6 and IL-10, which are produced by 
monocytes, DCs and B cells. These cytokines also have diverse roles including activation of 
B cells. IL-6 is a pro-inflammatory cytokine that can induce Th-17 differentiation and plasma 
cell differentiation. However, IL-10 has mostly regulatory effects, but can also promote B cell 
differentiation into IgG producing plasmablasts, which could be relevant in SLE (346, 403). It 
is therefore unclear whether it has a primary causal role in disease or is elevated in response 
to the inflammation but failing to suppress it (251). Blockade of IL-6 has shown clinical and 
serological improvements in an open-label phase 1 study involving a small group of patients 
with mild to moderate SLE, although it was accompanied by side effects such as neutropaenia 
(404). Blockade of IL-10 has also been shown to be beneficial in a small group of patients 
(405). However, larger RCTs of IL-6 and IL-10 blockade have not yet been reported. 
T cell derived cytokines 
The role of T cell derived cytokines in SLE is more controversial. Decreased IL-2 production 
is the most consistent abnormality that has been observed, but IL-15, which is part of the IL-2 
superfamily is increased (406). The precise reason for the reduced production of IL-2 and 
how this might contribute to clinical disease is unclear. IL-2 is important for maintaining T 
cell survival, in particular regulatory T cells, which are defective in SLE, although a clear link 
between these two defects has not been established. 
It has been hypothesized that cytokines from T cells provide help for B cells and stimulate 
autoantibody production. Helper T cells can be divided into four subtypes, which have 
distinct cytokine profiles; TH1 (IFN-γ), TH2  (IL-4), TH17 (IL-17) and TFH (IL-21). Each of 
these cytokines and/or their T helper subset has been found to be high in SLE (407), and all 
have been shown to influence antibody production (408-411), but a definite causal link 
between these cytokines and disease has not been established. However, the diverse range of 
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cytokines that have all been associated with the disease might explain the wide variety of 
manifestations that are seen in the disease. 
Chemokines 
Several chemokines, including MCP-1, TARC, RANTES and IP-10, which bind to CCR2, 
CCR4, CCR5 and CXCR3 respectively, have been found to be high in the blood and/or urine 
of patients and correlate with disease activity (388, 412, 413). B cells and PDCs can produce 
most of the chemokines that are high in SLE following stimulation with TLR-7 or TLR-9 
ligands (50, 414-416) or immune complexes bound to DNA (183), suggesting that they are 
the main source in the disease. There is less evidence of chemokine production by T cells, 
although they can produce RANTES and produce higher levels in patients with SLE because 
of reduced expression of microRNA-125a, an inhibitory post-transcriptional regulator of 
RANTES expression (417). Endothelial and tissue-derived cells can also produce some of 
these chemokines, either as a result of antibody stimulation (418), IL-1β stimulation by 
infiltrating IgG-stimulated lymphocytes (419) or TLR ligation by RNA (223, 420).  
 
1.5.1 Rituximab – mechanism of action 
Rituximab is a chimeric mouse/human monoclonal antibody that binds to the cell surface 
antigen CD20, which is expressed on all B cells from the pre-B cell stage to the mature B cell 
stage. The precise mechanisms by which B cells die following binding to rituximab are 
unclear, but are thought to be by antibody-induced cell mediated cytotoxicity, complement-
induced lysis and/or induction of apoptosis (421). It was first used in the treatment of B cell 
lymphomas, being approved by the Federal Drug Administration in November 1997. It has 
since been used in the treatment of autoimmune diseases including autoimmune 
thrombocytopaenia, haemolytic anaemia and rheumatoid arthritis. The efficacy of B cell 
depletion in autoimmune disease has often been attributed to the improvement in 
autoantibody titres that are thought to contribute to these diseases. However, rituximab has 
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also been used successfully in autoimmune diseases where a role for autoantibodies is not 
firmly established leading to the suggestion that B cells might be exerting antibody-
independent roles in specific diseases (422, 423).  
1.5.2 B cell depletion therapy in SLE 
Given that B cells, by producing autoantibodies, have been shown to have such a central role 
in SLE, in both animal models and human disease, it was hypothesized that the depletion of B 
cells could be an effective means of treating patients. B cell depletion therapy (BCDT) was 
first used for the treatment of SLE at University College London Hospitals (UCLH) in 2000 
in patients that were refractory to conventional immunosuppressants (424). In this open-label 
study 6 patients with SLE previously refractory to all other conventional treatments were 
given 2 infusions of rituximab 2 weeks apart in addition to 2 infusions of cyclophosphamide 
and 1 infusion of methylprednisolone. One patient was lost to follow-up, but the remaining 5 
patients all showed clinical and serological improvements at 6 months and there were no 
serious adverse events. A retrospective study of rituximab therapy given to 50 patients with 
SLE was then later reported in order to assess the efficacy further. This study reported 
complete remission in 42% of patients (defined as change in the BILAG A or B scores to C or 
D in every organ or system), partial remission in 47% of patients (defined as a change in the 
BILAG A or B scores to C or D in one or more organs or systems but with a persistent 
BILAG A or B score in one organ or system) and non-responsiveness to BCDT in 11% of 
patients that were available for assessment at least six months after the first cycle of therapy. 
A response to therapy was seen in all organ systems, although the percentage of patients that 
responded was lowest in the renal system compared to the other organ systems (425). Similar 
observations were seen in four other small open-label studies (426-429) and a prospective 
study from a national registry (430). However, two RCTs subsequently failed to confirm that 
BCDT is effective in SLE and lupus nephritis (431, 432).  
A number of possible explanations have been given for the failure of RCTs to demonstrate 
that BCDT is clinically effective (146). One important reason is that BCDT was compared 
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against a combination of high dose prednisolone and mycophenolate mofetil, which is known 
to inhibit activated B cells (433) and is very effective in SLE (434). BCDT was not compared 
against placebo alone, which would have probably observed that B cell depletion is an 
effective treatment in SLE, even if it is not necessarily superior to the currently used 
medications. A second important point is that the RCTs rely on the assumption that B cells 
exert equal and/or similar effects in all patients. However, B cells have multiple functions, in 
addition to antibody synthesis, and these functions might vary between patients with SLE. 
Understanding these differing functions and stratifying patients accordingly might lead to 
better outcomes in RCTs. 
Serological factors that predict clinical response or relapse post BCDT 
Reductions in the mean anti-dsDNA antibody and increases in C3 levels paralleled 
improvements in clinical disease in all but one study. Early relapse is associated with a 
reduction in anti-dsDNA antibody levels following BCDT (435), the presence of anti-ENA 
antibodies and hypocomplementaemia at baseline (436) and higher baseline levels of BAFF 
(437). 
As B cells repopulate, there is a variable increase in anti-dsDNA and anti-C1q antibody levels 
between patients (292) but studies have not shown if relapse coincides with a rise in 
autoantibody levels or a fall in complement levels. One small study of four patients showed 
that as B cells repopulated in two patients who subsequently relapsed, there was a rise in the 
levels of anti-dsDNA antibodies bearing the idiotope recognized by the 9G4 monoclonal 
antibody (435). 
Cellular factors that predict clinical response or relapse post BCDT 
Higher numbers of B cells at baseline have been associated with poorer clinical response 
(427). This association could possibly be explained by the earlier repopulation time of B cells 
in patients with higher B cell numbers at baseline, which might be due to higher BAFF levels 
as has been observed in a separate study of patients that relapse early (437). 
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Three studies have shown that the time to B cell repopulation varies considerably between 
patients, but did not observe a clear relationship between relapse and the repopulation of B 
cells. Each study, however, used different definitions of B cell repopulation and disease 
assessment tools, which might partially explain the differences in the results that were 
observed. 
The first study of 15 patients showed that the median time to repopulation, defined as more 
than 0.005 x 109 B cells/l, was five months (range, 4-11), but excluded two patients who had 
not repopulated during the study period, of whom one was deplete of B cells for over three 
years (435). Only six patients relapsed within one year of BCDT and one patient relapsed 
before B cells had repopulated. However, of the four patients that relapsed within one year of 
BCDT, four relapsed within one month of B cell repopulation suggesting that there is a close 
relationship between B cells and relapse in a subset of patients. 
The second study of 16 patients showed that the median time to repopulation, defined as more 
than 0.01 x 109 B cells/l, was seven months (range, 2-12), but excluded one patient who had 
not repopulated four years after therapy (427). B cells had repopulated in all seven patients 
that relapsed but the median time to relapse was 18 months (range, 10-40). 
The third study of 31 patients showed that the median time to repopulation, defined as more 
than 0.02 x 109 B cells/l, was 10 months (range, 2-16), although the definition of B cell 
repopulation was higher than has been used in other studies. The analysis also excluded 13 
patients whose B cells had not repopulated during the study period, of whom one had B cells 
deplete for 31 months (428). Eighteen patients relapsed with a median time of 11 months 
(range, 4-24). Of the 18 patients that relapsed only 10 had repopulated, although its definition 
of B cell repopulation was slightly higher than in the other studies. The median time between 
B cell repopulation and relapse was 6.5 months (range, 1-26) in those 10 patients. 
The reasons for the different definitions of B cell depletion in the three studies were not 
given. Whilst the differences in the B cell threshold between the studies do not appear 
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substantial it is noticeable that the study with the higher threshold for B cell depletion had the 
highest percentage of patients that relapsed without the B cells appearing to have repopulated. 
Evidence is required to define B cell depletion, i.e. the number of circulating B cells that 
contributes to clinical disease.  
B cells comprise multiple different subsets, and it is likely that relapse is dependent on the 
repopulation of one or more specific subset rather than all of the B cells. One study has shown 
that the initial B cells that repopulate are naïve and that remission correlates with a delay in 
the reconstitution of CD27+ memory B cells (438). A second study also showed that early 
repopulation of CD27+ memory B cells and high numbers of circulating plasmablasts at week 
26 was associated with early relapse (429). Other B cell subsets, such as the IgD–CD27– 
memory B cell, have also been shown to correlate with active disease but the relationship 
between the repopulation of these cells and relapse following BCDT have not been reported. 
Identifying all the subsets that are involved in the pathogenesis should improve the use of B 
cell counts in monitoring disease following BCDT. 
B cell depletion has also been shown to be associated with reductions in T cell activation 
markers, CD154, CD69 and HLA-DR (290, 294, 439) with improvements in regulatory T cell 
function (293), numbers, defined by the marker CD25 (290, 292), and Foxp3 expression 
(440). Two studies have also reported increases in the total numbers of CD4+ T cells in the 
blood (290, 292). Increased numbers of CD8+ T cells, NK cells and monocytes were also seen 
in one of the studies (292). However, it is not clear whether these changes were a direct result 
of the inhibition in B-T cell interaction or an indirect effect of reductions in autoantibody 
levels. In addition it is not clear how these T cell abnormalities specifically affect the disease 
process. Most studies have focused on the role of T cells in helping B cells make 
autoantibodies, but this is irrelevant if B cells are not present to differentiate into plasma cells 
and if the plasma cells are long-lived and continue to secrete autoantibodies independently of 
other cells, as has been observed. 
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Histological changes following BCDT 
Only one study has examined the changes in the cellular infiltrates of the inflamed tissue 
following BCDT from patients with SLE. This study examined the changes in the renal 
biopsies from six patients who were treated for active nephritis. Two of the six biopsies 
showed a moderate/large leukocytic infiltrate in the tissue after BCDT and three showed 
occasional leukocytic infiltrates. The infiltrates were mostly in the renal interstitium rather 
than the glomerulus. Most of the cells that were present were T cells and plasma cells, but in 
the two samples where there were moderate/large infiltrates a few B cells were also seen. 
Only one biopsy was taken both before and after B cells repopulated, which, therefore, made 
it difficult to establish if the B cells that were present in the biopsies of the other 5 patients 
were there as a result of repopulation and reinfiltration or if they were just not fully depleted. 
In the paired biopsies that were taken T cell numbers were low and B cells were 
undectectable at depletion, having both been present in higher numbers before BCDT, and 
both then increased after repopulation indicating that the cells had re-infiltrated the tissue. 
Interestingly, this was the only patient in the study that had low anti-dsDNA antibody levels 
(441).  
In a recent study of patients with multiple sclerosis who were treated with BCDT it was 
demonstrated that lower numbers of T cells were present in the cerebrospinal fluid of treated 
patients. These changes correlated with reductions in the chemokine CXCL13. Interestingly 
there were no significant changes in IgG levels or oligoclonal bands suggesting that the 
clinical response was due to the inhibition of T cell trafficking (442). 
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1.6.1 Model of disease 
There are four key disease stages in SLE. The first stage is the defective clearance of antigen 
from dying cells causing the activation of APCs. The second stage is the breakdown in T and 
B cell tolerance that leads to the production of autoantibodies, in particular antinuclear 
antibodies. The third stage is DC activation by immune complexes bound to nuclear antigen 
causing further dysregulation of B and T cells. In the final stage autoantibodies bind to tissue 
antigens causing a complement cascade, leukocyte recruitment or thrombosis. The proposed 
sequence of events is shown in Figure 1.6.1, similar to models proposed by others (443, 444). 
However, a number of observations do not fit this proposed model. Firstly, whilst over 100 
autoantibodies have been identified (178), very few are present in more than 25% of patients 
and correlate well with disease manifestations (140) or activity (127). They are often present 
even when there are no signs or symptoms of clinical disease (107). Secondly, therapeutic 
interventions, such as BCDT, do not always show a clear correlation between the treatment 
response and the clearance of circulating autoantibodies (33, 435). Thirdly, lymphocytic 
infiltrates are seen in the tissue (126), but it is not clear if these cells infiltrate the tissue 
before or after antibodies deposit in the tissue. The precise role of these cells and how they fit 
into the disease stages needs clarifying. 
To achieve more meaningful results from clinical trials a much clearer understanding of the 
disease is required, one that would allow the sequence of events that lead to symptoms and 
organ damage to be predicted. This thesis will try to answer two critical questions, which I 
believe will improve our understanding of the disease and help us to plan future clinical trials. 
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Figure 1.6.1 – A proposed sequence of events leading to inflammation and damage in the 
tissue.  
In the early stages nuclear antigen released by dying cells activates myeloid dendritic cells 
(D), which then present antigen and activate autoreactive T cells. Naïve autoreactive T cells 
(TN) then differentiate into effector T cells (TE), which provide help to naïve autoreactive B 
cells (BN) to differentiate into autoantibody secreting plasma cells (P). This stage starts in the 
circulation and therefore precedes the disease symptoms. In the later stages autoantibodies 
then either enter the tissue from the circulation and bind to antigen where they induce a 
complement cascade, bind to endothelial cells and recruit inflammatory cells, such as 
lymphocytes, neutrophils and macrophages to cause vasculitis or induce platelet, red blood 
cell and/or leukocyte aggregation within the blood vessel to cause thromboses. Vasculitis and 
thrombosis can be primary or secondary events.  
Circulating autoantibodies do not always correlate with active inflammation. One possible 
explanation is that a second ‘hit’ is required to cause autoantibodies to enter the tissue, which 
depend on antibody-independent functions of B cells. This thesis will examine the sequence 
of events that occur as B cells repopulate after BCDT in order to identify the source of 
autoantibody production and how they might get into the tissue. 
Key: Green arrows represent stimulation, blue arrows represent differentiation, red arrows 
represent migration or transfer into non-lymphoid tissue.  
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1.6.2 How do antibodies get into the tissue? 
The presence of antibodies and complement in the tissue is another defining aspect of the 
disease. However, it is not clear how antibodies enter the tissue from the blood. One 
possibility is that they are produced by plasma cells that are present in the tissue but this 
would then lead to the question of what mechanisms control the migration of B cells and/or 
plasma cells into the tissue. The second possibility is that antibodies are produced in SLOs 
and then cross the vascular endothelium from the blood. However, the latter explanation leads 
to the question of whether the endothelium is normally permeable to antibodies, actively 
transports antibodies from the blood or if the endothelium requires signals to allow passive 
transfer of antibodies. The ability of the vascular endothelium to allow transfer of 
autoantibodies to cross into the tissue has been examined in autoimmune diseases of the 
nervous system, which show that the disruption of the endothelial junctions is dependent on T 
cell interactions with endothelial cells (445-448). Vascular integrity does not appear to have 
been examined in SLE, although it has been suggested that it is likely to be an important 
factor in cerebral lupus (449). Arguably, vascular integrity is not as important in 
glomerulonephritis, as the glomerulus is more permeable to proteins than the endothelium 
around the brain.  
Assuming that the transfer of antibodies into the non-lymphoid tissue is an active process then 
it is likely to be independent of the process that regulates the production of autoantibodies, i.e. 
it is a second step or ‘hit’. This process needs to be clarified to understand fully the sequence 
of events that lead to clinical disease and, therefore, the kinetics of the disease. It might also 
help us to understand how some therapies might control the inflammatory process.   
1.6.3 Can B cells induce disease via an antibody independent mechanism? 
To date there has only been one study examining the possibility of an antibody-independent 
role for B cells in SLE (195). This was carried out in an MRL/lpr mouse strain, in which the 
B cells were genetically modified to not be able to secrete antibody. It was reported that the 
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mice that had B cells that could not secrete antibodies (mIgM Tg) had a higher mortality than 
mice without B cells. Intriguingly, whilst glomerular pathology was almost absent in the 
mIgM Tg mice, interstitial nephritis and vasculitis persisted, dominated by the presence of 
large numbers of perivascular T cells. In addition evidence of T cell activation could be seen 
in the splenic T cells suggesting that activation was occurring in the SLOs, most likely as a 
result of direct interactions between the B and T cells. 
The use of the MRL/lpr mouse strain has been criticized because it is heavily dependent on a 
single gene accelerator and they develop profound lymphoproliferation, which is not 
characteristic of the human disease (450). However, it is one of the few animal models that 
has been shown to develop multi-systemic disease, involving the joints, skin, kidneys and 
brain as is seen in human SLE.  The mice also develop vasculitis. By removing the antibodies 
from the MRL/lpr mouse strain Chan et al were able to examine the role of antibody-
independent function of B cells in causing inflammation in multiple organs.  
The study raised two important points. The first was to suggest that some of the inflammatory 
lesions that are seen in SLE and contribute to tissue damage and mortality, in particular the 
perivascular and interstitial lesions, are a result of T cell infiltration, whilst other lesions, such 
as glomerular lesions are due to immune complexes. The second was to show that this T cell 
infiltration was dependent on the presence of B cells. The external mechanisms that control T 
cell migration are not fully understood and whilst B cells have been shown to have multiple 
functions that are not related to antibody synthesis, such as antigen presentation and cytokine 
secretion, there have been no studies that have examined how B cells might influence T cell 
migration into the non-lymphoid tissue in SLE. Studies have also not examined the antibody 
independent roles of B cells in human autoimmune disease. However, a number of studies 
indicate that several cellular changes occur following BCDT that might not be due to changes 
in antibody levels (290).  
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1.7.1 Summary 
SLE is a heterogeneous and unpredictable disease. It is defined by the presence of antinuclear 
antibodies in the serum and immune complexes in non-lymphoid tissue, although the target 
tissue can vary between patients. Current understanding of the pathogenesis is that apoptotic 
antigen stimulates PDCs to make cytokines, which activate T cells and then B cell 
differentiation into autoantibody-producing plasma cells (Figure 1.6.1). However, there is a 
lack of evidence of a clear causal and temporal relationship between circulating antibodies 
and the inflammation in the tissue, with the possible exception of anti-dsDNA antibodies and 
glomerulonephritis, suggesting that an additional process or ‘hit’ is also required for disease. 
There are two specific questions regarding how antibodies/ immune complexes deposit in the 
tissue that have not been clearly explained; firstly, where are the autoantibody secreting 
plasma cells formed and if they originate in SLOs how do the antibodies that they secrete 
cross the vascular endothelium? B and T cells interact with each other and they both have 
functions that are not directly related to the production of antibodies. These functions might 
explain where antibodies are made and how they get into the tissue. The kinetics of this 
process might explain the period of ‘benign autoimmunity’. By examining the interactions 
between B and T cells and by appreciating both their antibody-dependent and independent 
functions, it should also be possible to get a better understanding of the disease and the 
differences in the response to therapies, including BCDT. 
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2 HYPOTHESIS 
2.1.1 Hypothesis 
During the period of benign autoimmunity, one or many active events occur that eventually 
lead to inflammation in the tissue, which is often characterized by the presence of immune 
complexes and complement. An additional ‘hit’ that either controls the production of 
antibodies inside the tissue or the dysregulation of the vascular endothelium is probably 
required. I hypothesize that that this additional process is mediated by an antibody-
independent function of B cells.  
Rituximab therapy offers an opportunity to examine the serological and cellular changes that 
occur in the circulation and tissue as B cells are first depleted and then repopulate and would 
help to identify the sequence of events that lead to the production of pathogenic 
autoantibodies and/or the dysregulation of the vascular endothelium. 
2.1.2 Aims of this study 
1. To establish the sequence of events that lead from remission (‘benign autoimmunity’) 
to disease by correlating the immunological events that occur as B cells repopulate 
following rituximab therapy with new symptoms and clinical events. 
2. To identify factors that influence B cell repopulation following rituximab therapy. 
3. To determine whether B cells interact with other cells in the immune system, in 
particular CD4+ T cells, and where in the body these interactions occur. 
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3 METHODS 
3.1.1 Samples 
Blood samples were obtained from patients who attended the clinic for autoimmune 
rheumatic disease at University College London Hospital (UCLH).  Patients were defined as 
having SLE if they fulfilled the ACR revised classification criteria for SLE (101). Healthy 
control samples were obtained from colleagues at the Windeyer Institute for Medical 
Research and medical students from University College London. Blood was obtained by 
consent with approval from the local ethics committee.  
40mls of blood was collected into a 50ml plastic Falcon tube containing 100µl of heparin, 
4mls of blood was collected into a BD vacutainer serum tube containing a clot activator and 
gel for separation and which was coated with silicone and another 4mls of blood was 
collected into a BD vacutainer whole blood tube containing 7.2mg K2 
ethylenediaminetetraacetic acid (EDTA). 
3.1.2 Assessment of disease activity 
Disease activity of the patients with SLE was assessed using the British Isles Lupus 
Assessment Group (BILAG) index. This is a composite scoring system developed to assess 
disease activity in patients with SLE who invariably have heterogeneous symptoms and 
mutliple organ involvement. It has also been developed to discriminate between an active on-
going disease process and longstanding damage in the specific affected organs. It was 
established to offer more than just a global score assessment of disease activity in SLE and 
was based on the priniciple of the physician’s ‘intention to treat’. Various studies have shown 
that the BILAG index has good inter-rater and within-rater reliability and valid when 
compared to the ‘gold standard’ criterion, which is the intention to treat, with an overall 
sensitivity of 87% and specificity of 99% (451). There is also a high positive predictive value 
overall of 80%, and for each-organ based system, with the exception of the neurological 
system. It has been compared to other scoring systems, such as the SLAM and SLEDAI, and 
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has been found to be the most sensitive instrument for measuring fluctuations in disease 
activity following the commencement of specific therapy (452, 453). It is therefore the best 
instrument for measuring individual responses to BCDT.  
The clinical features, which make up the majority of the assessment, were recorded 
independently by the physicians in the rheumatology clinic. Patients attended on average 
every 2 months. They were asked in detail about their symptoms, had a physical examination 
including a blood pressure measurement and a urine analysis for protein levels and had blood 
tests. These tests included a full blood count with white blood cell differential, urea, 
creatinine and electrolyte levels, liver function tests, an erythrocyte sedimentation rate, 
complement-3 (C3) and anti-dsDNA antibody levels. If indicated, blood tests are also carried 
out for muscle enzymes, a direct Coombs’ test, anti-cardiolipin antibodies and circulating 
anticoagulant, amongst others. Additional tests such as a chest x-ray, pulmonary function, 
nerve conduction, urine microscopy, muscle, lung or kidney biopsy and magnetic resonance 
scans were also requested if clinically indicated. The clinical data for each individual organ-
based system are recorded on a BILAG assessment form (appendix 1). The results of the 
relatively few blood tests required for the BILAG assessment were added later by the clinic 
nurse. Eight organ-based systems are included on the form; general, mucocutaneous, nervous 
system, musculoskeletal, cardiorespiratory, vascular, renal and haematology. The data were 
entered by the clinic nurse onto a computer, which determines the BILAG scores/grades. A 
grade is thus assigned to each organ-based system depending on the results of the clinical 
assessment; A denotes disease considered sufficiently active to require high dose steroids 
(intravenous methylprednisolone/ oral prednisolone > 20mg daily) or an increase in the 
immunosuppressant medication, B denotes less active disease with mild symptoms that can 
be corrected with symptomatic therapy such as anti-malarials, non-steroidal anti-
inflammatory drugs or a low dose of steroids, C denotes stable mild disease, D denotes 
system previously affected but currently inactive and E denotes system never involved. A 
numerical score can be allocated to each category; A equals 9, B is 3, C is 1 and both D and E 
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are 0. A global score is calculated by adding all of the scores given to each organ-system. 
Active disease is considered to be denoted by a BILAG score of greater than 6. Flare was 
defined as any new grade A or two new Bs. 
Although they do not affect the BILAG score, tests were also requested for erythrocyte 
sedimentation rate, C3 levels (measured by laser nephelometry) (normal = 0.9 to 1.8 ng/ml) 
and dsDNA antibody levels (measured by ELISA; Shield Diagnostics Dundee, UK) (normal 
< 50 Units/ml) as these are also indicative of active disease. However, these tests are not 
useful for all patients as many patients have active disease despite having normal levels of 
these markers (132) and vice versa (454). Antibodies to extractable nuclear antigens are 
assessed once every two years approximately, but exact titres are not calculated as these 
typically do not change or correlate with disease activity. 
3.1.3 B cell depletion therapy 
Between June 2000 and September 2010 79 patients were treated with BCDT in the 
department for rheumatology at UCLH. Patients were referred for BCDT by the clinicians at 
UCLH either if they had not responded to conventional immunosuppressants (azathioprine, 
mycophenolate mofetil, methotrexate, cyclosporin and/or cyclophosphamide) or developed 
unwanted side effects (75 patients) or if they presented de novo to the rheumatology clinic 
without previous use of immunosuppressants (4 patients). 
BCDT consisted of an infusion of 100-250mg methylprednisolone followed by an infusion of 
1 gram of rituximab, repeated after 14 days. Most patients were also given an infusion of 
500mg to 750mg cyclophosphamide the day after the infusion of rituximab, or in the case of 
the newly diagnosed patients, started on additional oral immunosuppression with 
azathioprine. Patients continued on lowering doses of prednisolone and hydroxychloroquine 
(400mg once a day) if they were taking them prior to BCDT. 
The circulating numbers of total lymphocytes, B cells, T cells and monocytes were measured 
at the haematology laboratory at UCLH. Complement levels were measured in the 
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biochemistry laboratory and autoantibody levels were measured in the immunology 
laboratory. 
 
3.2.1 Separation of PBMCs 
PBMCs were extracted by layering the blood gently onto Ficoll Hypaque at a dilution of 2:1 
into a 50 ml Falcon tube. The tubes containing the blood were then centrifuged at 850rpm for 
35 minutes at 20°C. The resulting leukocyte layer was then extracted using a Pasteur pipette, 
transferred to another Falcon tube and then made up to 50mls with RPMI. They were then 
centrifuged again at 500rpm for 12 minutes at 8°C. The supernatant was poured out and the 
pellet was gently resuspended in 10mls of RPMI. The cells were counted and 5 x 105 PBMCs 
would then be plated into 300µl U-shaped wells in 96 well plates for ex vivo analyses. The 
remaining cells were centrifuged again at 500rpm for 12 minutes at 8°C. The supernatant was 
poured away and the resulting pellet was resuspended in freezing medium (foetal calf serum 
(FCS) with 10% dimethyl sulphoxide (DMSO)) at a concentration of 1 x 107/ml in 1 ml 
cryovials (Nunc™). The cryovials were stored at –80°C. When the cells were required for use 
they were thawed in a 37°C waterbath and washed twice in 10 mls of 1 x phosphate buffered 
saline (PBS). 
3.2.2 Serum extraction 
Blood obtained in the serum tube was left to stand for 30 minutes. The tube was then 
centrifuged for 10 minutes at 1000 rpm. The supernatant was then extracted and stored in 2 
ml cryovials at –80°C. 
3.2.3 Depletion and isolation of B cells from PBMCs 
B cells were depleted from the PBMCs prior to culture. PBMCs were first washed in 1 x PBS 
and then divided into two equal aliquots. One aliquot was then spun down and resuspended in 
100 to 200 µl of 1xPBS and labelled with antibodies that bound to CD19 attached to magnetic 
MicroBeads (Miltenyi Biotec, Cat no. 130-050-301) by incubating the cells with the 
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antibodies for 20 minutes at 4°C. They were then washed twice in 2 mls of 1xPBS and then 
resuspended in 1 ml of 1 x PBS. An LD column (Miltenyi Biotec) that had been pre-cooled to 
–20°C was then suspended on a MidiMACS separator (Miltenyi Biotec). The separator 
contained a magnet to attract the cells bound to magnetic MicroBeads and allows non-bound 
cells to continue to flow through the column. The LD column was prepared by gently 
pipetting 1 ml of 1 x PBS onto the column. The solution was collected in a plastic falcon tube. 
Once this solution had passed through the column the 1ml cell suspension was then also 
gently pipetted onto the column. Again the suspension was collected in the plastic falcon 
tube. After the suspension was collected in the tube a further 2 mls of 1 x PBS were added to 
the LD column, 1 ml at a time to wash any remaining unlabelled cells out of the column. 
Once all of the cells had been collected the cell suspensions were washed twice in 5mls of 
complete medium and then resuspended in complete medium at a concentration of 1.5 x 106 
cells/ml. 
In separate experiments, B cells were isolated from PBMCs by negative selection using a B 
cell isolation kit containing a cocktail of biotin-conjugated antibodies against CD2, CD14, 
CD16, CD36, CD43, CD235a (Glycophorin A), i.e. surface markers that are not expressed by 
B cells, and anti-biotin MicroBeads (Miltenyi Biotec, Cat No. 130-091-151). The cells were 
first labeled with the antibodies by incubating them together for 5 minutes at 4°C and then 
incubated with the anti-biotin MicroBeads for an additional 10 minutes at 4°C. The cells were 
then suspended in 500 ml of 1 x PBS and then passed through an LS column using the same 
method described above. 
3.2.4 Counting of PBMCs for in vitro studies 
PBMCs for in vitro studies were counted using a haemocytometer. 10 µl of the cell 
suspension was diluted in trypan blue solution in a 1:2 dilution. 10 µl of the cell/trypan blue 
suspension was then counted on a haemocytometer, which contained a 5x5 grid. Dead cells 
were detected by increased intracellular staining with trypan blue. Live cells were counted 
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within the grid using a microscope and multiplied by the dilution of the suspension in trypan 
blue and then by the dilution in medium/1 x PBS to determine the total number of cells 
obtained. 
3.2.5 Cell culture and reagents 
3 x 105 PBMCs were cultured in 200 µl complete medium (containing RPMI 1640 with 10% 
FCS and 1% penicillin and streptomycin) in 300 µl U-shaped wells in 96 well plates. The 
cells were stimulated with either CpG ODN 2006 (Autogen Bioclear; Cat. no. tlrl-hodnb), 
goat F(ab’)2 anti-human IgM, (Southern Biotech, Cat. No. 2022-14) or goat F(ab’)2 anti-
human Ig (IgM, IgG and IgA) (Southern Biotech, Cat. No. 2012-01) with goat F(ab’)2 anti-
human IgD (Southern Biotech, Cat. No. 2032-01). Endotoxin-free plasmid DNA (pcDNA3.1; 
Invitrogen) was provided by Jane Samuel (post-doctoral researcher at UCL). B and T cell 
interactions were inhibited using functional grade purified human anti-CD2 antibody 
(ebioscience, Cat. No. 16-0029-85).  
Once the cells had been cultured for an adequate period of time the supernatants were gently 
extracted and stored at –20°C until required for chemokine analysis or the cells were stained 
for flow cytometric analysis. 
3.2.6 Flow cytometry 
Cells were stained for surface markers for flow cytometric analysis in 96 well plates. First 
they were washed three times with 200 µl of FACS buffer (1xPBS with 0.1% sodium azide 
and 1% FCS). They were then incubated with colour-conjugated antibodies for the markers in 
Table 3.2.1 and refrigerated in the dark at 4 to 8°C for 30 minutes. They were then washed 
three more times in FACS buffer to remove excess antibody before being fixed in 100 µl of 
2% parafomaldehyde. The cells were then diluted in sheath buffer and the expression of the 
cell markers were recorded on a BD FACSCalibur or BD LSR platform using Cellquest 
software. The data were analysed using FlowJo software. 
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Immunogen Colour 1 Colour 2 Colour 3 
CD19 PE (ebioscience) PE-Cy7 (ebioscience) APC (ebioscience) 
IgD FITC (BD)   
CD27 PE (BD)   
CD4 FITC (ebioscience) APC (BD)  
CD69 PE (BD) PE-Cy7 (BD)  
HLA-DR FITC (BD) PE (BD)  
CD49d APC (BD)   
CD45RA PE (BD) PE-Cy5 (BD)  
CD62L FITC (BD)   
CXCR3 PE-Cy5 (BD)   
CCR4 PE-Cy7   
CCR5 FITC (BD)   
CCR7 PE-Cy7 (BD)   
Table 3.2.1 – Antibody reagents for flow cytometry.  
Abbreviations – FITC (fluorescein isothiocyanate), PE (phycoerythrin), PE-Cy5 
(phycoerythrin-cyanine 5), PE-Cy7 (phycoerythrin-cyanine 7), APC (allophycocyanin) 
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3.2.7 Gating 
The gating of lymphocytes is illustrated in Figure 3.2.1. B cells were subsequently identified 
by the high expression of the surface marker CD19. T cells were identified by the high 
expression of the surface marker CD4. 
 
 
 
 
Figure 3.2.1 – Gating of lymphocytes 
Representative flow cytometric dot-plots showing the gating of live lymphocytes in the 
PBMCs of a patient with SLE prior to BCDT (A) and the CD4 and CD19 subsets within the 
live lymphocyte gate (B). Values shown are the percentage of cells within the gate. 
 
3.2.8 Cytometric Bead Array 
Chemokine levels in the serum and supernatants were measured by cytometric bead array 
(CBA) using a Human Chemokine Kit (BD, Cat. No. 552990) according to the manufacturers 
protocol. First a vial of lyophilized Human Chemokine Standards was reconstituted with 4 ml 
of assay diluent, gently mixed and left at room temperature for 15 minutes to equilibrate. The 
assay diluent with reconstituted protein was then serially diluted nine times. One tube 
containing only the assay diluent was prepared to serve as the negative control. The 
chemokine capture beads were then mixed by adding an aliquot (10 µl per test) from each vial 
into a single tube and vortexed thoroughly. 50 µl of the capture bead mixture was added to 
each assay tube with 50 µl of the assay diluent (negative control), standard dilutions or the 
sample being tested, followed by 50 µl the chemokine PE detection reagent. The assay tubes 
were incubated for 3 hours at room temperature in a dark cupboard and wrapped in 
aluminium foil to protect it from light. Afterwards 1 ml of wash buffer was added to each 
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assay tube and the tubes were then centrifuged at 200 g for 5 minutes. The supernatant from 
each assay tube was then aspirated and discarded. The bead pellets were resuspended in 300 
ml of wash buffer. The samples were acquired on a BD FACSArray and then analysed using 
FCAP Array software. 
 
3.3.1 Statistical analyses  
Statistical analyses were carried out using GraphPad Prism 4 Version 4.0c software for results 
chapter 5.1 and GraphPad Prism 6 Version 6.0b software for results chapters 5.2, 5.5, 5.6 and 
5.7.  A p value of < 0.05 was considered significant. 
Chapter 5.1 
Wilcoxon signed-rank test was used to compare paired data before and after BCDT. Mann–
Whitney test was used to compare unpaired data between groups. Kaplan–Meier curves were 
generated to compare time to B-cell repopulation. Log rank test was used to examine 
differences between the curves. Associations between the changes in anti-dsDNA antibody 
levels and duration of B cell depletion were tested by Pearson’s correlation coefficient (rp) for 
linear relationships. Lines of best fit were estimated by regression analysis. Fisher's exact test 
was used to determine the association of renal disease and raised anti-dsDNA antibody levels.  
Chapter 5.2 
Wilcoxon signed-rank test was used to compare paired data before and after BCDT. Mann–
Whitney test was used to compare unpaired data between groups. Associations between B and 
T cell subsets were tested by Pearson’s correlation coefficient (rp) for linear relationships and 
Spearman’s rank correlation coefficient (rs) for non-linear relationships. Lines of best fit were 
estimated by regression analysis. Changes in B cell numbers after BCDT were estimated 
using non-linear regression and the differences between groups were tested by repeated 
measure ANOVA using the extra sum-of-squares F test. Kaplan–Meier curves were generated 
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to compare time to clinical relapse. Log rank test for trend was used to examine differences 
between the curves.  
Chapter 5.5 
Wilcoxon signed-rank test or paired t-test was used to compare paired data before and after 
BCDT and before and after stimulation of PBMCs in vitro and Mann–Whitney test was used 
to compare unpaired data between groups. Associations between HLA-DR expression by 
CD4+ T cells and CD4+ T cell numbers were tested by Spearman’s rank correlation 
coefficient (rs) for non-linear relationships. 
Chapter 5.6 
Two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test was 
used to compare the means between the groups. One-way ANOVA was used to compare 
trends between groups. Mann-Whitney test was used to compare groups with data from 
healthy controls. Kaplan-Meier estimates were used to determine the median time to clinical 
relapse following BCDT. 
Chapter 5.7 
Associations between anti-dsDNA antibody and chemokine levels were tested by Pearson’s 
correlation coefficient (rp) for linear relationships. Two-way ANOVA followed by Sidak’s 
multiple comparisons test was used to compare data between groups of patients treated with 
BCDT. Paired t-test was used to compare paired data before and after BCDT. Wilcoxon 
signed-rank test was used to compare paired data before and after stimulation of PBMCs and 
B cells in vitro and Mann–Whitney test was used to compare unpaired data between groups. 
All data that was obtained from patients that attended the research phlebotomy clinic were 
included in the analyses in this thesis. Missing data were either a result of patients being lost 
to follow-up or non-attendance at the research phlebotomy clinic. 
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4 PATIENTS 
4.1.1 Patients 
Data were obtained from 71 of the 79 patients who were treated with BCDT in the department 
of adult rheumatology at UCLH and eight patients who were treated in other departments at 
UCLH or other hospitals in London or Birmingham between June 2000 and September 2010. 
Clinical data for these patients are shown in Table 4.1.1 and summarized in Table 4.1.2. One 
patient died four months after BCDT from myocarditis, approximately one month after her B 
cells returned (patient 23). Three patients died at least 18 months after the first cycle of 
BCDT (one from peritonitis (patient 5) and two from suicide (patients 38 and 70)). Eight of 
the 79 patients who were treated with BCDT in the department of adult rheumatology at 
UCLH were not included in the study because of the following reasons; there was insufficient 
data available and they were lost to follow-up prior to the commencement of my PhD (five 
patients), they were followed-up in other departments (two patients) and one patient died two 
weeks after BCDT was initiated because of a reaction to cyclophosphamide. 
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ID Ethnicity Gender Organ involvement Previous treatment Age at 
diagnosis 
Age at 
BCDT 
Cyc with 
BCDT* 
2 W F 
arthritis, serositis, skin 
vasculitis pred, hcq, mtx, cya 28 35 
 
yes 
3 W F 
arthritis, serositis, 
lymphadenopathy pred, hcq, mtx, aza, cya 26 36 
 
yes 
5 AC F 
arthritis, serositis, 
nephritis(IV), skin vasculitis  pred, hcq, aza, cyc, mmf 13 18 
 
yes 
6 W F arthritis, nephritis(IV), rash pred, hcq, aza, cyc  9 20 yes 
9 A M 
arthritis, serositis, nephritis 
(IV) pred, aza, cyc 15 26 
no 
10 AC F arthritis, nephritis (IV), rash pred, hcq, aza, cyc, mmf 15 30 yes 
11 O F 
fever, rash, serositis, nephritis 
(IV), neuropsychiatric pred, aza, cyc, cya, mmf 11 27 
 
yes 
12 AC F arthritis, nephritis (IV) pred, hcq, cyc 31 38 no 
13 W F fever, arthritis, nephritis (IV) pred, hcq, aza, cyc 15 18 yes 
14 W F TCP pred, hcq, aza 20 26 yes 
15 W F 
fever, arthritis, CNS vasculitis, 
nephritis (IV) pred, aza, cyc, mmf 15 19 
 
yes 
16 AC M 
haemolytic anaemia, nephritis 
(IV) pred, aza, cyc 16 23 
 
yes 
17 W/O F nephritis (IV) pred, aza, cyc, mmf 20 21 yes 
19 W F 
fever, arthritis, nephritis (IV), 
rash pred, hcq, aza, cyc, mmf 20 31 
 
yes 
21 AC F arthritis pred, hcq, mtx, aza, cyc,  37 40 yes 
22 W F arthritis, nephritis (IV) pred, hcq, aza, cyc 26 31 yes 
23 AC F 
fever, arthritis, nephritis (IV), 
organic brain syndrome pred, hcq, aza, cyc 23 24 
 
yes 
24 A F 
fever, arthritis, serositis, skin 
vasculitis pred, hcq, mtx, aza, cyc 16 35 
 
yes 
25 A F fever, rash, arthritis, anaemia pred, hcq, mtx, aza, cyc 19 33 yes 
26 W F 
arthritis, nephritis (IV), gut 
vasculitis pred, cyc, mepacrine 17 36 
 
yes 
27 O F rash, nephritis (IV) pred, hcq, mmf 29 33 yes 
28 W F 
photosensitivity, arthritis, 
serositis pred, hcq, mtx, aza, cyc 17 42 
 
no 
29 A F 
mouth ulcers, alopecia, 
arthritis, serositis pred, hcq, mtx, ssz, TNF 34 35 
 
yes 
30 W F 
arthritis, serositis, myositis, 
nephritis (IV) pred, hcq, mtx, aza, ssz, IVIG 23 33 
 
yes 
31 W F TCP pred, hcq 27 30 yes 
32 AC F arthritis, ILD pred, hcq, mtx, lfn N/A 49 no 
33 W F 
arthritis, pancytopaenia, 
nephritis (IV) pred, hcq, aza, mmf 16 17 
 
yes 
34 W F arthritis, nephritis (IV) pred, hcq, mtx, aza 13 22 yes 
35 A F arthritis, nephritis (IV) pred, aza, mmf, cyc 18 21 yes 
36 O F arthritis pred, ssz, aza, mtx 20 23 no 
38 A F 
arthritis, neuropsychiatric, 
nephritis (II) pred, mmf, mepacrine 36 39 
 
yes 
39 AC F arthritis, fatigue pred, hcq, mtx, 31 57 no 
40 W F skin vasculitis, TCP pred, hcq 17 41 no 
41 A F arthritis, rash, serositis pred, hcq, mtx, cya 19 21 yes 
42 A F arthritis, nephritis (IV) pred, aza, mmf 43 51 yes 
43 A F 
discoid rash, scarring alopecia, 
APS  pred, hcq, mtx  20 36 
 
yes 
44 O F APS (PE, DVT), nephritis (IV) pred, mmf, cyc 22 47 N/A 
45 A F neuropsychiatric  pred, hcq, aza, cyc, mmf 23 33 yes 
46 W F arthritis, serositis, nephritis pred, hcq, mmf, cyc 43 49 N/A 
47 A F arthritis, discoid rash pred, hcq, aza 14 27 N/A 
48 A F 
arthritis, rash, neuropsychiatric 
(epilepsy) pred, hcq, aza,  27 29 
 
yes 
49 AC F arthritis, rash, nephritis pred, aza 37 50 yes 
51 W F 
rash, nephritis, gut vasculitis, 
pulmonary haemorrhage pred 41 53 
 
yes 
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ID Ethnicity Gender Organ involvement Previous treatment Age at 
diagnosis 
Age at 
BCDT 
Cyc with 
BCDT* 
52 W F rash, arthritis, myositis pred, mtx 33 49 no 
53 A F 
arthritis, rash, alopecia, 
serositis, haemolytic anaemia hcq, aza, pred 14 24 
 
yes 
54 AC/A F arthritis, rash, nephritis pred, aza, cyc 18 46 yes 
55 A F arthritis, gut vasculitis pred, ssz, mtx 27 27 no 
56 W M 
nephritis, mouth ulcers, rash, 
alopecia pred, cyc, mmf 35 40 
 
yes 
57 AC F 
arthritis, rash, neuropsychiatric, 
TCP pred, aza, cyc 28 33 
 
yes 
58 W F rash, arthritis pred, aza, mtx, mmf 50 57 no 
59 W F arthritis, rash, nephritis (III, V) pred, aza, mepacrine, mmf 30 49 
 
yes 
60 W M rash, arthritis pred, aza, mtx 23 40 yes 
61 A F 
arthritis, alopecia, haemolytic 
anaemia pred 10 23 
 
yes 
62 AC F arthritis, rash none 47 48 yes 
63 AC F arthritis, serositis, rash hcq, pred, aza 38 47 yes 
64 W M rash, arthritis, nephritis pred, cyc, mmf 12 25 yes 
65 O F arthritis, alopecia hcq 27 27 no 
66 A F arthritis, rash, nephritis (IV)  24 28 yes 
67 AC F arthritis, nephritis pred, aza 24 28 yes 
68 AC F 
arthritis, discoid rash, alopecia, 
nephritis (V), serositis pred, mtx 18 22 
 
no 
69 W F 
arthritis, serositis, rash, mouth 
ulcers pred, aza 34 45 
 
yes 
70 O F arthritis, rash none 21 21 no 
71 AC F 
arthritis, serositis, mouth 
ulcers, nephritis pred, hcq, aza, mtx 21 24 
 
yes 
72 W F arthritis, rash pred, hcq, aza, mtx 44 55 yes 
73 AC/W F fever, arthritis, rash pred, hcq, aza, cyc 26 28 yes 
74 A F nephritis, arthritis, fever pred 25 25 yes 
75 W M arthritis  pred, mtx 66 73 yes 
76 A F 
arthritis, alopecia, mouth 
ulcers, nephritis (III + V), skin 
vasculitis pred, aza 29 50 
 
 
N/A 
77 AC F 
rash, arthritis, alopecia, PE 
(APS negative), 
lymphadenopathy hcq, pred, aza 8 21 
 
 
N/A 
78 A F 
arthritis, rash, serositis, 
myositis, skin vasculitis pred 14 24 
 
yes 
79 W F arthritis, serositis  39 39 yes 
A W F arthritis, APS, TCP N/A 59 N/A N/A 
B W F 
arthritis, rash, TCP, nephritis 
(IV) pred, aza, cyc 32 N/A 
 
N/A 
C W F rash, arthritis N/A 18 N/A N/A 
 
D 
 
A 
 
M 
arthritis, rash, ILD, nephritis 
(V), myositis 
 
N/A 
 
18 
 
18 
 
yes 
E AC M rash, nephritis (V) pred, aza, cyc 24 27 N/A 
F A F 
arthritis, rash, alopecia, 
serositis, nephritis (II) hcq, pred 7 14 
 
yes 
G AC F 
rash, alopecia, TCP, arthritis, 
fever pred 13 13 
 
yes 
H AC F arthritis, rash, nephritis (III, V) N/A 19 N/A N/A 
Table 4.1.1 – Baseline characteristics of patients with SLE treated with BCDT 
The abbreviations are explained on the next page  
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Abbreviations for Table 4.1.1: 
A (South Asian), AC (Afro-Caribbean), O (Oriental/ Far East Asian), W (White/ Caucasian), 
F (female), M (male), CNS (central nervous system), MRI (magnetic resonance imaging), 
APS (anti-phospholipid syndrome), DVT (deep vein thrombosis), PE (pulmonary embolus), 
TCP (thrombocytopaenia), ILD (interstital lung disease, pred (prednisolone/corticosteroid), 
LN (lymphadenopathy) aza (azathioprine), hcq (hydroxychloroquine), mtx (methotrexate), 
cyc (cyclophosphamide), mmf (mycophenolate mofetil), ssz (sulphasalazine), cya 
(cyclosporine), IVIG (intravenous immunoglobulin), lfn (leflunomide), TNF (anti-tumour 
necrosis factor), N/A (data not available). 
Lupus nephritis classification: I = minimal mesangial, II = mesangial proliferative, III = focal 
proliferative, IV = diffuse proliferative, V = membranous 
Patients 2 to 79 were treated with BCDT in the department for rheumatology at UCLH. 
Patients A to H were treated with BCDT in the department for haematology at UCLH (patient 
A), the department for adolescent rheumatology at UCLH (patients D, F and G) or in other 
hospitals within London (patients B, C and E) or Birmingham (patient H). Some baseline and 
follow-up data from patients A to H are therefore not known. 
*Refers to whether cyclophosphamide was given with rituximab during the patient’s first 
cycle of BCDT. Treatment regimens with subsequent cycles of BCDT were sometimes 
adjusted.   
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Table 4.1.2 – Summary of baseline characteristics of patients with SLE treated with 
BCDT  
Age	  at	  diagnosis:	  	  mean	  (range,	  number)	   24.8	  (7	  –	  66,	  78)	  
Age	  at	  BCDT:	  mean	  (range,	  number)	   33.3	  (13	  -­‐73,	  75)	  	   	  
Gender:	   Female	  Male	   Number/	  79	   Percentage	  71	  	   89.9	  8	   10.1	  	  
Ethnicity:	   Caucasian	  South	  Asian	  Afro-­‐Caribbean	  Far	  East	  Asian	  Mixed	  
Number/	  79	   Percentage	  30	   38.0	  21	   26.6	  19	   24.1	  6	   7.6	  3	   3.8	  	  
Organ	  involvement:	  Arthritis	  Renal	  Rash	  Serositis	  Cytopaenia	  Alopecia	  Neuropsychiatric	  Skin	  vasculitis	  Gut	  vasculitis	  CNS	  vasculitis	  Pulmonary	  haemorrhage	  Interstitial	  lung	  disease	  Myositis	  Fever	  Antiphospholipid	  syndrome	  
Number/	  79	   Percentage	  66	   83.5	  39	   49.4	  38	   48.1	  19	   24.1	  12	   15.2	  11	   13.9	  6	   7.6	  6	   7.6	  3	   3.8	  1	   1.3	  1	   1.3	  2	   2.5	  4	   5.1	  10	   12.7	  3	   3.8	  	  
Cyclophosphamide	  with	  
first	  cycle	  of	  BCDT:	   Yes	  No	  Data	  not	  available	  
	  
Number/	  79	  
	  
Percentage	  56	   70.9	  13	   16.5	  10	   12.7	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5 RESULTS 
5.1 B-cell numbers and phenotype at clinical relapse following BCDT 
differ according to anti-dsDNA antibody levels. 
5.1.1 Introduction  
It was hypothesized that if B cells have an important role in SLE then early relapse following 
BCDT would be associated with faster rates of B cell repopulation. It was also hypothesized 
that differences in the time to relapse and the number of B cells and B cell phenotype 
associated with relapse would vary depending on anti-dsDNA antibody levels. Therefore, the 
first aim of this study was to examine changes in B cell numbers in patients with SLE 
following BCDT.  
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5.1.2 Results 
A more rapid rate of B-cell repopulation in patients who relapse earlier 
The median B-cell number before treatment was 0.122  ×  109/l (range 0.010–0.679  ×  109/l). 
Following BCDT all patients achieved B-cell depletion, defined as a B-cell count of 
<0.01  ×  109/l. A Kaplan-Meier analysis showed that the median time to repopulation (defined 
as a B-cell count of >0.01  ×  109 B cells/l) following BCDT was 32 weeks and to clinical 
relapse (defined as a new BILAG A score or two new Bs) was 66 weeks. The rate of 
repopulation was greater than the rate of relapse (p  <  0.001, log-rank test) (Figure 5.1.1A). 
To examine whether early repopulation was associated with early relapse, patients were 
divided into three groups according to whether they repopulated before 16 weeks (n  =  10), 
between weeks 16 and 32 (n  =  22), or after 32 weeks (n  =  29). A Kaplan–Meier analysis 
showed that early repopulation was associated with early relapse (p  =  0.0002, log-rank test) 
(Figure 5.1.1B). Furthermore, 39 and 45% of patients had inactive disease for >2 years in the 
group of patients that repopulated between 16 and 32 weeks, and after 32 weeks, respectively, 
compared with only 10% of patients who repopulated before 16 weeks. 
Higher B-cell numbers can be seen as early as 8 weeks following BCDT in those patients who 
relapsed early (defined as occurring before 18 months, n  =  37) compared with patients who 
relapsed late (>18 months, or remain in remission, n  =  24) (p  =  0.0008, Mann-Whitney U test) 
(Figure 5.1.1C). 
B-cell numbers at relapse differ according to anti-dsDNA antibody levels 
B-cell numbers at relapse were lower than the B-cell numbers at baseline (p  =  0.006, Mann-
Whitney U test) (Figure 5.1.2A). Two distinct patient groups were identified based on anti-
dsDNA antibody levels; one with high levels (>100  IU/l, n  =  17) where relapse occurred with 
low B-cell numbers and a second with low or normal levels (<100  IU/l, n  =  20) where relapse 
occurred with normal or high B-cell numbers (Figure 5.1.2B). Thus patients with levels of 
anti-dsDNA antibodies >100  IU/l relapsed with lower B-cell numbers than patients with low 
or normal levels of anti-dsDNA antibodies (p  =  0.02, Mann-Whitney U test). However, 
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patients with high levels of anti-dsDNA antibody levels at baseline do not relapse earlier even 
though they relapse with fewer B cells. There was no correlation between B-cell numbers and 
C3 levels (data not shown). 
I next analysed whether anti-dsDNA antibody levels modified the association between earlier 
disease relapse and a faster rate of repopulation as shown in Figure 5.1.1. There is not a clear 
definition of B cell repopulation in SLE and therefore two values were chosen for this study; 
a low value of 0.01 ×  109 B cells/l, because this was the lowest baseline value of the patients 
in this study and the median value used in three previous studies of BCDT in SLE (427, 428, 
435), and a high value of 0.11 ×  109 B cells/l, because this was the lowest value of the healthy 
controls used in this study (Figure 5.5.1B). Disease relapse before 18 months (early) was 
significantly associated with earlier repopulation to B cell numbers >0.01 ×  109 B cells/l in 
patients with high anti-dsDNA antibody levels (p  <  0.01, log-rank test) (Figure 5.1.2C), but 
not low or normal anti-dsDNA antbibody levels (Figure 5.1.2D). However, repopulation to B 
cell numbers >0.11  ×  109 B cells/l) did not occur any more rapidly in patients with high anti-
dsDNA antibody levels in earlier relapsers (Figure 5.1.2D). In contrast, patients with low or 
normal anti-dsDNA antibody levels who relapsed before 18 months attained B-cell numbers 
>0.11  ×  109 B cells/l more rapidly than patients who relapsed after 18 months with low anti-
dsDNA antibody levels (p  =  0.01, log-rank test) (Figure 5.1.2D). 
The difference in the median time to repopulation (>0.01  ×  109 B cells/l) between those 
patients with high anti-dsDNA antibody levels who relapsed early and those who relapsed 
later or remained in remission was 13 weeks (25 weeks in the early relapse group, 38 weeks 
in the late relapse/remained in remission group). Conversely, in patients with low levels of 
anti-dsDNA antibodies early relapse was not associated with more rapid repopulation to 
>0.01  ×  109 B cells/l. However, this latter group attained higher B-cell numbers (>0.11  ×  109 
B cells/l) earlier than patients who relapsed late or remained in remission. The difference in 
the median time to repopulation to this higher B-cell level between early and late 
relapse/remained in remission in patients with low anti-dsDNA levels was >58 weeks [48 
weeks (early) compared with >104 weeks (late)]. 
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A decrease in anti-dsDNA antibody levels was associated with remission in patients with 
high levels at baseline 
To determine whether changes in anti-dsDNA antibody levels correlated with clinical relapse 
following BCDT, levels of anti-dsDNA antibodies were analysed at four time points: 
baseline, B-cell depletion, B-cell repopulation and relapse/remission (Figure 5.1.3A). 
Remission was defined as no relapse within 12 months of repopulation. In patients with high 
levels of anti-dsDNA antibodies who remain in remission (n  =  9), there was a significant 
decrease in levels of anti-dsDNA antibodies between baseline and repopulation (p  <  0.01, 
Wilcoxon matched-pairs sign rank test). Despite this decrease, anti-dsDNA antibody levels 
remained significantly higher in these patients compared with those who had low or normal 
levels at baseline and remained in remission (n = 15) (p < 0.05, Mann-Whitney U test), but 
not with those who had low or normal levels at baseline and then relapsed (n = 20). Levels of 
anti-dsDNA antibodies did not fall at any time point in patients with high levels at baseline 
who relapsed (n  =  17), rather there was a significant increase in anti-dsDNA antibody levels 
associated with relapse (p  <  0.05, Wilcoxon matched-pairs sign rank test). Overall, there was 
a larger percentage decrease in the levels of anti-dsDNA antibodies in those patients who who 
had baseline levels >100  IU/l and remain in remission (n = 8) compared with those who 
relapsed (n = 14) (p = 0.01, Mann-Whitney U test) (Figure 5.1.3B). Correlating the decrease 
in anti-dsDNA antibody levels with the duration of B-cell depletion indicates that there was a 
greater decline in anti-dsDNA antibody levels the longer B cells remained  <  0.01  ×  109 B 
cells/l (n = 48) (rp  =  –0.41, p  =  0.003) (Figure 5.1.3C). 
Different B-cell phenotypes correlate with disease relapse 
Given that patients with high anti-dsDNA antibody levels relapsed with lower B-cell numbers 
than patients with low anti-dsDNA antibody levels, I hypothesized that there might be 
differences in B-cell subsets according to anti-dsDNA antibody levels in patients during 
relapse and remission. In a subset of patients (n  =  32), I analysed the different B-cell subsets 
in relapsing patients and those who remained in remission. As shown in Figure 5.1.4, patients 
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who had high anti-dsDNA antibody levels at relapse (n  =  6) also had increased percentages of 
IgD−CD27hi plasmablasts (p  <  0.01, Mann-Whitney U test) compared with patients who 
remained in remission (n  =  9). In contrast, patients who had low or normal levels of anti-
dsDNA antibodies had an increased percentage of IgD−CD27− (double negative) memory B 
cells at relapse (n  =  10) compared with patients who did not experience a disease flare (n  =  7) 
(p  =  0.01, Mann-Whitney U test). 
Cyclophosphamide is not associated with differences in the rate of B cell repopulation or 
the time to disease relapse 
Cyclophosphamide was given to most of the patients with rituximab as part of the BCDT 
treatment regimen. It is an alkylating agent that can affect bone marrow function (455). It was 
therefore hypothesized that it might affect the rate of B cell repopulation and/or the time to 
disease relapse. However, Figure 5.1.5A shows that the rate of B cell repopulation was not 
significantly different between patients that were treated with cyclophosphamide (n = 45) 
compared to patients that were not treated with cyclophosphamide (n = 11). Figure 5.1.5B 
shows that the time to disease relapse was also similar in patients that were treated with 
cyclophosphamide (n = 53) compared to patients that were not treated with 
cyclophosphamide (n = 12). These results support studies that showed that cyclophosphamide 
does not impair B-lymphopoiesis in mice (456), and that rituximab monotherapy is as 
effective as combination therapy with cyclophosphamide in lupus nephritis (457). It would 
therefore appear that other factors are influencing the rate of B cell repopulation and the 
mechanisms that cause disease relapse.    
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Figure 5.1.1 – The rate of B-cell repopulation compared with the time to clinical relapse 
in patients with SLE following treatment with rituximab therapy.  
(A) Kaplan–Meier curves comparing the time to B-cell repopulation [>0.01  ×  109 B cells/l] 
with the time to clinical relapse following treatment with rituximab therapy [n  =  61] and (B) 
comparing the clinical relapse rates in patients who repopulate before 16 weeks [n  =  10], 
between weeks 16 and 32 [n  =  22], and after 32 weeks [n  =  29]. Analysis was carried out 
using the log rank test. (C) B-cell numbers are shown from baseline to week 52 between 
patients who relapse before 18 months [early, n  =  37] after treatment and patients who relapse 
(or remain in remission) after 18 months [late, n  =  24]. Columns indicate the mean B-cell 
number and bars indicate the S.E.M. Differences between groups were analysed by the 
Mann–Whitney U test. 
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Figure 5.1.2 – B-cell numbers in rituximab-treated patients who relapse with low anti-
dsDNA antibody levels compared with those that relapse with high anti-dsDNA 
antibody levels  
(A) B-cell numbers at baseline [n = 38] and clinical relapse [n  =  36] and (B) B-cell numbers 
at baseline and relapse divided according to whether anti-dsDNA antibody levels were low 
[low (<100 IU/l); n = 22 (baseline), n  =  19 (relapse)] or high [high (>100  IU/l); n = 16 
(baseline), n  =  17 (relapse)] at relapse. Data are shown as dot-plots with lines representing the 
mean. Differences between groups were analysed by the Mann–Whitney U test. (C) Kaplan–
Meier curves comparing time to B-cell repopulation >0.01  ×  109 B cells/l and (D) >0.11  ×  109 
B cells/l in patients who relapse either before (early) or after 18 months (late) with baseline 
anti-dsDNA antibody levels that were low (<100 IU/l) [n = 17 (early), n = 17 (late)] or high 
(>100 IU/l) [n = 16 (early), n = 12 (late)]. Comparisons of the curves were carried out using 
the log-rank test. NS  =  p  >  0.05. 
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Figure 5.1.3 – Changes in anti-dsDNA antibody levels following BCDT in relapsing 
patients compared with those that remain in remission  
(A) Anti-dsDNA antibody levels are shown at baseline (B), during B-cell depletion (D), at B-
cell repopulation (R) and at remission (I) or clinical relapse (A) in patients who had anti-
dsDNA antibody levels that were low [Low (<100 IU/l); n  =  15 (remission), n  =  20 (relapse)] 
or high [High (>100  IU/l); n  =  9 (remission), n  =  17 (relapse)] at baseline. Columns indicate 
the mean; bars indicate the S.E.M. Differences between the groups were analysed by the 
Wilcoxon matched-pairs signed rank test (B) Percentage change in anti-dsDNA antibody 
levels after BCDT in patients with high levels at baseline that go into remission [n = 8] or 
relapse [n = 14] after B cells repopulate. Lines inside the boxes indicate the median; outer 
borders of the boxes indicate the 25th and 75th percentiles; bars extending from the boxes 
indicate the range. Differences between the groups were analysed by the Mann–Whitney U 
test. (C) Correlation between the change in anti-dsDNA antibody levels prior to B-cell 
repopulation and the time to B-cell repopulation [n = 48]. 
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Figure 5.1.4 – B-cell subsets at clinical relapse in patients divided according to anti-
dsDNA antibody levels 
Peripheral blood B cells (gated on CD19) were analysed by flow cytometry for the expression 
of IgD and CD27. Representative and cumulative data are shown. Percentages of 
plasmablasts (IgD−CD27hi) or double-negative memory B cells (IgD−CD27−) in age- and sex-
matched healthy controls [HC; n  =  19] and in patients who are in remission or relapse with 
anti-dsDNA antibody levels that are low [lo (<100 IU/l); n  =  7 (remission), n  =  10 (relapse)] 
or high [hi (>100  IU/l); n  =  9 (remission), n  =  6 (relapse)] are indicated. Data are shown as 
box plots. Lines inside boxes indicate the median; outer borders of boxes indicate the 25th and 
75th percentiles; bars extending from boxes indicate the range. Diffences between groups 
were analysed by Mann-Whitney U test. 
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Figure 5.1.5 – Time to B cell repopulation and disease relapse following BCDT in 
patients given cyclophosphamide with rituximab compared to patients not given 
cyclophosphamide with rituximab 
(A) Kaplan–Meier curves comparing time to B-cell repopulation >0.01  ×  109 B cells/l and 
>0.11  ×  109 B cells/l in patients given cyclophosphamide with rituximab [Cyc+; n = 45] and 
patients not given cyclophosphamide with rituximab [Cyc–; n = 11]. (B) Kaplan–Meier curve 
comparing time to disease relapse in patients given cyclophosphamide with rituximab [Cyc+; 
n = 53] and patients not given cyclophosphamide with rituximab [Cyc–; n = 12]. 
Comparisons of the curves were carried out using the log-rank test. NS  =  p  >  0.05. 
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5.1.3 Discussion 
Relapse following BCDT is associated with a combination of four key factors; differences in 
B cell repopulation rates, B cell numbers, two different B cell subsets and changes in anti-
dsDNA antibody levels. How the B cell repopulation rate and B cell numbers affect relapse 
appears to depend on the last two factors. For example, relapse in patients with low anti-
dsDNA antibody levels at the time of relapse appears to be partially dependent on the rate of 
repopulation of B cells to baseline levels and the main B cell is the IgD−CD27− B cell subset. 
The rate of relapse in patients with high anti-dsDNA antibody levels is partially determined 
by how quickly B cells repopulate to low numbers (>0.01  ×  109 B cells/l) and the B cell 
associated with disease is the plasmablast. However, an additional variable needs to be 
considered in this last group, which is that their anti-dsDNA antibody levels might fall and 
this is also associated with a lower likelihood of relapsing, as has been observed in a previous 
study (435).  
The data therefore identify three different groups; 
1. Patients with low anti-dsDNA antibody levels that relapse with IgD−CD27− B cells 
(or its precursor cell). The role of this B cell and its precursor cell are not known 
(Figure 5.1.6). 
2. Patients with high anti-dsDNA antibody levels, whose response is associated with a 
fall in the anti-dsDNA antibody levels. It is likely that relapse is associated with the 
repopulation of the anti-dsDNA antibody producing plasma cells. The mechanisms 
that mediate the re-emergence of these B cell clones and the associated antibody 
producing plasma cells are not known, but will be examined later in this thesis. 
3. Patients with high anti-dsDNA antibody levels that do not fall and in whom relapse is 
associated with low B cell numbers and plasmablasts. It has been suggested that anti-
ENA antibodies arise from long-lived plasma cells (LLPC) and anti-dsDNA 
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antibodies arise from short lived plasma cells (SLPC) (286), but these data show that 
in a subset of patients there are also LLPCs that produce anti-dsDNA antibodies.  
It is not known why some patients have SLPCs whilst others have LLPCs. Various 
mechanisms have been proposed for the differences in the lifespan of plasma cells, such as 
differences in where B and T cells interact, cytokine stimulation of B cells and where plasma 
cells find a survival niche, but most studies are from animal models and these mechanisms 
have not been proven in humans. 
The next two chapters will examine factors that influence B cell repopulation and 
differentiation towards either plasmablasts or IgD−CD27− B cells. Chapter 5.4 will then 
compare differences in histology between patients with low and high anti-dsDNA antibody 
levels. Chapter 5.5 will examine the mechanism of disease in patients with low anti-dsDNA 
antibody levels and the potential role of the IgD−CD27− B cell in the disease. Chapters 5.6 
and 5.7 will compare immunological and clinical factors between the three different patient 
groups separated according to their anti-dsDNA antibody levels as outlined above. 
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Figure 5.1.6 – Active SLE is associated with two B cell subsets 
Naïve B cells (BN) can differentiate into either plasmablasts or IgD–CD27– B cells (BDN). 
Plasmablasts, which differentiate into plasma cells (P), are associated with active disease after 
BCDT in patients with high anti-dsDNA antibody levels, but IgD–CD27– B cells are 
associated with active disease after BCDT in patients with low anti-dsDNA antibody levels. 
The role of IgD–CD27– B cells in SLE and the mechanisms that induce their differentiation 
have not been established. 
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5.2 Memory T cell subsets predict the rate of B cell repopulation following 
BCDT in SLE 
5.2.1 Introduction 
CD4+ T helper cells have been shown to have an important role in controlling the humoral 
immune response. However, they have also been shown to be important in the immune 
dyregulation that is seen in autoimmune diseases, which are often characterized by the 
presence of circulating autoantibodies.  
T cells go through progressive stages of differentiation, which can be identified by the 
expression of the surface receptors CD45RA, CD28, CD27 and CCR7 (59). CD4+ T cells that 
are CD28−CD27−CCR7− are considered to be the most terminally differentiated. CD45RA 
expression is mostly seen on naïve CD4+ T cells but can also be seen on a small population of 
terminally differentiated T cells. There is evidence of increased terminal differentiation of 
CD4+ T cells in several autoimmune diseases, including SLE (247, 248, 458), but the precise 
role of these memory T cells subsets in autoimmunity has not been fully elucidated. 
In the previous chapter it was shown that the rates of B cell repopulation following BCDT in 
SLE vary between patients. In addition, there are two different B cell phenotypes that are 
associated with clinical relapse; IgD−CD27hi plasmablasts, in patients that relapse with high 
anti-dsDNA antibody levels, and IgD−CD27− memory B cells, in patients that relapse with 
low anti-dsDNA antibody levels. Whilst IgD−CD27− B cells have been shown to be atypical 
memory B cells (238), it is not known whether they share the same B cell precursor and 
originate from the same differentiation pathway as IgD−CD27+ memory B cells and 
plasmablasts, which are associated with antibody production.  
CD4+ memory T cell subsets have been shown to have differing effects on antibody synthesis 
by healthy B cells (459). We hypothesized that different memory T cell subsets might be 
associated with differences in B cell expansion and differentiation and account for some of 
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the differences in clinical response that have been observed following BCDT in patients with 
SLE. 
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5.2.2 Results 
Memory T cell phenotypes do not change after BCDT 
In chapter 5.2.1 it was observed that patients with low anti-dsDNA antibody levels 
experienced clinical relapse after BCDT with higher B cell numbers and had a high 
percentage of IgD−CD27− memory B cells whilst patients with high anti-dsDNA antibody 
levels relapsed with lower B cell numbers and had a high percentage of IgD−CD27hi 
plasmablasts. I therefore examined whether there were differences in T cell memory 
phenotypes in patients with either high or low anti-dsDNA antibody levels and assessed 
whether they are affected by the presence of B cells by measuring changes after BCDT.  
Patients with active disease with low anti-dsDNA antibody levels (n = 16) had significantly 
lower percentages of naïve CD4+ T cells in the CD4+ T cell population than healthy controls 
(n = 19) (p < 0.01). There were no significant differences in the percentages of 
CD45RA−CD27+ central memory (Tcm), CD45RA−CD27− effector memory (Tem) and 
CD45RA+CD27− revertant memory (Trm) CD4+ T cells between these two groups of patients, 
although there were three patients with low anti-dsDNA antibody levels with consistently 
high percentages of Tem and Trm cells (Figure 5.2.1). There were no statistically significant 
differences in the T cell memory phenotypes between patients with active disease and high 
anti-dsDNA antibody levels (n = 12) and healthy controls and between patients with active 
disease, with either low or high anti-dsDNA antibody levels, and patients with inactive 
disease (n = 26). 
After BCDT the percentage of T cell memory phenotypes did not change at either week 6 or 
week 12 in the patients with low or high anti-dsDNA antibody levels, suggesting that B cells 
do not influence T cell differentiation. 
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Terminally differentiated CD4+CD27− T cells are positively associated with IgD−CD27− 
(Double Negative) B cells and negatively associated with IgD+CD27+ non-switched 
memory B cells 
CD4+ T helper cells can influence B cell differentiation and antibody synthesis (460). I 
therefore hypothesized that terminally differentiated memory T cells would positively 
correlate with memory B cells and/or plasmablasts. However, the low percentage of naïve T 
cells in patients with low levels of anti-dsDNA antibodies suggests that terminally 
differentiated memory T cells might correlate with non-antibody producing B cells instead. 
To examine if terminally differentiated memory T cells correlate with one or more of the 
memory B cell subsets I compared the percentage of different B cell memory phenotypes 
from patients with SLE who had not previously been treated with rituximab (n = 28) and 
healthy controls (n = 12) with the percentage of terminally differentiated CD4+CD27− T cells 
from the same time point. 
The data show that there was a moderate positive correlation between the percentage of 
terminally differentiated CD4+CD27− T cells and IgD−CD27− CD19+ B cells (rp = 0.47, p = 
0.002) and a weak negative correlation between CD4+ T cells and IgD+CD27+ CD19+ B cells 
(rp = −0.38, p = 0.02) that are non-switched memory B cells (Figure 5.2.2). There were no 
statistically significant correlations between CD4+CD27− T cells and IgD−CD27int CD19+ B 
cells (switched memory B cells) or IgD−CD27hi CD19+ B cells (plasmablasts). 
The relationship between Tem (CD4+CD45RA−CD27−) and Trm (CD4+CD45RA−CD27−) 
cell subsets and B cell subsets vary depending on the Trm:Tem ratio 
Memory T cell subsets have different effects on B cell differentiation in vitro (459).  
Although both Tem and Trm cells are terminally differentiated they might have different 
functions (59). I therefore compared the relationship between the percentage of the different 
B cell subsets with the Trm:Tem ratio of patients with SLE who had not previously been 
treated with rituximab (n = 28) and healthy controls (n = 12). Figure 5.2.3 shows that there 
was a moderate positive correlation between the Trm:Tem ratio and IgD−CD27− CD19+ B 
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cells (rp = 0.47, p = 0.002) but there were no significant correlations between the Trm:Tem 
ratio and IgD+CD27+ B cells, IgD−CD27int CD19+ B cells or IgD−CD27hi CD19+ B cells. 
There appeared to be two distinct group of patients according to the Trm:Tem ratio. The 
relationship between the memory B cell subsets and Trm:Tem ratio appeared to differ in 
patients with a Trm:Tem ratio >0.15 compared to patients with a Trm:Tem ratio <0.15. 
To investigate in more detail the relationship between the memory B cell subsets and the 
memory T cell subsets, Tem and Trm, the patients and healthy controls were divided into two 
groups according to whether they had a Trm:Tem ratio <0.15 (n = 33) or >0.15 (n = 7). There 
was a moderate positive correlation between Tem cells and IgD−CD27hi plasmablasts (rp = 
0.40, p = 0.02), a weak positive correlation between Tem cells and IgD−CD27− B cells (rp = 
0.39, p = 0.03) and a weak positive correlation between Trm cells and IgD−CD27hi 
plasmablasts (rp = 0.36, p = 0.04) in the group with a low Trm:Tem ratio (<0.15) but not in the 
group with a high Trm:Tem ratio (Figure 5.2.4). However, there was a very strong positive 
correlation seen between Trm cells and IgD−CD27− B cells (rp = 0.92, p = 0.004), a strong 
negative correlation between Trm cells and IgD+CD27+ non-switched memory B cells (rs = 
−0.89, p = 0.01) and a strong negative correlation between Tem cells and IgD+CD27+ non-
switched memory B cells (rp = −0.78, p = 0.02) in the group with a high Trm:Tem ratio but 
not in the group with a low Trm:Tem ratio.  
Terminally differentiated CD4+CD27− T cells positively correlate with non-switched 
memory B cells and IgD−CD27− B cells after BCDT. 
CD4+CD27− T cells were correlated with B cell memory phenotypes from patients who had 
had BCDT (n = 39) in order to determine whether a similar relationship between B and T cell 
memory subsets occurred after B cells repopulate. A moderate positive correlation was seen 
again between CD4+CD27− T cells and IgD−CD27− B cells (rp = 0.35, p = 0.03), but there 
were no significant correlations seen between CD4+CD27− T cells and the other memory B 
cell subsets (Figure 5.2.5).  
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I again carried out a subanalysis to examine the relationship between the memory B cell 
subsets and the memory T cell subsets, Tem and Trm, of the patients treated with BCDT who 
were divided into two groups according to whether they had a Trm:Tem ratio <0.15 (n = 34) 
or >0.15 (n = 5). There was a very strong positive correlation between Trm cells and 
IgD−CD27− B cells (rp = 0.88, p < 0.05) in patients with a high Trm:Tem ratio, but there were 
no other significant associations seen between the B cell subsets and the Tem or Trm subsets 
in patients with high or low Trm:Tem ratios (Figure 5.2.6). 
The rate of B cell repopulation is higher in patients with high percentages of Trm cells. 
If CD4+ T cell memory subsets do not change after BCDT then the positive associations that 
are seen between the Tem with IgD−CD27hi plasmablasts and IgD−CD27− B cells and Trm 
cells with IgD−CD27− B cells indicate that T cells are inducing B cell differentiation. CD4+ T 
cells might therefore influence B cell expansion after BCDT and the differences in the 
percentage of CD4+ T cell memory subsets might then be associated with different rates of B 
cell repopulation. In order to investigate possible differences in B cell repopulation patients 
were divided into a group that had high percentages of Trm cells (>0.8%), a group that had 
high percentages of Tem cells (>3%) but low/normal percentages of Trm cells and a group 
with low percentages of Tem cells. 
B cells repopulate significantly faster in patients with high percentages of Trm cells (n = 10), 
followed by patients with high percentages of Tem cells but low percentages of Trm cells (n = 
31) and the slowest in patients with low percentages of Tem cells (n = 13) (p < 0.0001) 
(Figure 5.2.7B). A difference in B cell numbers between patients with low percentages of 
Tem cells and patients with high percentages of Tem cells +/− high percentages of Trm cells 
became noticeable after approximately 20 weeks, whilst a difference in B cell numbers 
between patients with high percentages of Tem cells but low percentages of Trm cells and 
those patients with high percentages of Trm cells became noticeable after approximately 40 
weeks. 
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Patients with high fractions of Trm cells relapse earlier 
It has previously been shown that early B cell repopulation is associated with early relapse. It 
was therefore predicted that the time to clinical relapse would be reduced in patients with a 
high percentage of Trm cells, whose B cells repopulate at a faster rate, followed by patients 
with a high percentage of Tem cells but a low/normal percentage of Trm cells. 
In parallel with the rates of B cell repopulation that were seen between the 3 groups, patients 
with high percentages of Trm cells (n = 11) relapsed the earliest, followed by patients with a 
high percentage of Tem cells but a low/normal percentage of Trm cells (n = 35) and then 
patients with low percentages of Tem cells (n = 13)  (P < 0.05) (Figure 5.2.7C). The median 
time to relapse was 41 weeks for patients with a high percentage of Trm cells, 56 weeks for 
patients with a high percentage of Tem cells but a low percentage of Tem cells and over 104 
weeks for patients with a low percentage of Tem cells. Similar to the differences in the rates 
of B cell repopulation the difference in the rates of relapse between patients with a low 
percentage of Tem cells and patients with a high percentage of Tem cells became noticeable 
at 29 weeks and the difference in the rates of relapse between patients with a high percentage 
of Tem cells but a low/normal percentage of Trm cells and patients with a high percentage of 
Trm cells became noticeable at 41 weeks. It is also notable that all but one of the 11 patients 
with a high percentage of Trm cells relapsed by 70 weeks. 
In chapter 5.2.1 it was shown that patients with high levels of anti-dsDNA antibody levels 
relapse with lower numbers of B cells. I therefore hypothesized that patients with higher 
percentages of terminally differentiated T cells and high anti-dsDNA antibody levels would 
relapse earlier than patients with low anti-dsDNA antibody levels because the time to the B 
cell numbers required to relapse would be lower in the patients with high anti-dsDNA 
antibody levels. The results show that amongst patients with high percentages of Trm cells 
the patients with high anti-dsDNA antibody levels (n = 3) relapsed earlier than patients with 
low anti-dsDNA antibody levels (n = 8) (p = 0.003). There were no significant differences in 
the rates of relapse between patients with a high percentage of Tem cells but a low/normal 
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percentage of Trm cells with low anti-dsDNA antibody levels (n = 13) and patients with high 
anti-dsDNA antibody levels (n = 22) and between patients with a low percentage of Tem cells 
with low anti-dsDNA antibody levels (n = 7) and patients with high anti-dsDNA antibody 
levels (n = 6) (Figure 5.2.8). 
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Figure 5.2.1 – Changes in CD4+ T cell memory subsets after BCDT 
Comparison of the percentage of CD4+ T cell memory subsets in the peripheral CD4+ T cell 
pool between healthy controls [HC; n = 19], patients with inactive SLE [Inact; n = 26] and 
active SLE with either low [Low DNA (<100 IU/L); n = 16] or high anti-dsDNA antibody 
levels [High DNA (>100 IU/L); n = 12] at baseline and following BCDT at weeks 6 and 12. 
Results are shown for CD4+CD45RA+CD27+ naïve T cells, CD4+CD45RA−CD27+ central 
memory T cells (Tcm), CD4+CD45RA–CD27– effector memory T cells (Tem) and 
CD4+CD45RA+CD27– revertant memory T cells (Trm). Representative and cumulative data 
are shown. Differences between groups were analysed by the Mann-Whitney U test for 
unpaired data or the Wilcoxon signed rank test for paired data.  
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Figure 5.2.2 – Relationship between the percentage of CD4+CD27– memory T cells in the 
circulating CD4+ T cell pool and the percentages of CD19+ B cell memory subsets before 
BCDT  
CD19+ B cell memory subsets were identified using the surface markers IgD and CD27; non-
switched memory, IgD+CD27+ (A), switched-memory, IgD−CD27int (B), plasmablasts, 
IgD−CD27hi (C) and double-negative memory, IgD−CD27– (D). The data from healthy 
controls [n = 12] and patients with SLE who had not been treated with rituximab [n = 28] are 
represented as scatter plots and lines of best fit (for healthy controls and SLE patients 
combined). The Pearson correlation coefficient (rp) is provided for each association. NS = p > 
0.05. 
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Figure 5.2.3 – Relationship between the ratio of CD4+CD45RA+CD27– (Trm) and CD4+-
CD45RA–CD27– (Tem) cells in the circulating CD4+ T cell pool and the percentages of 
CD19+ B cell memory subsets before BCDT  
CD19+ B cell memory subsets were identified using the surface markers IgD and CD27; non-
switched memory, IgD+CD27+ (A), switched-memory, IgD−CD27int (B), plasmablasts, 
IgD−CD27hi (C) and double-negative memory, IgD−CD27– (D). The data from healthy 
controls [n = 12] and patients with SLE who had not been treated with rituximab [n = 28] are 
represented as scatter plots and lines of best fit (for healthy controls and SLE patients 
combined). The vertical dotted line shows the separation of patients with a low Trm:Tem 
ratio (<0.15) from patients with a high Trm:Tem ratio (>0.15). The Pearson correlation 
coefficient (rp) is provided for each association. NS = p > 0.05.  
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Figure 5.2.4 – Relationship between the percentages of CD4+CD45RA−CD27− effector 
memory T cells (Tem) and CD4+CD45RA+CD27−	  revertant memory T cells (Trm) in the 
circulating CD4+ T cell pool and the percentages of CD19+ B cell memory subsets before 
BCDT  
CD19+ B cell memory subsets were identified using the surface markers IgD and CD27; non-
switched memory, IgD+CD27+ (A), switched-memory, IgD−CD27int (B), plasmablasts, 
IgD−CD27hi (C) and double-negative memory, IgD−CD27− (D). The data from individuals 
(healthy individuals and patients with SLE who had not been treated with BCDT) with high 
Trm:Tem ratios [High (>0.15); n = 7] and with low Trm:Tem ratios [Low (<0.15); n = 33] are 
represented as scatter plots and lines of best fit. The Pearson correlation coefficient (rp) is 
provided for linear relationships and Spearman Rank correlation coefficient (rs) is provided 
for curvilinear relationships. NS = p > 0.05. 
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Figure 5.2.5 – Relationship between the percentage of CD4+CD27− memory T cells in the 
peripheral CD4+ T cell pool and the percentages of CD19+ B cell memory subsets after 
BCDT  
CD19+ B cell memory subsets were identified using the surface markers IgD and CD27; non-
switched memory, IgD+CD27+ (A), switched-memory, IgD−CD27int (B), plasmablasts, 
IgD−CD27hi (C) and double-negative memory, IgD−CD27− (D). The data from patients with 
SLE who have been treated with BCDT [n = 39] are represented as scatter plots and lines of 
best fit. The Pearson correlation coefficient (rp) is provided for each association. NS = p > 
0.05. 
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Figure 5.2.6 – Relationship between the percentages of CD4+CD45RA−CD27− effector 
memory T cells (Tem) and CD4+CD45RA+CD27−	  revertant memory T cells (Trm) in the 
circulating CD4+ T cell pool and the percentages of CD19+ B cell memory subsets after 
BCDT 
CD19+ B cell memory subsets were identified using the surface markers IgD and CD27; non-
switched memory, IgD+CD27+ (A), switched-memory, IgD−CD27int (B), plasmablasts, 
IgD−CD27hi (C) and double-negative memory, IgD−CD27− (D). The data from individuals 
(healthy individuals and patients with SLE who had not been treated with BCDT) with high 
Trm:Tem ratios [High (>0.15); n = 5] and with low Trm:Tem ratios [Low (<0.15); n = 34] are 
represented as scatter plots and lines of best fit. The Pearson correlation coefficient (rp) is 
provided for linear relationships and Spearman Rank correlation coefficient (rs) is provided 
for curvilinear relationships. NS = p > 0.05. 
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Figure 5.2.7 – Comparison of the rates of B cell repopulation and clinical relapse 
according to memory T cell phenotypes  
(A) Examples of two-parameter dot plots obtained by flow cytometry from one healthy 
individual and five rituximab-naive SLE patients. The dot plots illustrate the relationship 
between CD4+ memory T cells, CD4+CD45RA−CD27−	   (Tem)	   and	   CD4+CD45RA+CD27−	  (Trm), and the B cell subsets, CD19+IgD–CD27hi plasmablasts and CD19+IgD–CD27– double 
negative (DN) memory B cells (gate percentages are shown in bold). Three SLE groups are 
shown; 1. Tem cells <3% (Low Tem) associated with low percentages of plasmablasts and 
IgD–CD27– B cells, 2. Tem cells >3% but Trm cells <0.8% (High Tem/ Low Trm) associated 
with high percentages of plasmablasts and IgD–CD27– B cells, 3. Tem cells >3% and Trm 
cells >0.8% (High Trm) associated with low percentages of plasmablasts but high percentages 
of IgD–CD27– B cells. (B) Comparison of the changes in B cell numbers after BCDT using 
repeated measures ANOVA. Curves show the circulating B cell numbers over time of SLE 
patients who had been treated with BCDT, divided into 3 groups; Low Tem [n = 13], High 
Tem/ Low Trm [n = 31] and High Trm [n = 10]. The lines were fitted using non-linear 
regression and compared using the extra sum-of-squares F test. (C) Kaplan-Meier estimates 
of the time to clinical relapse following BCDT according to the 3 groups; Low Tem [n = 13], 
High Tem/ Low Trm [n = 35], High Trm [n = 11]. Differences were tested using the log-rank 
test for trend.  
IgD 
C
D
27
 
C
D
45
R
A 
CD27 
CD19 
CD4 
18.6 
9.8 
7.33 
0.09 
9.61 
9.58 
5.49 
0.05 
3.26 
1.26 
3.77 
0.04 
5.28 
29.6 
0.43 
13.3 
20.4 21.7 
8.5 3.71 
3.13 
3.05 
1.59 
0.05 
SLE - Low Tem Healthy SLE - High Tem/Low Trm SLE – High Trm 
32.6 
65.7 67.5 
31.2 
14.6 12.6 
65.7 
0.97 0.58 
69.0 
9.36 14.1 
53.8 
40.6 
0.44 
3.09 
63.5 
13.8 
0.88 
24.5 6.63 
39.6 
34.1 
58.5 
26.9 
44.2 
24.9 
49.7 
0.34 
23.4 3.94 
37.4 
0.22 
4.62 9.75 
71.7 
Revertant 
   (Trm) 
Effector 
 (Tem) 
Naïve 
  
Central 
 (Tcm) 
Plasmablasts 
IgD−CD27−  
(DN) B cells 
Switched 
memory 
Non-
switched 
memory 
Naive 
Non-
classified 
B C 
A 
B cell repopulation
0 20 40 60
0.0
0.1
0.2
0.3
Weeks
N
um
be
r o
f B
 c
el
ls
 x
10
9 /L High Trm
High Tem/ Low Trm
Low Tem
p<0.0001
Time to clinical relapse
0 20 40 60 80 100
0
20
40
60
80
100
Weeks
Pe
rc
en
t r
el
ap
se
High Trm
HighTem/Low Trm
Low Tem
p<0.05
 136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.8 – Comparison of the rates of clinical relapse according to memory T cell 
phenotypes and anti-dsDNA antibody levels  
Kaplan-Meier estimates of the time to clinical relapse following BCDT in patients with Tem 
cells <3% (Low Tem) with anti-dsDNA antibody levels >100 IU/L [high DNA; n = 6] or 
<100 IU/L [low DNA; n = 7], Tem cells >3% but Trm cells <0.8% (High Tem/ Low Trm) 
with anti-dsDNA antibody levels >100 IU/L [high DNA; n = 22] or <100 IU/L [low DNA; n 
= 13] and Tem cells >3% and Trm cells >0.8% (High Trm) with anti-dsDNA antibody levels 
>100 IU/L [high DNA; n = 3] or <100 IU/L [low DNA; n = 8]. Differences were tested using 
the log-rank test for trend. NS = p > 0.05.  
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5.2.3 Discussion 
Rituximab depletes the blood and SLOs of CD20+ mature B cells but not the B cell 
precursors, which do not express the surface marker CD20. The mature B cell compartment is 
repleted either by proliferation of B cells that have survived following treatment, possibly by 
being protected by the microenvironment or due to resistance of the B cell to rituximab 
induced cell death (461), or they emerge from the production of new immature B cells within 
the bone marrow (lymphopoiesis) followed by selection and maturation of the B cells in the 
SLOs (differentiation) and then activation of mature B cells. 
CD4+ memory T cells can be found in the bone marrow (462), but whilst they have been 
shown to influence B cell differentiation (459), they have not, to my knowledge, been shown 
to have a direct effect on B lymphopoiesis. It is, therefore, possible that the CD4+ memory T 
cells that are present in the bone marrow prevent the deletion of naïve autoreactive B cells to 
allow them to migrate to SLOs, where they then induce B cell maturation and then activation 
and expansion of memory B cells from the naïve B cell pool. In lupus-prone mice CD4+ T 
cells have been shown to play an important role in the clonal expansion of autoreactive B 
cells and autoantibody secretion (203, 463), probably as a result of IL-4, IL-10, IFN-γ and/or 
CD40 stimulation, depending on the mouse strain. Antigen-specific cognate interactions 
between B and CD4+ T cells might not be necessary. In one strain of lupus-prone mice the 
interaction between CD4+ T cells and autoreactive B cells was shown to occur in the follicles 
of the spleen (464).  
Similar mechanisms of T-cell induced B cell activation have also been shown in human 
studies. For example, B cells from patients with SLE produce autoantibodies in response to 
CD40 stimulation by T cells (237). T cells from patients with SLE can also produce the B cell 
stimulating cytokine, BAFF, which is elevated in the serum of patients with SLE, both 
directly (267, 465) and indirectly by stimulating peripheral blood monocytes with IFN-γ 
(466). BAFF plays an important role in rescuing newly formed autoreactive B cells and 
allowing them to enter normally restricted niches in SLOs (467, 468). Inhibition of BAFF in 
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patients with SLE leads to a decrease in naïve and transitional B cells initially, then memory 
B cells and plasmablasts accompanied by a decline in serum IgM levels (469). T-cell derived 
IL-6 might also be important for polyclonal B cell activation and autoantibody production 
(470), supported by observations that IL-6 blockade leads to a reduction in IgD−CD27+ 
memory B cells and an increase in IgD+CD27− antigen-inexperienced mature B cells (471). In 
contrast to BAFF blockade, IL-6 blockade leads to an increase in naïve B cells, possibly 
because IL-6 induces the differentiation of pre-activated B cells, i.e. a later stage of B cell 
development (472).  
It would be useful to know if the high percentage of circulating Tem and Trm cells in patients 
with SLE correlate with higher levels of these T cells in the bone marrow, where they have 
been found to preferentially localize (462), as this might provide a mechanism for how 
immature naïve autoreactive B cells are rescued from deletion and a possible explanation for 
the higher rate of B cell expansion that is seen in patients with high percentages of Trm cells. 
However, IL-7, produced by stromal cells in the bone marrow, has been shown to induce both 
B lymphopoiesis and the differentiation of Tem cells to Trm cells (462, 473). It is therefore 
possible that the higher rate of B cell expansion that is seen in patients with high percentages 
of Trm cells is due to a shared microenvironment rather than due to direct interaction between 
B and T cells.  However, as the percentage of CD4+ memory T cell subsets does not change 
after BCDT and that a similar correlation between CD4+CD27− T cells and IgD−CD27− B 
cells is seen both before and after BCDT the most likely explanation is that these memory T 
cell subsets are influencing the differentiation of B cells.   
My data suggest that Tem and Trm cells have different roles in the activation of mature B 
cells; Tem cells positively correlate with IgD−CD27− B cells and IgD−CD27+ memory B cells 
and plasmablasts, although only when there is a low Trm:Tem ratio, and Trm cells positively 
correlate with IgD−CD27− memory B cells and are negatively associated with IgD+CD27+ 
memory B cells. These two memory T cell subsets have been shown to have slightly different 
 139 
functions (462). Tem cells are more likely to be activated and appear to express higher levels 
of CD40 ligand, which might explain their positive association with plasmablasts.  
The role and function of IgD−CD27− B cells in the disease is unknown but this study shows 
that they might arise from a different differentiation pathway to IgD−CD27int memory B cells, 
via stimuli from different CD4+ memory T cell subsets, and it would therefore support the 
hypothesis that they have different roles in the disease. They are increased in healthy elderly 
individuals (474) and healthy individuals exposed to respiratory syncytial virus (277), which 
supports a relationship with Trm cells, as they are also increased in the elderly (475) and 
following persistent viral infection (462). Phenotypic studies of elderly individuals show that 
IgD−CD27− B cells express IgG but express low levels of CD80 and HLA-DR suggesting that 
they do not act as APCs. They also do not express significant levels of CD40. In SLE, these 
cells have not been shown to have any specific function and it is unclear whether they have a 
role in active disease (238, 271). 
Whilst studies have shown that IgD−CD27− B cells are increased in SLE IgD+CD27+ B cells 
are reduced (277). This observation is supported by the finding that there is a significant 
negative association between IgD−CD27− B cells and IgD+CD27+ B cells (rp = −0.31, p = 
0.04), whilst there is a positive association between IgD−CD27int switched memory B cells 
and IgD−CD27hi plasmablasts (rp = 0.46, p = 0.002) (data not shown). There is no association 
between IgD−CD27int switched memory B cells or IgD−CD27hi plasmablasts and IgD−CD27− 
B cells. It is therefore possible that there are two distinct differentiation pathways, that are 
mediated by differences in the percentages of Tem and Trm cells. 
 Although Tem cells correlate with plasmablasts CD4+ memory T cell subsets do not differ 
significantly in patients with high or low anti-dsDNA antibodies, suggesting that CD4+ T 
cells do not necessarily influence anti-dsDNA antibody synthesis. However, the presence of 
anti-dsDNA antibodies is associated with a faster rate of relapse in patients with high 
percentages of Trm cells, suggesting that anti-dsDNA antibodies might have a role in 
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exacerbating the pathogenic function of CD4+ T cells. As CD4+ T cells do not express Fc 
receptors, this is likely to be an indirect role. 
Despite the various studies that show how T cells can influence B cell function, I am unaware 
of any study in mice or humans, which show that CD4+ effector and/or revertant memory T 
cell subsets can influence the differentiation of memory B cell subsets in vivo.  One study has 
shown that Tem and Trm function differs in vitro (462), but there have been no in vivo 
functional studies, which is important because stimulating resting T cells in vitro might be 
different to antigen activated cells in vivo. Similarly, there have been no studies, which have 
looked at how T cell function differs when there are different Trm:Tem cell ratios. 
The results show that there are three distinct patterns of B cell expansion following BCDT, 
which are associated with different percentages of circulating CD4+ memory T cell subsets. 
Patients with high percentages of Tem cells but low/normal percentages of Trm cells have 
higher numbers of B cells as early as week 2 but they do not rise as rapidly as the B cell 
numbers of patients with high percentages of Trm cells after week 20, whilst patients with 
low percentages of Tem and Trm cells do not see a substantial rise in B cell numbers for at 
least one year. The higher B cell numbers at week 2 of patients with high percentages of Tem 
cells but low percentages of Trm cells might be due to inadequate depletion of B cells but I 
cannot provide an explanation for how this could be due to Tem cells. A more likely 
explanation is provided by the observation that Tem cells are associated with plasmablasts, 
suggesting that this early repopulation is due to the production of small numbers of 
plasmablasts, which has been seen in a group of patients with a higher risk of relapse within 
the first 18 months (429). The B cell numbers (measured using the CD19 marker) of the 
patients with high percentages of Tem cells but low/normal percentages of Trm cells might 
not appear to rise as rapidly as the group with high percentages of Trm cells after week 20 
because the plasmablasts are differentiating into CD19− plasma cells, which are not included 
in the B cell count. Trm cells are associated with IgD−CD27− B cells rather than plasmablasts 
and IgD−CD27− B cells have not been shown to differentiate into antibody producing plasma 
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cells. It is therefore likely that this rapid rise in B cell numbers in the patients with high 
percentages of Trm cells after week 20 is partly due to a steady accumulation of IgD−CD27− 
B cells. However, the B cell expansion that is seen in the patients with high percentages of 
Trm cells cannot only be attributed to a rise in IgD−CD27− B cells because they only make up 
4.1% (mean) of the B cell population, suggesting that other B cell subsets are also expanding. 
My data indicate that long-term control of disease is more likely if T cells are less 
differentiated. The mechanisms that influence T cell differentiation might be useful 
therapeutic targets but they are currently unclear. Certain factors that have been shown to be 
important include TCR engagement with antigen and stimulation by pro-inflammatory 
cytokines such as IFN-α and IL-6, both of which are known to be high in SLE as a result of 
immune complex activation of PDCs. Interestingly, IL-6 blockade leads to an increase in 
CD4+CD45RA+CCR7+ naïve T cells (471), suggesting that this might be a possible strategy 
for inducing long-term disease remission.  
A model of disease is proposed where immune complexes bound to protein containing RNA 
induce PDCs to express cytokines, probably IFN-α and/or IL-6, which cause the 
differentiation of CD4+ T cells into memory T cell subsets, which in turn influence B cells to 
differentiate into either plasmablasts or IgD−CD27− B cells (Figure 5.2.9).  The questions that 
result from this study are what factor leads to the preferential differentiation of T cells to Trm 
or Tem, which factors influence the differentiation of B cells towards either plasmablasts or 
IgD−CD27− B cells and what is the role of IgD−CD27− B cells in the disease. 
Finally, this study shows that the rate of B cell repopulation matches the rate of clinical 
relapse supporting evidence that B cells have an important role in disease. The different rates 
of B cell repopulation might partially explain the heterogeneity of the disease, in particular 
the differences in clinical response to B cell targeted therapy. Results of future clinical trials 
might be improved by stratifying patients according to their circulating CD4+ T cell memory 
subsets and anti-dsDNA antibody levels.  
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Figure 5.2.9 – Plasmablasts and IgD–CD27– B cells correlate with different memory T 
cells  
Plasmablasts (P) correlate with CD4+CD45RA–CD27– effector T cells (TE) and IgD–CD27– B 
cells (BDN) correlate with CD4+CD45RA–CD27– effector T cells (TE) and 
CD4+CD45RA+CD27– revertant T cells (TR). Memory T cells do not change after BCDT, 
therefore suggesting that these T cells induce the differentiation of B cells. 
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5.3 Pregnancy might induce B cell repopulation after BCDT in SLE 
5.3.1 Introduction 
Chapter 5.1 showed an association between B cell repopulation and clinical relapse following 
BCDT in SLE. Chapter 5.2 showed that memory T cells might influence B cell differentiation 
and expansion in some patients, but other factors are also likely to influence B cells. The 
increased incidence of SLE in young women (118) and the possible increase in disease flares 
during pregnancy (119) suggest that female hormones influence lymphocyte numbers and/or 
function. 
Circulating B cell numbers have been shown to either remain stable (476) or fall during 
healthy pregnancy (477, 478), but I am not aware of any study that has examined the effect of 
pregnancy on circulating B cell numbers in patients with SLE. The cases of four patients who 
became pregnant at least one year after BCDT are described. Three of these patients 
developed disease flares shortly after becoming pregnant. The changes in B cell numbers, 
anti-dsDNA antibody and C3 levels following BCDT, during pregnancy and flare are 
described and shown in Figure 5.3.1.  
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5.3.2 Case Histories 
Patient 47 is a 28-year-old Indian woman who was treated with her first cycle of rituximab 
for arthritis and cutaneous disease.  She was positive for Ro, Sm and RNP antibodies and 
negative for lupus anticoagulant and anticardiolipin antibodies. Her anti-dsDNA antibody 
level was 203 IU/Land C3 level was 0.69 g/L prior to therapy. After rituximab therapy her 
symptoms resolved even though her anti-dsDNA antibody levels transiently rose above the 
pre-treatment level on two separate occasions. Her C3 steadily increased to normal levels. 
She became pregnant 96 weeks after rituximab therapy. It was her third pregnancy. Her first 
child was born five years previously, with no significant foetal complications. She was 
induced and subsequently had an emergency Caesarean section for presumed foetal distress. 
However, she had a lupus flare in the post-partum period. Her second pregnancy was 
terminated two years previously because her SLE was active and shortly afterwards she was 
treated with rituximab. At the time of conception she was taking azathioprine 100 mg, 
hydroxychloroquine 400 mg and prednisolone 15 mg. 
From B cell depletion to conception her B cell count was less than 0.005 x 109/L but was 0.01 
x 109/L 13 weeks after the estimated time of conception. This small rise in her B cell count 
coincided with a disease flare with symptoms of chest and back pain, thought to be due to 
serositis, arthralgia and a malar rash (3 x BILAG B scores). During this flare her anti-dsDNA 
antibody level was 164 IU/L, which was elevated but lower than previous measurements. Her 
C3 level was 0.88 g/L and had not fallen significantly. Her symptoms settled with 30 mg of 
oral prednisolone. There were no further complications during her pregnancy and she 
delivered a healthy baby, weighing 2350 g, at 38+3 weeks. Three weeks after she gave birth 
her B cell count was 0.111 x 109/L and continued to rise to a peak level of 0.181 x 109/L. She 
had two further disease flares, one six months (fever, lymphadenopathy, rash; 2 x BILAG A 
scores) and the other 18 months after labour (fever, arthralgia; 2 x BILAG B scores). Both 
flares required admission to hospital, and both responded to intravenous methylprednisolone. 
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During each flare of lupus her anti-dsDNA level was elevated, although had not increased 
prior to or during the flare and below the pre-rituximab level. Her C3 levels remained normal. 
Patient 10 is a 38-year-old Afro-Caribbean woman with a history of class IV 
glomerulonephritis, arthritis and cutaneous disease. She was positive for Sm and RNP 
antibodies and negative for lupus anticoagulant and anticardiolipin antibodies. She had had 
three previous pregnancies, with one live birth at 34 weeks by spontaneous vaginal delivery 
and two previous early miscarriages. Her previous successful pregnancy was complicated by 
possible pre-eclampsia or flare of lupus nephritis. 
She was treated with her fourth cycle of rituximab. Her anti-dsDNA antibody level was 120 
IU/L and C3 level was 0.83 g/L prior to therapy. After therapy her urinary protein to 
creatinine ratio (PCR) fell from 156 to 92 and her symptoms improved. Her anti-dsDNA 
antibody level fell to normal levels and the C3 level also increased. She became pregnant for 
the fourth time 78 weeks after her first rituximab infusion. 
From B cell depletion to conception her B cell count was less than 0.01 x 109/L. Ten weeks 
after the estimated date of conception her B cell count was 0.012 x 109/L and continued to 
rise both during and after pregnancy to a peak level of 0.079 x 109/L at 62 weeks after 
conception and then fell to 0.029 x 109/L. 
The second pregnancy was complicated by thyrotoxicosis, microcytic anaemia (Hb 8.8) and 
hypertension. Blood pressure (BP) at booking was 160/85, which was treated with nifedipine 
10 mg once per day (od). Her SLE was controlled with prednisolone 5 mg od.  She was 
commenced on aspirin and ferrous sulphate 10 weeks into her pregnancy. At 11 weeks, she 
was noted to have mild leg tremors, minimal exopthalmos and a small diffuse thyroid. She 
was therefore started on propylthiouracil (PTU) 100 mg twice per day (bd) and propranolol 
40 mg three times per day (tds). The symptoms of thyrotoxicosis subsided, and six weeks 
later her PTU was reduced to 50 mg bd and her propranolol stopped. Her blood pressure rose 
to 142/92 at 19 weeks, attributed to stopping propranolol. However this remained high 
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(167/97) and the nifedipine dose was doubled to 20 mg bd. Review at 20 weeks noted her 
lupus to be quiescent. At 23 weeks she developed proteinuria 2+, which increased over the 
next three weeks to 4+. This was associated with mild bilateral leg swelling. Her blood 
pressure remained stable, and she had no other pre-eclampsia symptoms. At 30 weeks her 
serum creatinine had inceased to 134, and the PCR increased to 194. Her nifedipine was 
increased to 30mg bd. A plan was made after 32 weeks to consider early delivery if the serum 
creatinine rose above 170 to prevent irreparable damage to maternal renal function. Over the 
next 2 weeks her serum creatinine increased to 160, and PCR rose to 404. 
Thromboprophylaxis and labetolol 100 mg tds were introduced at 34 weeks, and her BP 
remained below 135/85. She continued to have heavy proteinuria but her blood test results 
and symptoms were not suggestive of pre-eclampsia.  Labour was induced at 35+4 weeks 
because of the increasing serum creatinine. A live infant was delivered by ventouse, weighing 
1899 g.  
After the pregnancy she continued to require anti-hypertensive medication. Her PCR peaked 
at 665 at 27 weeks after the pregnancy and then fell to between 169 and 275. Her creatinine 
did not improve after the pregnancy and continued to rise steadily. Her C3 level fell 9 weeks 
after labour (44 weeks after conception) from 1.44 to 0.93 g/L. At 88 weeks her anti-dsDNA 
antibody level increased from 27 to 127 IU/L, which was associated with a rise in her 
creatinine from 187 to 306 (1 x BILAG A score). Her prednisolone dose was then increased 
to 20 mg and she was also commenced on Mycophenolate Mofetil, which resulted in her anti-
dsDNA antibody levels returning to normal and a small improvement in her creatinine.  
Patient 57 is a 34-year-old Afro-Caribbean woman with a history of arthralgia, 
photosensitivity, a malar rash, glomerulonephritis with minimal change on biopsy and 
neuropsychiatric lupus. She was positive for Sm and RNP antibodies and negative for lupus 
anticoagulant and anticardiolipin antibodies. She had had three previous pregnancies. Her 
first pregnancy was terminated when she was 15 years old, she then had a miscarriage at 24 
years of age, followed by a live pregnancy at 33/40 when she was 30 years old.  This 
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pregnancy followed a period of subfertility, due to being unable to conceive for over nine 
months.   
Her first live pregnancy was associated with a flare of lupus at eight weeks, which settled by 
increasing her prednisolone dose to 8 mg od. She was already taking azathioprine 75 mg od 
and hydroxychloroquine 400 mg od. At 12 weeks, she complained of fatigue only. At 21 
weeks, she was well, with no active lupus but later the pregnancy was complicated by 
worsening fatigue, joint pain, swelling and difficulty moving. She delivered a healthy baby at 
33 weeks at another hospital, although it was monitored on SCBU for two weeks. Post partum 
her symptoms worsened and her steroids were increased to 15 mg od for one month, tapered 
down to 10mg maintenance dose. She continued with hydroxychloroquine and azathioprine at 
the same doses. 
Two years later her lupus became active again and she was treated with rituximab and the 
azathioprine was stopped. Her anti-dsDNA antibody level was less than 10 IU/L and C3 level 
was 1.25 g/L prior to therapy and they remained within the normal range following therapy. 
She became pregnant for the fourth time 59 weeks after her first rituximab infusion. 
Her B cells were undetectable six weeks after rituximab was given but 26 weeks later her B 
cell count had risen to 0.014 x 109/L and peaked at 0.023 x 109/L after another 16 weeks. Her 
B cell count did not change significantly after she conceived.  
A malar rash appeared at the end of the first trimester (1 x BILAG B score). At 33 weeks 
following conception she complained of arthralgia and mild dyspnea (1 x BILAG B score), 
which improved after increasing the dose of prednisolone to 15 mg od. There were no 
changes in her anti-dsDNA antibody and C3 levels during the pregnancy. She delivered a girl 
weighing 2210 g at 35+5/40 by normal vaginal delivery. Ten weeks after she gave birth her B 
cell count fell to 0.012 x 109/L.  
She had a partial collapse of the 8th thoracic vertebra consistent with osteoporosis three 
months post-partum. She was started on risedronate and her prednisolone dose was reduced 
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but her arthralgia worsened and she was then retreated with azathioprine (1 x BILAG B 
score).  
Patient 24 is a 40-year-old mixed race woman with a history of arthralgia, serositis, 
cutaneous vasculitis and digital arterial thrombosis. She was positive for RNP antibodies and 
was negative for lupus anticoagulant and anticardiolipin antibodies. She had had no previous 
pregnancies. 
Her disease remained active despite treatment with methotrexate, azathioprine and 
cyclophosphamide and she was then treated with her first cycle of rituximab. Prednisolone 
5mg od was given as maintenance treatment. Her anti-dsDNA antibody level was 89 IU/L 
and C3 level was 1.25 g/L prior to therapy. After treatment her anti-dsDNA antibody level 
immediately fell to less than 10 IU/L and her C3 level increased to a peak of 1.77 g/L after 
145 weeks. She became pregnant for the first time 260 weeks after her first rituximab 
infusion.  
Her B cells were undetectable three weeks after rituximab was given and remained deplete 17 
weeks later. They rose to 0.02 x 109/L 38 weeks after treatment and remained at this level 
until she conceived when her B cell count rose to 0.059 x 109/L at 20 weeks before falling to 
0.013 x 109/L at 39 weeks. Her lupus remained quiescent during the pregnancy apart from 
alopecia (1 x BILAG B score), which was noted at 38 weeks, and her anti-dsDNA antibody 
and C3 levels remained within the normal range. She delivered a healthy baby at 40 weeks by 
Caesarean section at another hospital. Her B cells steadily rose to 0.068 x 109/L 47 weeks 
after she gave birth but there was no change in her condition or serology. 
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Figure 5.3.1 – Changes in B cell numbers, C3 levels and anti-dsDNA antibody levels 
during pregnancy in patients with SLE treated with BCDT 
B cell numbers, C3 levels and anti-dsDNA antibody levels of patients 10, 24, 47 and 57, and 
urine protein/creatine ratio and serum creatinine level of patient 24, following rituximab 
therapy and then during pregnancy. The graphs start from the time of the first rituximab 
infusion (R). Week 0 represents the estimated time of conception (C). Arrows indicate disease 
flares.  
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5.3.3 Discussion 
These four cases show that pregnancy might be an additional cause for B cell expansion and 
activation in some patients. During healthy pregnancy the immune system changes in order to 
prevent rejection of the semi-allogeneic foetus. In healthy pregnant mice sex steroids reduce 
B lymphopoiesis by inhibiting the IL-7 responsiveness of B cell precursors (479), possibly 
explaining an observed reduction in the numbers of B cell precursors and increase in the 
number of mature B cells (480). Early studies in healthy pregnant women showed that the 
concentrations of circulating immunoglobulin do not appear to change and immunization to 
tetanus toxoid results in a normal humoral response, suggesting that B cell function does not 
change (481). However, later studies have shown that pregnancy is associated with an 
increase in antibodies that protect the pregnancy, called assymetric antibodies because they 
have had an oligosaccharide group of the high mannose type added to one of the two Fab 
fragments during post-translational modification (482). These antibodies bind to paternal 
antigens but do not activate an immune effector function. A subset of transitional B cells that 
secrete IL-10, called regulatory B cells, might also be important for protecting the pregnancy. 
These regulatory B cells express the receptor for the human chorionic gonadotrophin 
hormone (hCG), which might encourage its expansion during the early stages of pregnancy 
when hCG levels rise (483). There appears, however, to be a lack of studies examining 
possible changes, both functional and phenotypic, in mature B cells during healthy pregnancy 
in humans. 
The higher incidence of SLE in women and the observations that it is often worse during 
specific phases of the menstrual cycle, pregnancy or when patients take the oral contraceptive 
pill has implicated the female sex hormones in the disease pathogenesis, in particular 
oestrogen and prolactin. These two hormones have been shown to activate B cells and cause 
an increase in autoantibody production in several murine models (119, 484), although they 
appear to cause differences in the maturation of identical DNA reactive B cells with oestrogen 
causing the B cells to become marginal zone B cells and prolactin causing the B cells to 
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become follicular B cells (484). In vitro studies show that both hormones can induce 
autoantibody production by B cells from SLE patients when they are cultured with other 
mononuclear cells (485, 486), but studies comparing sex hormones with changes in B cell 
numbers and function during pregnancy in patients with SLE are lacking. 
A study of patients with pre-eclampsia has intriguingly shown that the CD5+ B cell subset, 
which produces autoantibodies against angiotensin type 1 receptor II and are found in the 
placenta of pre-eclamptic pregnancies, can be expanded by hCG (487). As hCG is elevated in 
the first few weeks of pregnancy this would be a possible candidate for the cause of B cell 
expansion that occurred shortly after conception in patients 10 and 47. 
After pregnancy, when the pregnancy related hormones were no longer high, the B cell 
numbers were maintained within normal levels. The mechanism that sustains B cell numbers 
after repopulation is not known, but it is possibly induced by autostimulation, either by 
cytokine production or direct cell contact (280, 488, 489). 
This study also shows that there are three distinct patterns of relapse following B cell 
repopulation after BCDT, with regards to changes in anti-dsDNA antibody levels and 
circulating B cell numbers. 
1. Patient 47 went into remission even though her anti-dsDNA antibody levels did not 
fall but relapsed as soon as the B cells started to repopulate without a rise in her anti-
dsDNA antibody levels. The low B cell count at the time of relapse was consistent 
with the observation made in chapter 5.1 that patients with high anti-dsDNA antibody 
levels relapse with low B cell numbers. This observation suggests that anti-dsDNA 
antibodies may cause disease by interacting with B cells either directly or indirectly. 
2. Patient 10 went into remission when her B cells were depleted but after repopulation 
there was a two-year delay before her anti-dsDNA antibody levels rose with a large 
rise in her creatinine. During those two years she had a series of non-specific 
changes, including a rise in her blood pressure, headaches, proteinuria and a small 
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rise in her creatinine, which indicated a problem within her kidneys but could not be 
clearly attributed to active glomerulonephritis, as this would have required a renal 
biopsy, particularly in the absence of haematuria or rapidy deteriorating renal 
function. The source of her anti-dsDNA antibodies was not certain but as her only 
problems prior to the rise in anti-dsDNA antibody levels arose from her kidneys 
(indicated by the proteinuria, hypertension and creatinine rise), it is tempting to 
speculate that they may have arisen from B cells in her kidney. 
3.  Patient 57 did not have any anti-dsDNA antibodies in her serum and normal 
complement levels but still responded to BCDT. Her first symptom of this relapse 
was a malar rash, which is consistent with studies that show that the malar rash is an 
early symptom of SLE (110, 112). The absence of anti-dsDNA antibodies raises the 
possibility that the relapse was due to an antibody independent function of B cells. In 
the next chapter I will compare the skin histology of two patients with low anti-
dsDNA antibody levels who had early/low-grade disease with malar rashes with the 
skin histology from three patients with high anti-dsDNA antibody levels who had 
chronic and/or multi-systemic disease with diffuse skin rashes. 
Interestingly, in one murine model of SLE, oestrogen was shown to exacerbate immune 
complex mediated glomerulonephritis but ameliorate T cell mediated vasculitis (490). This 
might explain the lack of flare that was observed in patient 24 who was initially treated for a 
vasculitis but had no symptoms of active SLE and low anti-dsDNA antibody levels during the 
pregnancy even though the B cells had repopulated. Anti-dsDNA antibodies and low 
complement are associated with pregnancy-related complications in SLE (491), which 
supports the murine study that suggests that immune complex mediated disease is more 
susceptible to pregnancy-related flare.  
This study shows that an antibody-independent function of B cells might also be an important 
factor in active disease. More research is needed to confirm this observation and to 
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understand which B cell subset is involved and how they might induce inflammation. In the 
next chapters, the possible mechanisms behind these three different disease patterns and the 
possible antibody-independent role of B cells in SLE will be examined. 
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5.4 Lymphocytic infiltrates in active skin lesions of patients before 
treatment with BCDT might differ according to anti-dsDNA antibody 
levels 
5.4.1 Introduction 
In chapter 5.1 it was shown that disease relapse was associated with different B cell numbers 
and phenotypes depending on whether patients had low or high anti-dsDNA antibody levels. 
Anti-dsDNA antibodies have been strongly associated with renal disease (187) but 
associations between anti-dsDNA antibodies and other manifestations of the disease are less 
clear (140). This chapter describes the histopathology from skin biopsies of active lesions 
from five patients before they had BCDT and compares the histology with their anti-dsDNA 
antibody levels. 
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5.4.2 Results 
Patient 62 presented with a plaque and swelling on her left cheek, patient 78 had a chronic 
bilateral malar rash with acneform erythematous papules, patients 54 and G had sudden-onset 
diffuse erythema affecting their face, trunks and limbs and patient F had diffuse discrete 
macular and annular lesions on her face, trunk and arms. Biopsies were therefore taken from 
the malar region from patients 62 and 78 and from the arms from patients 54, F and G (Table 
5.4.1).  
Histological evidence of active lupus was seen in two of the biopsies, from patients 62 and 
54. In the biopsy of patient 62 there was mild hyperkeratosis, occasional follicular plugging, 
mild atrophy of the epidermis and lymphocytic infiltrates in the epidermis, dermoepidermal 
junction, around the blood vessels and hair follicles consistent with chronic cutaneous lupus 
erythematosus. In the biopsy of patient 54 the epithelium showed hyperkeratosis. There was 
also spongiosis and basal cell vacuolation damage associated with lymphocyte exocytosis 
from the dermis and the dermis showed mild oedema with a lymphocytic infiltrate consistent 
with acute cutaneous lupus erythematosus. The biopsy of patient 78 showed features more 
consistent with ulceration. The biopsy of patient F the features were non-specific and the 
biopsy of patient G showed features consistent with ‘burnt-out’ interface dermatitis possibly 
due to previous lupus. 
Patient 62 had an anti-dsDNA antibody level of 11 IU/L and normal complement level at the 
time that the biopsy was taken but the biopsy revealed a dense lymphocytic infiltration of the 
dermis. Patient 78 also had dense lymphocytic infiltrate associated with a mildly raised anti-
dsDNA antibody level of 62 but normal complement level, whilst in patient 54, who had a 
mildly raised anti-dsDNA antibody level of 70 IU/L and reduced complement level of 0.6 
g/dL, there was only scattered lymphocytic infiltration within the dermis and a perivascular 
lymphocytic infiltrate. In patients F and G who had the highest anti-dsDNA antibody levels 
(366 and 300 respectively) there were only perivascular lymphocytic infiltrates. Circulating 
lymphocyte numbers were at the lower limit of normal in patients 62 and 78 (1.58 and 1.56 
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respectively) but they fell after the biopsy was taken. The circulating lymphocyte numbers in 
patients 54, F and G were all significantly below normal. 
Immunohistochemical stains for the lymphocyte markers CD3, CD4, CD8, CD20 and the 
monocyte marker CD14 were performed. The stains revealed that the infiltrates were only 
CD3+ T cells in the biopsies of patients 62, 54, F and G. In the biopsy of patient 78 the 
lymphocytes were mostly CD3+ T cells, of which 70% were CD4+, but small aggregates of 
CD19+ B cells could also be seen within the T cell infiltrates. A few CD14+ monocytes were 
also seen in the biopsies of patients 78, F and G (data shown in chapter 5.7). 
Direct immunofluorescence showed immune deposits consistent with cutaneous lupus in the 
biopsies of patients 62, 54, F and G. An immunofluorescent stain was not performed on the 
biopsy of patient 78. 
Patients 62, F and G were treated with rituximab shortly after the biopsies were taken, which 
was followed by an improvement in the skin lesions and extracutaneous symptoms in those 
patients. Patient 78 was initially given topical tacrolimus in addition to regular low-dose oral 
prednisolone and hydroxychloroquine but six months later she developed a diffuse cutaneous 
vasculitis associated with a rise in her anti-dsDNA antibody level to 2686 IU/L, which then 
led to her being treated with rituximab. Patient 54 was initially treated with intravenous 
methylprednisolone and cyclophosphamide but she relapsed five months later and was then 
treated with rituximab. 
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Table 5.4.1 – Comparison between lymphocytic infiltrates in lupus skin lesions and anti-
dsDNA antibody and C3 levels before BCDT 
Immunohistochemical analysis of T (CD3+) and B (CD19+) lymphocytes in tissue biopsies of 
active skin lesions from 5 patients with SLE who were rituximab naïve (ID numbers 54, 62, 
78, F and G). Original magnification: x40. Results from the direct immunofluorescence are 
also given with symptomatology, disease duration, ENA antibody seropositivity, anti-dsDNA 
antibody levels, C3 levels and lymphocyte numbers. Three types of lymphocytic infiltration 
are shown; interstitial aggregates (large white arrows), scanty interstitial infiltration (small 
white arrows) and perivascular aggregation (small black arrows). CD3+ T cells were seen in 
all biopsies but CD19+ B cells were only seen in the biopsy of patient 78. 
 
 
 
  
!
!!ID! CD3+!cells! CD19+!cells! IMF! Disease!
duration!
Symptoms! ENA! Anti>
dsDNA!
(IU/L)!
C3!
(g/dL)!
Lymph!
(x109/L)!
!!62!
!
! !
Granular!deposits!of!IgM!and!C3!at!the!BMZ.!In!addition!there!is!epidermal!ANA!staining.!!
7!months!(2008)! Malar!rash,!fatigue!and!arthralgia! Ro+!La+! 11! 0.83! 1.58!
!!78!
! !
Data!not!available! 11!years!(1999)! Malar!rash!only.!No!constitutional!symptoms!!(Digital!vasculitis!and!fever!after!9!months)!
RNP+!Sm(+)!Ro(+)! 62!!!!!(2686!after!9!months)!
1.07!!!!(0.30!after!9!months)!
1.56!!!!(1.06!after!9!months)!
!!54!
! !
Speckled!BMZ!staining!with!IgM,!IgA!and!to!a!lesser!extent!with!C3.!
22!years!(1985)! Diffuse!desquamating!rash,!serositis!and!fever!
Negative! 70! 0.60! 0.27!
!!F!
! !
Granular!deposits!of!IgM,!IgG,!IgA!and!C3!at!the!BMZ.!!
7!years!(2002)! Diffuse!macular!rash,!alopecia,!mouth!ulcer,!nephritis!(class!II),!arthralgia,!!and!fever!
Ro+! 366! 0.39! 0.49!
!!G!
! !
Granular!deposits!of!IgM,!IgG,!IgA!at!the!BMZ!and!colloid!bodies!labelling!with!IgM,!IgG!and!IgA!in!the!papillary!dermis!and!along!the!dermoVepidermal!junction.!
1!month!(2010)! Diffuse!desquamating!rash,!hair!loss,!thrombocytopaenia,!arthralgia,!weight!loss!and!fever!
Negative! 300! 0.38! 0.89!
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5.4.3 Discussion 
Skin lesions occur in 72-85% of patients with SLE (492). There are four types of lesions in 
SLE according to the Dusseldorf classification; acute cutaneous lupus erythematosus 
(ACLE), which includes a localized form (malar dermatitis) and a generalized form, subacute 
cutaneous lupus (SCLE), chronic cutaneous lupus erythematosus (CCLE), including discoid 
lesions, and intermittent cutaneous lupus erythematosus (ICLE). 
Skin lesions in active lupus are classified histologically into early, fully developed, late or 
special manifestations (e.g. lupus erythematosus profundus) (126). The histological findings 
of early lupus erythematosus include sparse superficial perivascular lymphocytic infiltrates, 
similar to the infiltrates that were seen in the biopsy of patient 54. The histological findings of 
fully developed lupus erythematosus include dense perivascular and periadnexal lymphocytes 
in the papillary and reticular dermis, similar to the findings that were seen in the biopsy of 
patient 62. Therefore, histological chronicity is partly determined by the extent of 
lymphocytic infiltrates. However, this appears to contrast with the time since diagnosis and 
the anti-dsDNA antibody and C3 levels that were seen in the sera of patients 62 and 54, which 
suggested that patient 62 had early disease and patient 54 had chronic disease with an acute 
flare. 
The role of autoantibodies in cutaneous lupus is unclear. Whilst immune deposits are often 
seen in active lesions, particularly at the dermoepidermal junction, they can also be seen in 
non-lesional skin (493). Ro antibodies, which were found in three of the patients, have been 
associated with photosensitivity and also the malar rash (494, 495), Sm and RNP antibodies, 
which were found in patient 78, have been associated with the malar rash in two studies (140, 
494) and Ribosomal P antibodies have been associated with alopecia (140), but there is no 
clear explanation for how these antibodies might mediate skin inflammation.  
Anti-dsDNA antibodies are often seen in patients with acute cutaneous LE lesions (496) and 
titres also correlate with the intensity of dermoepidermal junction immunofluorescence in the 
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lupus band test (493). One study has shown a possible association between anti-dsDNA 
antibodies and the malar rash, although this was seen in patients that also had Sm antibodies 
(495). Extracellular DNA has been seen in lesional skin in the basement membrane zone, 
vascular wall, and hair follicles (497), which could potentially complex with circulating anti-
dsDNA antibodies. 
The malar rash has been shown to be a common early manifestation of SLE (496) and a 
feature of ILE that predicts the development of complete SLE (110, 112). Lymphocytic 
infiltrates are a consistent finding in early discoid lupus (126) but immune deposits are not 
(493), suggesting that, in discoid lupus, lymphocytes migrate to the skin before immune 
complexes are deposited. 
Whilst the numbers in this study are small, it is possible to suggest that there are at least four 
patterns of lymphocytic infiltration in the inflamed skin of patients with active disease; 
localized lesions with dense T cell infiltrates alone, dense T cell infiltrates with B cells, and 
diffuse lesions with perivascular infiltrates +/– scattered lymphocytic infiltrates. Importantly 
the presence of T cells in the skin precedes the appearance of anti-dsDNA antibodies in the 
serum, and also appears to be inversely related to the anti-dsDNA antibody levels and 
hypocomplementaemia. 
It is intriguing that B cells are seen aggregating with T cells in the biopsy of patient 78 shortly 
before there was a sharp rise in her anti-dsDNA antibody levels and it is tempting to speculate 
that the cells were forming ELT, which produces plasma cells capable of producing the anti-
dsDNA antibodies that then contributed to the more diffuse cutaneous vasculitis. This 
hypothesis is supported by three larger studies of renal biopsies that showed similar T and B 
cell infiltrates in conjunction with more severe immune-complex mediated pathology. The 
first study of seven renal biopsies showed ICOS+ T cells in close contact with B cells and 
plasma cells in tissue that also stained for prominent IgG, IgA and IgM deposits (265). The 
presence of ICOS+ T cells is significant because these cells have been shown to activate B 
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cells and enhance the production of anti-dsDNA antibodies (288). The second study of 68 
renal biopsies showed features of higher order lymphoid structures composed of both B and T 
cells in the tubular interstitium that were strongly associated with immune complex 
deposition in the tubular basement membrane (152). There was evidence of intrarenal B cell 
clonal expansion and ongoing somatic hypermutation, which the authors concluded was 
driven by the coresident T cells. Sixty-five of the 68 biopsies showed features of either class 
III, IV or V glomerulonephritis but a correlation between the different lymphoid-like 
structures and the glomerular lesions was not performed. Nevertheless, they concluded that 
the deposition of immune complexes in glomeruli likely arises from a breach in systemic 
tolerance but that interstitial nephritis is associated with in situ tolerance diatheses. In other 
words they conclude that there are two separate immune complex-mediated inflammatory 
processes - one that starts in the SLOs and the other within the inflamed tissue.  
The second study compared the B and T cell infiltrates in 192 renal biopsies (153) using a 
novel classification of renal histology according to the B cell infiltrates (498). The 
classification defines 5 distinct groups; grade 0 aggregates with T cell infiltrates alone, grade 
1 aggregates with scattered T and B cells, grade 2 aggregates with cluster-like structures but 
no T- and B-cell zones, grade 3 aggregates with distinct T- and B-cell zones and grade 4 
aggregates with the highest level of microanatomical organization with a central network of 
FDCs. They found that 38.5% of the biopsies were grade 0, 44.8% were grade 1, 8.9% were 
grade 2 and 7.8% were grade 3. There were no grade 4 type infiltrates. B cell aggregates were 
mostly seen in the tubulointerstitium rather than in the glomerulus. They found that the 
presence of B cells was associated with class IV nephritis, higher blood urea and creatinine 
levels and higher SLE Disease Activity Index (SLEDAI) scores but there were no differences 
between grades 1, 2 or 3. The presence of B cells was also associated with higher activity and 
chronicity indices. However, 24-hour urinary protein and anti-dsDNA antibody levels did not 
differ between the groups. The skin histology of patient 78 appeared similar to the grade 3 
class, because the T and B cells were aggregating with distinct T and B cell zones. I did not 
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look for the presence of FDCs and, therefore, cannot be certain whether ELT was formed. 
However, two of the three studies that looked for the presence of FDCs found that they were 
seen in only a small number of specimens, suggesting that they might not be crucial for 
inducing B cell differentiation into antibody secreting plasma cells in non-lymphoid tissue.  
These studies suggest that there is a specific inflammatory process within the non-lymphoid 
tissue, which is initiated by T cell infiltration, followed by B cells, then FDCs, which results 
in the formation of ELT. Plasma cells are then formed which produce autoantibodies that 
react to local antigen, form immune complexes and recruit other inflammatory cells (Figure 
5.4.1). It could therefore be argued that the “fully developed” lesions are in fact part of an 
early localized inflammatory phase that precedes the systemic inflammation. 
The formation of ELT is a normal part of the local immune response to infection (72) and it 
has been shown in mice that the first cells that infiltrate the tissue and initiate the formation of 
ELT are mature CD3+CD4+ T cells (499). However, ELT should disappear once the infection 
has been cleared. Therefore, the presence of large numbers of T cells in the tissue of patients 
with SLE suggests that there is a defect in their survival and retention within the tissue, which 
needs to be explained. It is also important to try to understand what induces their migration, 
why T cells should preferentially migrate to the face and kidneys, as seen in this study and the 
studies that were discussed above, and whether similar T cell infiltrates and ELT are seen in 
other organs that are typically affected in SLE (e.g. brain and joints). The recruitment and 
retention of T cells to specific tissue are likely to be controlled by the interaction of tissue-
specific chemokine receptors and adhesion molecules expressed on the T cells with specific 
chemokines and integrins expressed by the endothelium and cells in the tissue. It is not known 
if the recognition of tissue antigen is important. 
Given the good response of patient 62 to BCDT it is possible to hypothesize that B cells are 
inducing T cell migration. This hypothesis is supported by a study that genetically modified 
the B cells of MRL/lpr mice, which normally get a severe lupus-like disease associated with 
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antinuclear antibodies, so that they could not secrete immunoglobulin. The mice did not die as 
rapidly as the typical MRL/lpr mice but died earlier than mice that did not have any B cells 
(195). They did not get glomerulonephritis but did get an interstitial nephritis associated with 
a dense T cell infiltrate that looked similar to the T cell infiltrate seen in the skin biopsy of 
patient 62 and the T cell infiltrates in the renal histology studies that were discussed. Another 
study observed a reduction in the number of CD3+ T cells in the renal biopsies in 50% of the 
patients who had been treated with BCDT (441). In multiple sclerosis and rheumatoid arthritis 
infiltrating T cells are also dependent on the presence of B cells (442, 500). 
The next chapter will examine if and how B cells induce T cell activation and possible 
migration, particularly in patients with low levels of anti-dsDNA antibodies.  
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Figure 5.4.1 – T and B cells aggregate in the tissue in the early stages of inflammation  
T cells are the first lymphocytes in the tissue. They then aggregate with B cells and follicular 
dendritic cells to form ectopic lymphoid tissue. With the appropriate stimuli in the ectopic 
lymphoid tissue B cells differentiate into antibody producing plasma cells, including plasma 
cells that produce anti-dsDNA antibodies.  
T cell infiltration is the first stage in the formation of ectopic lymphoid tissue. The 
mechanisms that induce T cell infiltration are not fully understood but an animal study 
suggests that B cells might have an important role in the process (195). It was hypothesized 
that IgD–CD27– B cells influence the migration of T cells into the non-lymphoid tissue. 
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5.5 HLA-DR expression by CD4+ T cells is inversely related to CD4+ T cell 
numbers in patients with low anti-dsDNA antibody levels and can be 
induced by BCR or TLR-9 stimulated B cells 
5.5.1 Introduction 
In chapter 5.1 it was observed that patients that relapsed with low anti-dsDNA antibody levels 
had high percentages of IgD−CD27− B cells. The function of these cells has not been 
established. In chapter 5.4 it was found that the two patients with low levels of anti-dsDNA 
antibodies had only localized cutaneous disease, with minimal systemic symptoms but the 
biopsies showed extensive T cell infiltration around the blood vessels and in the dermis. It 
was proposed that this might be the first step towards the development of ELT, which lead to 
the production of pathogenic autoantibodies and more diffuse cutaneous disease and systemic 
symptoms. It was hypothesized that IgD−CD27− B cells might induce the migration of T cells 
into the tissue. 
Previous studies have shown that circulating CD4+ T cells are dysregulated and activated. 
However, the functional role of activated CD4+ T cells in SLE has been disputed. The most 
widely held view is that CD4+ T cells induce autoantibody production, although it is not clear 
if this occurs in SLOs or the tissue. CD4+ T cells also produce cytokines, which might 
activate other cells. 
In this chapter I describe the changes in lymphocyte numbers after BCDT and examine 
whether they correlate with the expression of activation markers on CD4+ T cells. 
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5.5.2 Results 
B cell repopulation is associated with a fall in lymphocyte levels that coincides with or 
precedes clinical relapse 
In the previous chapter I showed that the circulating lymphocyte numbers were on the lower 
limit of normal in the two patients with active cutaneous lupus and low anti-dsDNA antibody 
levels and continued to fall after the biopsies were taken but before the patients were given 
systemic therapy. Lymphocytes are mostly composed of CD3+ T cells. It was therefore 
hypothesized that if B cells are contributing to T cell migration and if lymphopaenia is a 
consequence of T cell migration then lymphocyte numbers should fall when B cells 
repopulate after rituximab therapy. 
The lymphocyte numbers were compared in patients with SLE who had been treated with 
rituximab at baseline, at the last period of B cell depletion, at the point at which B cells were 
first recorded to have repopulated above 0.01 x 109 cells/L and at 6 months after repopulation 
if they still had inactive disease or at relapse if the disease was active (Figure 5.5.1A). To 
examine if there were differences in the changes in lymphocyte numbers in patients with low 
or high anti-dsDNA antibody levels during remission or relapse patients were divided into a 
group with low anti-dsDNA antibody levels (<100 IU/L) that either remained in remission 6 
months after repopulation (n = 13) or relapsed by 6 months after repopulation (n = 16), and a 
group that had high anti-dsDNA antibody levels that either remained in remission 6 months 
after repopulation (n = 8) or relapsed by 6 months after repopulation (n = 11). 
In patients that relapsed with either low or high anti-dsDNA antibody levels there was a 
significant fall in lymphocyte numbers from baseline to depletion (p = 0.01 and p = 0.04 
respectively, Wilcoxon matched-pairs signed rank test).  This was possibly due to the 
depletion of B cells. From depletion to repopulation there was a significant rise in lymphocyte 
numbers in patients that relapsed with either low or high anti-dsDNA antibody levels (p = 
0.01 and p = 0.03 respectively, Wilcoxon matched-pairs signed rank test), which was likely to 
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be due to the repopulation of B cells. However, in patients with low anti-dsDNA antibody 
levels that relapsed there was a fall in lymphocyte numbers between repopulation and relapse 
(p = 0.03, Wilcoxon matched-pairs signed rank test). A significant fall in lymphocyte 
numbers was not observed in the other groups. Given that B cell numbers are increasing 
during this period, the decrease in lymphocyte numbers that was seen in patients with low 
anti-dsDNA antibody levels that relapse was most likely to be due to a decrease in CD3+ T 
cell numbers. In patients that remained in remission the only significant change in 
lymphocyte numbers that was observed was a rise between depletion and repopulation in the 
patients with high anti-dsDNA antibody levels (p = 0.008, Wilcoxon matched-pairs signed 
rank test).  
A subanalysis showed that lymphopaenia at baseline is most likely to be due to low T cell 
numbers, particularly the CD4+ subset, as T cell numbers were significantly lower in patients 
with active disease before BCDT (n = 9) compared to healthy controls (n = 34), with the 
greatest statistical significance in the CD4+ subset (p = 0.0005 for CD3+, p = 0.003 for CD4+ 
and p = 0.02 for CD8+ subsets, Mann-Whitney U tests). B cell numbers were not significantly 
lower in patients with active disease before BCDT (Figure 5.5.1B). However, both B and T 
cell numbers were significantly lower in patients in remission who have not been treated with 
rituximab (n = 7) compared to healthy controls (p = 0.0007 for B cells, p = 0.006 for CD3+, p 
= 0.006 for CD4+ and p = 0.04 for CD8+ subsets Mann-Whitney U test). B cell numbers were 
also significantly lower in patients in remission compared to patients with active disease (p = 
0.04, Mann-Whitney U test), which supports evidence that they are an important factor in 
active disease and might be causing the fall in T cell numbers, either directly or indirectly. 
The low T cell numbers in patients who are in long-term remission might support the 
observation that relapse is associated with a decrease in T cell numbers rather than the 
absolute number that is present in the circulation, which is further illustrated in the case 
studies below. 
 167 
Case studies of patients with low levels of anti-dsDNA antibody levels at the time of B 
cell repopulation showing the rise in B cell numbers is first followed by a fall in 
lymphocyte numbers and then by a rise in anti-dsDNA antibody levels 
The six cases shown in Figure 5.5.2 suggest a relationship between the repopulation of B cells 
with the subsequent fall in the lymphocyte numbers followed by a rise in anti-dsDNA 
antibody levels and flare of the disease in some patients. All six patients had anti-dsDNA 
antibody levels below 50 IU/L at the time of B cell repopulation. Patients 29, 39 and 11 had 
high percentages of Trm cells and patients 54, 51 and 61 had high percentages of Tem but 
low percentages of Trm cells. Trm cells have previously been shown to positively correlate 
with the percentage of IgD−CD27− B cells, which were high during relapse in patients 29, 39 
and 11. The percentages of IgD−CD27− B cells in patients 51 and 61 were not available at the 
time of clinical relapse. The CD4+HLA-DR+ T cells of the patients also had high expression 
of CD49d.  
Patient 29 relapsed with arthralgia shortly after her B cells repopulated at week 34. Her 
lymphocyte levels fell from 1.89 to 0.76 x 109 cells/L at week 44 but her anti-dsDNA 
antibody levels remained below 10 IU/L. Retreatment with rituximab improved her symptoms 
but the problems recurred each time her B cells repopulated, again coinciding with a fall in 
her lymphocytes from 1.47 to 0.75 x 109 cells/L. 
Patient 39 relapsed with arthritis shortly after her B cells repopulated at week 48, which 
coincided with a large fall in her lymphocyte levels from 4.09 to 2.79 x 109 cells/L and a 
small rise in her anti-dsDNA antibody levels from 42 to 69 IU/L. She was retreated with 
rituximab and the B cells repopulated at 86 weeks, coinciding with a fall in her lymphocyte 
levels from 4.22 to 2.54 x 109 cells/L and another rise in her anti-dsDNA antibody level from 
28 to 66 IU/L. 
The B cells of patient 11 repopulated at week 36. Her lymphocytes started to fall at week 64 
from 1.92 to 1.56 x 109 cells/L. She initially relapsed with a malar rash at week 74. Her rash 
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and lymphocyte level improved with a course of oral prednisolone but as the dose was 
reduced her lymphocyte level fell again to 0.34 x 109 cells/L and remained low, although 
there was not a recurrence of her rash. At week 290 she developed a nephrotic-like syndrome 
with an increase in her urinary protein levels, hypoalbuminaemia and peripheral oedema. She 
also developed memory loss, which was attributed to cerebral lupus. There had been a small 
but steady rise in her anti-dsDNA antibody level from less than 10 at B cell repopulation to 
99 IU/L at week 308 when she had her second cycle of BCDT. 
Patient 54 relapsed with serositis when her B cells repopulated at week 30, which was 
followed by a fall in her lymphocyte count from 0.93 to 0.56 x 109/L. She was initially treated 
with intramuscular steroids but her pain worsened and she developed a skin rash at week 71 
after her lymphocyte count fell again from 1.11 to 0.44 x 109 cells/L and her anti-dsDNA 
antibody level had risen from 72 to 96 IU/L. At baseline she had had a skin biopsy, which 
showed a scattered lymphocytic infiltration within the dermis and a perivascular lymphocytic 
infiltrate that was only composed of CD3+ T cells, shown in chapter 5.4, supporting the 
hypothesis that the fall in the lymphocyte count in the blood is due to sequestration of T cells 
into the tissue. 
The B cells of patient 51 repopulated at week 37. Her lymphocyte count did not start falling 
until week 90, when her B cell count peaked at 0.114 x 109 cells/L. Her lymphocyte number 
fell from 2.12 to 0.66 x 109/L steadily over 120 weeks. Her anti-dsDNA antibody level only 
started rising at week 160 when it rose from less than 10 to 51 IU/L at week 196 when she 
developed a cutaneous vasculitis, abdominal pain and dyspnea. 
The B cells of patient 61 repopulated at week 23. Her lymphocyte count did not start falling 
until week 62 when her B cell count peaked at 0.131 x 109 cells/L. Her lymphocyte number 
fell from 0.99 to 0.2 x 109 cells/L. Her anti-dsDNA antibody levels started rising at week 94 
from 23 to 7472 IU/L when she developed a cutaneous vasculitis. 
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It has been suggested that lymphopaenia might be due to the lymphocytotoxic effects of anti-
dsDNA antibodies (375), but the results of patients 29, 51 and 61 show that the fall in 
lymphocyte numbers is unlikely to be due to anti-dsDNA antibodies as the anti-dsDNA 
antibodies were either not detectable (patient 29) or appeared after the lymphocyte numbers 
fell. It is more likely that the falling lymphocyte numbers reflects a process of T cell 
migration and tissue infiltration that leads to the production of anti-dsDNA antibodies. 
Following BCDT HLA-DR expression by CD4+ T cells falls but only in patients with low 
anti-dsDNA antibody levels 
It was hypothesized that B cells induce changes in CD4+ T cells to induce their migration into 
the tissue. If disease is characterized by T cell infiltration and a fall in circulating lymphocyte 
numbers in patients with low anti-dsDNA antibody levels then the changes in CD4+ T cells 
should be most noticeable in this group of patients. Studies have previously reported that the 
T cell expression of the activation markers, CD40L, CD69, HLA-DR and ICOS fall after 
BCDT in patients with SLE (290, 439, 501). The expression of the activation markers, CD69 
and HLA-DR by CD4+ T cells from patients were therefore compared before and after BCDT 
to confirm the results that were found in these studies and to determine whether changes in T 
cell activation markers differ in patients according to whether they had either low or high 
anti-dsDNA antibody levels (Figure 5.5.3). 
Patients with low anti-dsDNA antibody levels did not have significantly higher percentages of 
HLA-DR+ CD4+ T cells at baseline (n = 15) compared to healthy controls (n = 24) or with 
patients with inactive disease who had low anti-dsDNA antibody levels (n = 13). The 
expression of HLA-DR was lower than baseline at 6 weeks after BCDT (n =15) (p = 0.02, 
Wilcoxon matched-pairs signed rank test, two tailed) and at 16 weeks (n = 14) (p = 0.05, 
Wilcoxon matched-pairs signed rank test, two tailed; p < 0.03, Wilcoxon matched-pairs 
signed rank test, one tailed). The absolute numbers of CD4+HLA-DR+ T cells at baseline were 
also similar to healthy controls and patients with inactive disease. The numbers of CD4+HLA-
DR+ T cells was lower than baseline 6 weeks after BCDT (p = 0.02, Wilcoxon matched-pairs 
 170 
signed rank test, two tailed) and at 16 weeks (p = 0.04, Wilcoxon matched-pairs signed rank 
test, two tailed) and increased when B cells repopulated compared to week 6 after BCDT (p = 
0.03, Wilcoxon matched-pairs signed rank test, two tailed). 
Patients with high anti-dsDNA antibody levels at baseline (n = 13) had similar percentages of 
HLA-DR+ CD4+ T cells compared to healthy controls (n = 24) and patients with inactive 
disease (n = 5) with high anti-dsDNA antibody levels. The expression of HLA-DR did not 
change after BCDT at week 6 (n = 13), week 16 (n = 8) or at repopulation (n = 7). The 
absolute numbers of CD4+HLA-DR+ T cells also did not differ significantly between patients 
with active disease at baseline and healthy controls and patients with inactive disease and did 
not change significantly after BCDT. 
In patients with active disease at baseline the percentage of CD69+ CD4+ T cells was higher 
than in healthy controls in the groups with low anti-dsDNA antibody levels and the group 
with high levels (both p < 0.001, Mann-Whitney U test, two-sided). There was no difference 
seen between patients with active disease at baseline and patients with inactive disease and it 
did not change after BCDT in either the group with low anti-dsDNA antibody levels or the 
group with high levels. The absolute numbers of CD4+CD69+ T cells were not different 
between the healthy controls, the patients with active disease at baseline and the patients with 
inactive disease in either the group with low anti-dsDNA antibody levels or the group with 
high levels. 
Expression of HLA-DR by CD4+ T cells inversely correlates with absolute CD4+ T cell 
numbers after B cells repopulate in patients with low anti-dsDNA antibody levels 
A study has shown that during active SLE a fall in CD4+ T cell numbers coincides with a rise 
in the percentage of CD4+ T cells expressing HLA-DR and an increase in activated B cells 
(502). It was therefore hypothesized that there would be an inverse relationship between 
CD4+ T cell numbers and HLA-DR expression by CD4+ T cells, which would be dependent 
on the presence of B cells. CD4+ T cell numbers were plotted against the percentages of 
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HLA-DR expressing CD4+ T cells from patients treated with BCDT at least six months 
previously and then subanalysed according to whether B cells had repopulated to high 
numbers (>0.11 x 109 cells/L, n = 15), as defined in results chapter 5.1.2, low numbers (0.01 
to 0.11 x 109 cells/L, n = 28) or were still deplete of B cells (<0.01 x 109 cells/L, n = 10).  
There was a moderate inverse correlation between the absolute CD4+ T cell numbers and the 
percentages of CD4+ T cells expressing HLA-DR (rs = –0.47, p = 0.0004) and a weak inverse 
correlation between the absolute CD4+ T cell numbers and the percentages of CD4+ T cells 
expressing CD69 (rs = –0.39, p = 0.004) (Figure 5.5.4A).  
The inverse correlation between the CD4+ T cell numbers and the percentage of CD4+ T cells 
expressing HLA-DR was strong in patients with high B cell numbers (rs = –0.64, p = 0.01) 
and moderate in patients with low B cell numbers (rs = –0.48, p = 0.01). The inverse 
correlation between the CD4+ T cell numbers and the percentage of CD4+ T cells expressing 
HLA-DR was not significant in patients who were still deplete of B cells (rs = –0.57, p = 
0.09). The inverse correlation between the CD4+ T cell numbers and the percentage of CD4+ 
T cells expressing CD69 was strong in patients with high B cell numbers (rs = –0.63, p = 
0.01), but there was no significant correlation in patients with low B cell numbers or who 
were still deplete of B cells (rs = –0.28, p = 0.14 and rs = –0.38, p = 0.28 respectively) (Figure 
5.5.4B). 
It was shown in chapter 5.1.2 that relapse in patients with low anti-dsDNA antibody levels 
was associated with attainment of B cell numbers >0.11 x 109 cells/l. Amongst the 15 patients 
that had high B cell numbers two patients had an anti-dsDNA antibody level above 100 IU/L. 
When these patients were excluded the inverse correlation between the CD4+ T cell numbers 
and the percentage of CD4+ T cells expressing HLA-DR became stronger (rs = –0.77, p = 
0.003). The inverse correlation between the CD4+ T cell numbers and the percentage of CD4+ 
T cells expressing CD69 also became stronger (rs = –0.73, p = 0.007) (Figure 5.5.5). 
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There were 16 patients in the group who had active disease. Three of the patients were still B 
cell deplete. The inverse correlation between the CD4+ T cell numbers and the percentage of 
CD4+ T cells expressing HLA-DR was strong in the 13 patients that had active disease with B 
cells (rs = –0.68, p = 0.01) but weak in the 30 patients in remission with B cells (rs = –0.39, p 
= 0.03) (Figure 5.5.6A). Three of the 13 patients had anti-dsDNA antibody levels above 100 
IU/L. When only the 10 patients with low anti-dsDNA antibody levels were included in the 
analysis the inverse correlation between the CD4+ T cell numbers and the percentage of CD4+ 
T cells expressing HLA-DR again increased further (rs = –0.76, p = 0.01) (Figure 5.5.6B). The 
inverse correlation between the CD4+ T cell numbers and the percentage of CD4+ T cells 
expressing CD69 was moderate in the 13 patients that had active disease with B cells (rs = –
0.57, p = 0.04) but not significant in the 30 patients in remission with B cells (rs = –0.35, p = 
0.06) (Figure 5.5.6A). However, when the three patients with high anti-dsDNA antibody 
levels were excluded from the group with active disease the inverse correlation between the 
CD4+ T cell numbers and the percentage of CD4+ T cells expressing CD69 was no longer 
significant (rs = –0.52, p = 0.13) (Figure 5.5.6B). 
CD49d expression by CD4+HLA-DR+ T cells is higher in patients with active disease 
following B cell repopulation 
Studies have shown that CD3+ T cells in inflamed tissue in patients with SLE and other 
autoimmune rheumatic diseases, express HLA-DR and adhesion molecules (503-505), 
suggesting that CD4+HLA-DR+ T cells are inclined to migrate from the blood to the tissue. 
The adhesion molecules LFA-1 and VLA-4 are expressed at high levels on the CD4+ T cells 
of patients with SLE, although high VLA-4 expression was only seen in patients that 
developed vasculitis (164). Consistent with these studies, I found that the expression of 
CD49d, the alpha-4 subunit of VLA-4, was higher on the CD4+HLA-DR+ T cells from 
patients with active disease (n = 13) compared to patients that were in remission after B cells 
had repopulated following BCDT (n = 25) (p < 0.05, Mann-Whitney U test) (Figure 5.5.7). 
However, none of the patients that relapsed had vasculitis. It was also observed that in 
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patients with active disease, CD4+HLA-DR+ T cells expressed higher levels of CD49d than 
CD4+HLA-DR– T cells (p = 0.003, Wilcoxon matched-pairs signed rank test), suggesting that 
CD4+HLA-DR+ T cells are more likely to adhere to the vascular endothelium. 
HLA-DR expression by CD4+ T cells positively correlates with the percentage of IgD–
CD27– B cells before and after BCDT 
In chapter 5.1 it was shown that clinical relapse with low anti-dsDNA antibody levels 
following BCDT was associated with high percentages of IgD–CD27– B cells. As the fall in 
HLA-DR expression by CD4+ T cells following BCDT was only seen in patients with low 
anti-dsDNA antibody levels it was decided to test whether HLA-DR expression by CD4+ T 
cells correlated with IgD–CD27– B cells. Comparison of the expression of HLA-DR by CD4+ 
T cells with memory B cell subsets in healthy individuals (n = 14) and SLE patients who had 
not been treated with BCDT (n = 41) (Figure 5.5.8A) showed that there was a moderate 
positive correlation between the percentage of HLA-DR+ CD4+ T cells and the percentage of 
IgD–CD27– B cells (rp = 0.48, p = 0.002). There was also a moderate negative correlation 
between the percentage of HLA-DR+ CD4+ T cells and the percentage of IgD+CD27+ B cells 
(rp = –0.42, p = 0.006). There were no significant correlations between the percentage of 
HLA-DR+ CD4+ T cells and the percentage of IgD–CD27int B cells or IgD–CD27hi 
plasmablasts. 
A comparison of the percentage of HLA-DR+ CD4+ T cells and memory B cell subsets in 
patients treated with BCDT following B cell repopulation (n = 32) showed there was again a 
modest positive correlation between the percentage of HLA-DR+ CD4+ T cells and the 
percentage of IgD–CD27– B cells (rp = 0.34, p = 0.05) (Figure 5.5.8B). However, in contrast to 
the SLE patients and healthy individuals who had not been treated with rituximab there was 
not a significant correlation between the percentage of HLA-DR+ CD4+ T cells and the 
percentage of IgD+CD27+ B cells. There were also no significant correlations between the 
percentage of HLA-DR+ CD4+ T cells and the percentage of IgD–CD27int B cells or the 
percentage of IgD–CD27hi plasmablasts. 
 174 
During relapse the fall in CD4+ T cell numbers is related to the expression of HLA-DR 
but during remission the rise in CD4+ T cell numbers is independent of HLA-DR 
expression 
Figure 5.5.9 shows the changes in HLA-DR expression by CD4+ T cells with changes in 
CD4+ T cell numbers at different stages after BCDT; the first stage shows the changes in the 
first six months after BCDT, the second stage shows the changes during a later period after 
BCDT with prolonged B cell depletion and the third stage shows the changes when B cells 
repopulate. Patient 11 shows that HLA-DR expression falls immediately after BCDT but 
CD4+ T cell numbers remain low for the first 22 weeks. Patient 10 shows that in a patient who 
is still deplete of B cells between 30 and 73 weeks there is an increase in CD4+ T cell 
numbers but this is not related to HLA-DR expression by CD4+ T cells. Patient 56 shows that 
as B cells repopulate the CD4+ T cell numbers decrease as HLA-DR expression by the CD4+ 
T cells increase. 
B cells stimulated with either hypomethylated DNA or a BCR stimulant induce HLA-
DR expression via LFA-2 
EBV-transformed B cells can transfer HLA-DR to T cells via cognate interactions (506). 
Increased B cell activity in SLE has been attributed to abnormal signaling via the BCR (507, 
508) and TLR-9 (509). It was therefore decided to test whether BCR or TLR-9 stimulation of 
PBMCs from healthy controls (n = 5) and SLE patients (n = 5) for 96 hours could induce B 
cells to activate CD4+ T cells. (Fab’)2 anti-human IgM was used to stimulate the BCR and 
CpG 2006, which is hypomethylated DNA (198), was used to stimulate TLR-9. There was an 
increase in HLA-DR expression by CD4+ T cells when PBMCs from the healthy controls and 
SLE patients were stimulated with either (Fab’)2 anti-human IgM (p = 0.02 for healthy 
controls and p = 0.04 for SLE patients, paired t test) or CpG 2006 (p = 0.002 for healthy 
controls and p = 0.009 for SLE patients, paired t test). The B cells were depleted from the 
PBMCs to determine whether they were involved in the (Fab’)2 anti-human IgM or CpG 2006 
induced expression of HLA-DR by CD4+ T cells. The depletion of B cells from the PBMCs 
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of the healthy controls and SLE patients resulted in reduced expression of HLA-DR by CD4+ 
T cells of unstimulated PBMCs from the SLE patients (p = 0.02, paired t test), but not of 
unstimulated PBMCs from the healthy controls, and PBMCs stimulated with (Fab’)2 anti-
human IgM (p = 0.04 for healthy controls and p = 0.02 for SLE patients, paired t test) or CpG 
2006 (p = 0.01 for both healthy controls and SLE patients, paired t test) (Figure 5.5.10A). The 
expression of HLA-DR by CD4+ T cells did not differ between healthy controls and SLE, 
possibly because the PBMCs were taken from SLE patients without active disease at the time 
of the study. By contrast, stimulation of PBMCs with (Fab’)2 anti-human IgM  resulted in a 
significant increase in the expression of CD69 by CD4+ T cells from PBMCs of the healthy 
controls (p = 0.04, paired t test) but not from PBMCs of patients with SLE. Stimulation of 
PBMCs with CpG 2006 did not result in a significant change in CD69 expression by CD4+ T 
cells from healthy controls or SLE patients. The depletion of B cells from PBMCs resulted in 
a surprising rise in CD69 expression by CD4+ T cells from unstimulated PBMCs of the 
healthy individuals (p = 0.03, paired t test) but not of the SLE patients. There were no other 
changes in CD69 expression of CD4+ T cells from PBMCs depleted of B cells. 
To test whether the increased expression of HLA-DR by CD4+ T cells requires cognate 
interactions between CD4+ T cells and APCs, including B cells, (Fab’)2 anti-human IgM  
stimulated PBMCs were co-cultured with an antibody that blocks LFA-2 (CD2), which is a 
cell adhesion molecule found on T cells that binds to LFA-3 on APCs (510). Stimulation of 
PBMCs with (Fab’)2 anti-human IgM resulted in an increase in the expression of HLA-DR by 
CD4+ T cells from PBMCs of healthy controls (p = 0.009, paired t test) and SLE patients (p = 
0.03, paired t test). Blockade of LFA-2 resulted in reduced HLA-DR expression by CD4+ T 
cells from unstimulated PBMCs of healthy controls (p = 0.001, paired t test) and SLE patients 
(p = 0.008, paired t test) and from (Fab’)2 anti-human IgM stimulated PBMCs of healthy 
controls (p = 0.003, paired t test) and SLE patients (p = 0.02, paired t test) (Figure 5.5.10B). 
There was a small but significant increase in HLA-DR expression by CD4+ T cells of PBMCs 
stimulated with (Fab’)2 anti-human IgM and co-cultured with anti-CD2 compared to CD4+ T 
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cells of PBMCs stimulated with (Fab’)2 anti-human IgM without anti-CD2 (p < 0.05 for 
healthy controls and p  = 0.01 for SLE patients, paired t test), suggesting that factors other 
than LFA-2 are also involved in (Fab’)2 anti-human IgM induced HLA-DR expression by 
CD4+ T cells. 
DNA antibody rich serum combined with plasmid DNA can increase CD69 but not 
HLA-DR expression by CD4+ T cells in healthy PBMCs 
Patient 47, who was previously discussed in chapter 5.3, had high anti-dsDNA antibody 
levels at the time that her B cells started to repopulate and experienced 3 clinical relapses that 
were not associated with a substantial rise in her anti-dsDNA antibody levels or a fall in C3 
levels. However, her relapses were associated with a sharp fall in lymphocyte numbers 
(Figure 5.5.11A).  
It was previously shown that hypomethylated DNA can induce HLA-DR expression by CD4+ 
T cells when cultured with B cells. It was therefore hypothesized that anti-dsDNA antibodies 
induce HLA-DR expression by CD4+ T cells. PBMCs from healthy individuals (n = 6) were 
therefore cultured in heat-inactivated sera from patients with high anti-dsDNA antibody 
levels (>100 IU/L) with CpG or plasmid DNA.  The results show that the addition of CpG 
2006 to the healthy and SLE serum resulted in an increase in HLA-DR expression by CD4+ T 
cells (p = 0.03, Wilcoxon matched-pairs signed rank test) in contrast with the previous 
experiment, but was not affected by the SLE serum (Figure 5.5.11B). The addition of plasmid 
DNA to serum from SLE 2 also resulted in an increase in HLA-DR expression (p = 0.03, 
Wilcoxon matched-pairs signed rank test), but it was not significantly higher than the HLA-
DR expression by CD4+ T cells from the PBMCs cultured with healthy serum and plasmid 
DNA. 
The expression of CD69 is upregulated by Type 1 IFNs (511), which are produced at higher 
levels when PBMCs are cultured with anti-dsDNA antibody rich serum and plasmid DNA 
(181). It was therefore hypothesized that combining anti-dsDNA antibodies with 
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unmethylated DNA might induce CD69 expression by CD4+ T cells when added to PBMCs. 
In contrast to the previous experiment, the addition of CpG resulted in an increase in CD69 
expression by CD4+ T cells (p = 0.03, Wilcoxon matched-pairs signed rank test) but it was 
not affected by serum containing anti-dsDNA antibodies. Plasmid DNA also resulted in an 
increase in CD69 expression by CD4+ T cells but it was only statistically significant when it 
was added to the serum from patients 1 and 2 (p = 0.03, Wilcoxon matched-pairs signed rank 
test) and it was significantly higher in the PBMCs that were cultured in the serum from 
patient 2 with plasmid DNA compared to the PBMCs that were cultured in healthy serum 
with plasmid DNA (p = 0.03, Wilcoxon matched-pairs signed rank test) (Figure 5.5.11B). 
This experiment shows that B cells stimulated with CpG or via the BCR can induce HLA-DR 
expression by CD4+ T cells but stimulation of B cells with immune complexes bound to DNA 
did not have any effect on HLA-DR expression by CD4+ T cells, although it did increase 
CD69 expression. 
  
 178 
A  
  
 
 
 
 
 
B
 
Figure 5.5.1 – Changes in lymphocyte numbers following BCDT in relapsing patients 
compared with those that remain in remission 
(A) Lymphocyte numbers are shown at baseline (Pre), during B cell depletion (Dep), at B cell 
repopulation (Rep) and at remission (6 months post repopulation; Rem) or at clinical relapse 
in patients (Rel) who had either low anti-dsDNA antibody levels [low (<100 IU/L); n = 13 
(remission), n = 16 (relapse)] and high anti-dsDNA antibody levels [high (>100 IU/L); n = 8 
(remission), n = 11 (relapse)]. Columns indicate the means; bars indicate the S.E.M. 
Differences between the groups were analysed by Wilcoxon matched-pairs signed rank test. * 
p < 0.05, ** p < 0.01. (B) Comparison of T and B cell numbers between healthy controls 
[Healthy; n = 34], SLE patients with active disease at baseline [Active; n = 9] and rituximab 
naïve SLE patients in remission [Remission; n = 7]. Data are shown as dot plots with the 
mean represented by a horizontal bar. Differences between the groups were analysed by the 
Mann-Whitney U test. NS = p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Figure 5.5.2 – Changes in lymphocyte numbers, B cell numbers and anti-dsDNA 
antibody levels following BCDT 
Illustrations of the parallel changes in lymphocyte and B cell numbers and anti-dsDNA 
antibody levels following BCDT in six patients (ID numbers 11, 29, 39, 51, 54 and 61). The 
first cycle of therapy starts at week 0. An asterisk (*) is shown when BCDT is repeated 
(patients 29 and 39). Lymphocyte numbers (left Y-axis) and B cell numbers (right Y-axis) are 
both shown using a linear scale. A triangle (Δ) is shown when intramuscular 
methylprednisolone or a reducing course of high dose oral prednisolone was given for a flare 
of disease (patients 11 and 54). Anti-dsDNA antibody levels are shown using a logarithmic 
scale. 
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Figure 5.5.3 – Changes in the percentages and absolute numbers of CD4+ T cells 
expressing the activation markers, HLA-DR and CD69, following BCDT  
CD4+ T cells from patients with SLE were analysed for changes in the percentages and 
absolute numbers of cells expressing HLA-DR and CD69 before and after BCDT. Healthy 
controls [HC; n = 24], SLE patients with low anti-dsDNA antibody levels (Low DNA (<100 
IU/L)) with inactive disease [Inactive; n = 13], with active disease pre-BCDT [Baseline; n = 
15] at weeks 6 [6wk; n = 15] and 16 [16wk; n = 14] after BCDT and/or after B cell 
repopulation (B cell numbers >0.01 x 109/L) [Repop; n=11] and SLE patients with high anti-
dsDNA antibody levels (High DNA (>100 IU/L)) with inactive disease [Inactive; n = 5], with 
active disease pre-BCDT [Baseline; n = 13] at weeks 6 [6wk; n = 13] and 16 [16wk; n = 8] 
after BCDT and/or after B cell repopulation [Repop; n = 7]. Columns indicate the means; bars 
indicate the S.E.M. Differences between groups were analysed by Mann-Whitney U test for 
non-paired data or the Wilcoxon matched-pairs signed rank test for paired data. * p < 0.05, 
*** p < 0.001. 
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Figure 5.5.4 – Relationship between absolute CD4+ T cell numbers and the percentage of 
CD4+HLA-DR+ T cells and CD4+CD69+ T cells in the CD4+ T cell pool after BCDT  
Data were obtained at least 24 weeks following the last cycle of therapy and shown as scatter 
plots with lines of best fit, from (A) all SLE patients [n = 53], and (B) according to whether 
patients were deplete of B cells [B cell deplete (<0.01 x 109/L); n = 10], had low levels of B 
cells [Low no. of B cells (0.01 to 0.11 x 109/L); n = 28] or had high levels of B cells [High no. 
of B cells (>0.11 x 109/L); n = 15]. The Spearman Rank correlation coefficient (rs) is provided 
for each association. 
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Figure 5.5.5 – Relationship between absolute CD4+ T cell numbers and the percentage of 
CD4+HLA-DR+ T cells and CD4+CD69+ T cells in the CD4+ T cell pool from SLE 
patients with high B cell numbers and low anti-dsDNA antibody levels after BCDT  
Data were obtained at least 24 weeks following the last cycle of BCDT and shown as scatter 
plots with lines of best fit, from SLE patients with high B cell numbers (>0.11 x 109/L) and 
low anti-dsDNA antibody levels (<100 IU/L) after BCDT [n = 13]. The Spearman Rank 
correlation coefficient (rs) is provided for each association. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.6 – Relationship between absolute CD4+ T cell numbers and the percentage of 
CD4+HLA-DR+ T cells and CD4+CD69+ T cells in the CD4+ T cell pool after B cells have 
repopulated following BCDT  
Data were obtained at least 24 weeks following the last cycle of BCDT and shown as scatter 
plots with lines of best fit, from SLE patients with B cell numbers >0.01 x 109/L from (A) 
SLE patients with active disease [Relapse + B cells; n = 13] or in remission [Remission + B 
cells; n = 30] and (B) in SLE patients patients with B cell numbers >0.01 x 109/L with low 
anti-dsDNA antibody levels (<100 IU/L) and active disease  [n = 10]. Data are shown as 
scatter plots with lines of best fit. The Spearman Rank correlation coefficient (rs) is provided 
for each association.  
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Figure 5.5.7 – CD49d expression by CD4+ T cells in patients with SLE treated with 
BCDT 
Peripheral blood CD4+ T cells were analysed by flow cytometry for the expression of HLA-
DR and CD49d. Mean fluorescence intensity (MFI) of CD49d expression by CD4+HLA-DR– 
and CD4+HLA-DR+ T cells from age- and sex-matched healthy controls [HC; n = 10], SLE 
patients in remission post-BCDT [remission; n = 25] and SLE patients at relapse post BCDT 
[relapse; n = 13] are indicated. Columns indicate the means; bars indicate the S.E.M. 
Differences between groups were analysed by the Mann-Whitney U test for unpaired data and 
Wilcoxon matched-pairs signed rank test for paired data. Representative two-parameter dot 
plots obtained by flow-cytometry are shown. 
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Figure 5.5.8 – Relationship between the percentage of CD4+HLA-DR+ T cells in the 
peripheral CD4+ T cell pool and the percentages of CD19+ B cell memory subsets before 
and after BCDT 
CD19+ B cell memory subsets were identified using the surface markers IgD and CD27; non-
switched memory, IgD+CD27+, switched-memory, IgD−CD27int, plasmablasts, IgD−CD27hi 
and atypical memory, IgD−CD27−. (A) Pre-BCDT data from age- and sex-matched healthy 
controls [HC; n = 14] and patients with SLE who had not been treated with rituximab [SLE; n 
= 41]. (B) Post-BCDT data from SLE patients who had been treated with rituximab at least 24 
weeks previously [Repopulated; n = 32]. Data are represented as scatter plots with lines of 
best fit. The Pearson correlation coefficient (rp) is provided for each association. NS = p > 
0.05. 
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Figure 5.5.9 – Comparison of the changes in HLA-DR expression by CD4+ T cells and 
changes in CD4+ T cell and total lymphocyte numbers following BCDT 
Illustration of the three stages after BCDT – early depletion (first 24 weeks), late depletion 
(after 24 weeks) and B cell repopulation - showing the relationship between changes in CD4+ 
T cell numbers with changes in HLA-DR expression by CD4+ T cells when B cells are either 
deplete (patients 10 and 11) or repopulating (patient 56). HLA-DR expression of CD4+ T cells 
and CD4+ T cell numbers from different time-points after BCDT are shown with matched 
regression curves for patients who are deplete of B cells or have repopulated with B cells (left 
column) are shown with the changes in lymphocyte and B cell numbers (right column) in 
three patients who have been treated with BCDT. Patient 11 demonstrates changes that occur 
during the first 24 weeks following her second cycle of BCDT at week 301. Patient 10 
demonstrates changes during a period of B cell depletion at least 24 weeks after her last 
course of BCDT. Patient 56 demonstrates changes following a relapse in disease after B cells 
have repopulated. The numbers in the figures on the right correspond with time-points (in 
weeks) in the graphs on the left. An asterisk (*) marks disease flare. A dashed arrow marks 
retreatment with BCDT. The figures illustrate the dynamic relationship between activated T 
cells leaving the circulation and non-activated T cells entering the circulation and suggest that 
B cells are involved in the homeostatic control of circulating T cell numbers (shown in the 
schematic). CD49dhiHLA-DR+ T cells, which are induced by IgD–CD27– B cells, leave the 
circulation by migrating through the vascular endothelium whilst naïve HLA-DR– T cells 
enter the circulation after being produced by the bone marrow. 
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Figure 5.5.10 – Activation of CD4+ T cells by B cells in vitro  
(A) Changes in the expression of HLA-DR and CD69 by CD4+ T cells by depleting B cells 
from PBMCs of healthy individuals [n = 5] and patients with SLE [n = 5]. B cells were 
depleted by incubating the PBMCs with antibodies to CD19 attached to MicroBeads and 
passing the cells through magnetic columns. 2.5 x 106 cells were cultured in 200 µl of 
complete medium (RPMI with 10% foetal calf serum) for 96 hours with either no stimulant 
(Nil), 2.5 µg/ml F(ab’)2 anti-IgM (aIg) or 2 µM CpG 2006 (CpG). PBMCs with B cells are 
shown in black columns (B+) and without B cells are shown in grey columns (B–). Data are 
shown as the mean ± SEM. Differences between the groups were analysed by paired t test.    
* p < 0.05, ** p < 0.01. (B) Changes in the expression of HLA-DR by CD4+ T cells in 
PBMCs of healthy individuals [n = 6] and patients with SLE [n = 6] following inhibition of 
LFA-2 (CD2). 2.5 x 106 cells were cultured in 200 µl of complete medium (RPMI with 10% 
foetal calf serum) for 96 hours with either no stimulant (Nil), 2.5 µg/ml F(ab’)2 anti-IgM 
(aIg), 2 µg/ml anti-CD2 (aCD2) or both. PBMCs cultured without anti-CD2 are shown in 
dark columns and with anti-CD2 in light columns. Data are shown as the mean ± SEM. 
Differences between the groups were analysed by paired t test. * p < 0.05, ** p < 0.01. 
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Figure 5.5.11 – Activation of CD4+ T cells by anti-dsDNA antibodies in vitro 
(A) Illustration of the parallel changes in lymphocyte and B cell numbers with the changes in 
anti-dsDNA antibody levels following BCDT in patient 47. BCDT starts at week 0. 
Lymphocyte numbers (left Y axis) and B cell numbers (right Y-axis) are both shown using a 
linear scale. A black arrow is shown when intramuscular methylprednisolone or a reducing 
course of high dose oral prednisolone was given for a flare of disease. Anti-dsDNA antibody 
levels are shown using a linear scale. (B) Changes in the expression of HLA-DR and CD69 
by CD4+ T cells following co-culture of healthy PBMCs with SLE serum and plasmid DNA. 
PBMCs were obtained from healthy individuals [n = 6]. 2.5 x 106 cells were cultured in 200 
µl of medium (RPMI with 10% heat-inactivated human serum) for 72 hours with either no 
stimulant (Nil), 2µM CpG 2006 (CpG) or 10 µg/ml plasmid DNA (pDNA). Serum was 
obtained from one healthy individual as a control and three SLE patients with high anti-
dsDNA antibody levels. Differences between groups were analysed by Wilcoxon matched-
pairs signed rank test. NS = p > 0.05, * p < 0.05.  
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5.5.3 Discussion 
Two studies showed that lymphopaenia (a lymphocyte count of less than 1.5 x 109 cells/L) 
was seen in 75% and 82% of patients with active SLE at the time of presentation (369, 512), 
but in one of the studies most of the remaining patients also developed lymphopaenia during 
another episode of active SLE after the initial presentation. The cumulative frequency of 
lymphopaenia in the course of SLE in this study was 93%. It is the most prevalent laboratory 
abnormality at presentation, although there is disagreement about whether it predicts (513) or 
develops during disease exacerbations (370). 
A large multicentre study showed that lymphopaenia at presentation is positively associated 
with anti-dsDNA and Ro antibodies, renal disease, higher disease activity and damage accrual 
(368). Separate studies of patients with cutaneous disease have shown an association between 
lymphopaenia and antibodies to Ro, La and snRNPs (372) and with systemic disease (514). 
The association with systemic disease is consistent with observations seen in the five cases of 
cutaneous disease that were described in chapter 5.4. 
Lymphocytotoxic antibodies were first shown to be present in the serum of SLE patients over 
40 years ago (515), but their precise specificity and how they induce cell death has not been 
established. Some autoantibodies have been shown to bind to surface proteins on 
lymphocytes, including the surface protein CD4, but these autoantibodies have not been 
shown to have cytotoxic effects and, therefore, might not cause lymphocyte depletion (376, 
516, 517). One study has shown that two out of 25 anti-dsDNA antibodies produced from 
human-human hybridomas have lymphocytotoxic activity, but as most did not they are 
unlikely to be the cause of lymphopaenia in the majority of patients (375).  
Other mechanisms of lymphocytotoxicity have been suggested, including complement-
induced lysis (518), apoptosis (519) and viral destruction of T cells (520). Two studies have 
suggested that lymphopaenia might be due to lymphocyte sequestration into the tissue, but 
only one study has provided experimental data to support the hypothesis (384, 520). This is 
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surprising because there is now a large amount of evidence that lymphocytes, T cells in 
particular, infiltrate the tissue during active disease. The possibility that T cells can migrate 
into the tissue, whilst also being lysed by antibodies or dying by other mechanisms seems 
contradictory. Lymphopaenia in SLE is mostly due to low numbers of CD3+ T cells because 
they make up approximately 80% of all circulating lymphocytes. There is also evidence of a 
greater decrease in CD3+ T cells compared to B cells in active disease. It, therefore, seems 
logical that T cell sequestration into the tissue or SLOs is the cause of lymphopaenia.  
There have been several studies that have examined the mechanisms of T cell migration in 
systemic autoimmune diseases, although most use animal models (521). My observation that 
HLA-DR expression inversely correlates with CD4+ T cell numbers suggests that it has a 
functional role in T cell migration. This notion is supported by studies that show a high 
percentage of HLA-DR expression by T cells in the inflamed tissue, including in the renal 
interstitium and skin (297, 522).  High frequencies of circulating CD8+HLA-DR+ T cells has 
been shown to correlate with NPLE (523) and infiltration of the kidneys by CD8+ T cells 
(155). Another study showed profound lymphopaenia with high expression of HLA-DR by 
CD8+ T cells in patients with SLE (297). The observation that HLA-DR is co-expressed with 
CD49d in patients with active disease is consistent with the observation that CD4+ T cells 
from patients with scleroderma that migrate through endothelium are more likely to express 
HLA-DR and also express CD49d, in addition to other adhesion molecules (524).  
HLA-DR is a T cell activation marker. It might, therefore, be suggested that T cells are 
disappearing from the blood due to activation-induced cell death. However, T cells that have 
increased susceptibility to elimination by activation-induced cell death do not express higher 
levels of HLA-DR (525). Activation-induced cell death would also fail to account for the 
increase in lymphocytes, including HLA-DR+ lymphocytes, which are seen in the inflamed 
tissue during active disease. 
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To my knowledge, HLA-DR expression has not previously been shown to induce the 
migration of T cells but studies show that ligation of HLA-DR molecules on CD4+ T cells 
increases adhesion with other T cells by upregulating the adhesion pathways between the 
cells, including the LFA-2/LFA-3 interaction (526, 527). As mentioned in chapter 5.4, T cells 
are often seen in tissue without other cells present (152, 153) and it was suggested that T cell 
aggregation is the first stage of ELT formation. The fall in circulating lymphocyte numbers 
possibly reflects the aggregation of T cells and the formation of ELT. This is supported by the 
observation in this study of anti-dsDNA antibody levels rising shortly after the lymphocyte 
numbers fall in patients with low anti-dsDNA antibody levels at remission. It is also 
supported by observations in this and another study of HLA-DR expression by CD4+ T cells 
preceding the rise in anti-dsDNA antibody levels (502). It is therefore possible that the B cell 
induced HLA-DR expression by T cells initiates the formation of ELT. 
IgD–CD27– B cells are atypical memory B cells that have been shown to be associated with 
SLE (238, 271), but their function and role in the disease has not been clearly established. 
The data from this study provides evidence to suggest that IgD–CD27– B cells or their 
precursors might be transferring HLA-DR onto the surface of CD4+CD49dhi T cells, which 
increases the ability of T cells to adhere to other lymphocytes and potentially then aggregate 
in non-lymphoid tissue. This process would be limited by the number of IgD–CD27– B cells 
present, providing a possible explanation for the observation from chapter 5.1 that patients 
with low anti-dsDNA antibody levels relapse with higher B cell numbers than patients with 
high anti-dsDNA antibody levels. The results also provide the first evidence of an antibody-
independent role for B cells in causing human disease and supports the study of lupus-prone 
mice that showed T cell infiltration of the renal interstitium that was dependent on a non-
antibody secreting B cell (195). 
The role of the small collection of perivascular T cells that were seen in the patients with high 
anti-dsDNA antibody levels in chapter 5.4 is less clear. It is possible that they make the 
endothelium more permeable to antibodies. This hypothesis is supported by studies of neural 
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inflammation that showed disruption of the tight junctions between endothelial cells where 
activated non-neural specific T cells accumulated, allowing the development of autoantibody 
associated nerve damage (445-447). Endothelial cells can present antigen to T cells, including 
autoantigen, resulting in their activation (528, 529). What induces the binding of T cells to 
endothelial cells in SLE is not clear, but several factors that have been associated with active 
SLE can upregulate the expression of adhesion molecules by endothelial cells, including 
ultraviolet light (530), pro-inflammatory cytokines (531, 532), anti-dsDNA antibodies (159), 
and antiphospholipid antibodies (160). Intermittent upregulation of adhesion molecules on 
endothelial cells by these factors might explain the sudden small fall in circulating 
lymphocyte numbers during clinical relapse that was seen in the patient with high anti-
dsDNA antibodies prior to clinical relapse (patient 47). 
A new proposed model of peripheral inflammation is shown (Figure 5.5.12) that suggests that 
amongst patients with low anti-dsDNA antibody levels at remission tissue inflammation starts 
with lymphocyte migration, first T cells then B cells and FDCs, which create ELT from 
where anti-dsDNA antibody producing plasma cells can form resulting in immune complex 
deposition in the tissue, mediated by T cell induced dysregulation of the endothelial cells. 
Importantly, this pathway can be separated into 10 phases, some of which can possibly be 
determined by different biomarkers (Table 5.5.1). The process starts with the abnormal 
clearance of nuclear antigen (phase 1), which causes the activation of APCs, which then 
induce the differentiation of CD4+ T cells into either Tem or Trm cells (phase 2). These T 
cells induce a rise in B cell numbers with high percentages of the IgD–CD27– B cell subset 
(phase 3), followed by increasing numbers of CD4+CD49dhiHLA-DR+ T cells which is 
associated with a fall in circulating T cell numbers (phase 4), then a fall in B cell numbers 
(phase 5), causing ELT to form in the tissue (phase 6) and culminating in a rise in anti-
dsDNA antibody levels (phase 7) and immune complex deposition/ vasculitis leading to a fall 
in complement levels (phase 8 or 9). Thrombosis might then occur, either as a result of 
endothelial damage or the release of procoagulant factors during the inflammatory process 
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(533), although it can also occur in the absence of inflammation, particularly in patients with 
antiphospholipid antibodies (phase 10). The possible use of HLA-DR expressing T cells as a 
biomarker is supported by a study showing a positive correlation between CD4+HLA-DR+ T 
cells and SLE disease activity using the SLAM scale (534). 
It could possibly be assumed that the plasma cells that arise from this pathway are short-lived 
because anti-dsDNA antibody levels fall quite soon after BCDT. However, as this disease 
pathway only applies to patients who have low anti-dsDNA antibody levels at disease 
remission or during B cell depletion two important questions arise; where are the LLPCs that 
produce persistent circulating anti-dsDNA antibody levels being synthesized and what is the 
role of these persistent anti-dsDNA antibodies in the disease?  
The possible association between B cell activation of CD4+CD49dhi T cells and the 
subsequent formation of ELT is intriguing because blockade of VLA-4, using natalizumab, 
has been tried successfully in other autoimmune diseases where rituximab has also been 
shown to be beneficial (535), supporting the possibility of a linked mechanism of action 
between these two factors. It might also explain the reported associations of progressive 
multifocal leukoencephalopathy, a cerebral infection due to JC virus, with both of these drugs 
(536).  
B cell depletion has also been linked to reactivation of other viruses, including hepatitis B and 
C, cytomegalovirus, parvovirus, echovirus and varicella-zoster virus (537, 538), and 
cryptococcal infections in the blood, brain and bone (539-541), usually when co-administered 
with high dose chemotherapy. It could be suggested that the viral reactivation is due to the 
chemotherapy, but IgD–CD27– B cells have been shown to increase during infection with 
respiratory syncytial virus (277), suggesting that B cells have an important anti-viral role. The 
data from this study and the model proposed suggest that this effect might not only be due to 
antibody synthesis, but also IgD–CD27– B cells, which might have an important role in 
activating T cells to survey tissue that cannot be easily penetrated by circulating antibodies. 
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Studies suggest that B cells from patients with SLE are activated by antigen via the BCR 
(507, 508) and/or TLR-9 stimulants (509). This study shows that BCR and TLR-9 stimulants 
have similar effects on the activation of T cells by B cells. It therefore does not establish 
which specific stimulant, if any, is important in activating T cells in patients with SLE. Future 
work would examine the signaling pathways of these B cells because this will provide a better 
understanding of the factors that stimulate them and be a potential target for treatment, 
particularly in the patients with high expression of CD49d by CD4+ T cells. 
CD69 is a C-type lectin protein that is expressed on the surface of T cells at a very early stage 
of activation. Its expression on CD4+ T cells, which is high in patients with SLE (542), is 
increased by cytokines such as IFN-α but only substantially when the TCR is also stimulated 
(511). Whilst B cells present antigen they do not secrete certain cytokines, in particular IFN-
α, which might explain why CD69 expression did not decrease after BCDT – although this 
result contrasts with two previously published studies (290, 294), the reasons for which are 
not clear. Its expression could be increased by TLR-9 stimulation, but only when PBMCs 
were cultured in human serum and not when they were cultured in fetal calf serum. The 
reason for this difference is unclear but it is possibly due to the presence of human 
immunoglobulins in the human serum, which can activate APCs via Fc receptors. 
The ligand for CD69 is not known but animal studies suggest that its expression on CD4+ T 
cells has an important role in regulating T cells in (543, 544). More interestingly, it has also 
been shown to regulate the generation of memory T cells, their homing and survival in the 
bone marrow and assist the production of high affinity antibodies by controlling the homing 
of LLPC precursors to the bone marrow (545). A role for CD69 in T cell homing is supported 
by another study showing that it also controls thymic emigration (546). It is not known if it 
has similar functions in humans but the data from this study show that, like HLA-DR, it might 
also inversely affect T cell numbers in the circulation. However, whilst HLA-DR appears to 
induce the migration of T cells into non-lymphoid tissue to form ELT and SLPCs, the animal 
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studies suggest that CD69 instead increases the migration of T cells from the blood into the 
bone marrow where it provides help for LLPCs. 
Finally, it should be noted that HLA-DR expression by CD4+ T cells from SLE patients and 
healthy individuals did not differ when PBMCs were cultured in vitro but did differ when 
measured ex vivo. The most likely explanation for the different result is that the SLE patients 
chosen for the in vitro study were in remission, and one of the patients had very low numbers 
of B cells, which lowered the mean. 
In conclusion, this study suggests a sequence of events in patients with low anti-dsDNA 
antibody levels, starting with B cell expansion of the IgD–CD27– memory subset, followed by 
activation of CD4+CD49dhi T cells resulting in the disappearance of T cells from the 
circulation and a rise in anti-dsDNA antibody levels, presumably because ELT are formed in 
the tissue. This accounts for the formation of SLPCs in a subgroup of patients but does not 
explain the mechanisms that form LLPCs, which are more likely being generated in SLOs. 
The next study will examine further T cell differences between patients with anti-dsDNA 
antibodies produced by SLPCs and those produced by LLPCs. 
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Figure 5.5.12 – Development of anti-dsDNA antibodies in ectopic lymphoid tissue 
The inflammatory process of patients with low anti-dsDNA antibody levels during inactive 
disease can be divided into 10 possible phases, which can be identified by different 
biomarkers. First there is a rise in circulating B cell numbers, probably IgD–CD27– B cells. 
This is followed by reduced numbers of circulating CD4+ T cells. HLA-DR expression by 
CD4+ T cells is inversely correlated with circulating T cell numbers when B cells have 
repopulated after BCDT. In active disease after BCDT HLA-DR is expressed with CD49d 
(VLA-4), which is an adhesion molecule that binds to ligands on endothelial cells. Expression 
of HLA-DR by CD4+ T cells can be induced by TLR-9 or BCR stimulated B cells via LFA-1, 
which is expressed on T cells. After circulating CD4+ T cell numbers fall patients might 
develop symptoms, such as a rash, or they then develop ELT as B cells, and possibly FDCs, 
aggregate with T cells. There is then a rise in anti-dsDNA antibody levels, which leads to 
immune complex deposition or vasculitis. The inflammatory process of patients with high 
anti-dsDNA antibody levels during inactive disease is unclear. 
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Table 5.5.1 – Summary of the sequence of immunological events and correlations with 
biomarkers and clinical symptoms in patients with low anti-dsDNA antibody levels 
during inactive disease 
  
Immunological+event+ Biomarker+ Symptoms+
Phase+1+ Release&of&nuclear&
an-gen&
/& None&
Phase+2+ Dendri-c&cell&ac-va-on&
&
T&cell&diﬀeren-a-on&
Cytokines&(e.g.&IFN/alpha)&
&
Memory&T&cell&phenotypes&
Non/speciﬁc&symptoms&/&
Fa-gue,&myalgia&
Phase+3+ Expansion&of&IgD–CD27–&
B&cells&
&
&
Ac-va-on&of&T&cells&
Rising&circula-ng&B&cell&
numbers&with&high&%&of&
IgD–CD27–subset&
&
High&%&of&
CD4+Cd49dhiHLA/DR+&cells&
Phase+4+ T&cell&inﬁltra-on&of&non/
lymphoid&-ssue&
T&Lymphopaenia& Mild&focal&symptoms&/&
Malar&rash,&arthri-s,&
headache&Phase+5+ B&cell&inﬁltra-on&of&non/
lymphoid&-ssue&–&
crea-ng&B:T&aggregates&
B&Lymphopaenia?&
Phase+6+ Follicular&dendri-c&cells&
join&B:T&aggregates&in&
non/lymphoid&-ssue&–&
crea-ng&ectopic&
lymphoid&-ssue&
/&
Phase+7+ Forma-on&of&short/
lived&plasma&cells&
Rising&an-/dsDNA&
an-body&levels&
Fevers?,&arthralgia?&
Phase+8+ Immune&complex&
deposi-on&
Fall&of&complement&levels& Diﬀuse&rash,&serosi-s,&
glomerulonephri-s&
Phase+9+ Endothelial&damage& Vasculi-s&
Phase+10+ Thrombosis& An-phospholipid&
an-bodies&
DVT,&PE,&Stroke,&
Myocardial&infarc-on&
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5.6 Chemokine receptor expression by CD4+ T cells differs according to 
how anti-dsDNA antibody levels change after BCDT in SLE 
5.6.1 Introduction 
In chapter 5.1 it was suggested that there are three patterns of disease defined by the levels of 
anti-dsDNA antibodies and how they change following BCDT; active disease with low anti-
dsDNA antibodies but with high B cell numbers with a high percentage of IgD–CD27– B 
cells, active disease with high anti-dsDNA antibody levels that are high during the period of 
active disease and fall during periods of remission and active disease with persistently 
elevated anti-dsDNA antibodies that do not correlate with disease activity. Examples of these 
three patterns of clinical disease were provided by the case studies in chapter 5.3. In chapter 
5.4 it was shown that there are histological differences in the inflamed tissue with some 
possible links to the anti-dsDNA antibody level, with patients with low levels having more T 
cell infiltration. However, anti-dsDNA antibodies appeared later in the patient that also had B 
cells in the infiltrate suggesting that T cell infiltration is the first stage in the formation of 
ELT. In chapter 5.5, it was shown that B cell repopulation is associated with a fall in 
circulating T cell numbers, which correlates with the expression of HLA-DR by 
CD4+CD49dhi T cells. HLA-DR expression by CD4+ T cells correlated with the percentage of 
IgD–CD27– B cells, suggesting that these cells are inducing the migration of CD4+ T cells.  
In most patients there was a rise in anti-dsDNA antibody levels shortly after T cell numbers 
fell, supporting the hypothesis that these T cells are migrating to form ELT. It would appear 
that the plasma cells that produce these anti-dsDNA antibodies are short-lived, as the anti-
dsDNA antibody levels fall after BCDT. By contrast anti-dsDNA antibodies that persist after 
BCDT are most likely secreted by long-lived plasma cells (LLPC) (547). Studies of humans 
and mice with autoimmune disease have shown that these LLPCs mostly reside in SLOs (548, 
549), but they have also been found in the inflamed kidneys of mice with lupus-like disease 
(550). Repeat biopsies of kidneys from SLE patients treated with rituximab have shown that 
plasma cells remain present in the tissue even when B cells are absent (441). However, it is 
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not known if the LLPCs that are seen in the peripheral tissue are arising from ELT or 
migrating from SLOs.  
It was hypothesized that if anti-dsDNA antibodies that disappear after BCDT are initially 
arising from ELT then the time at which they reappear would depend on the rate of T cell 
migration to the non-lymphoid tissue and the number of circulating IgD–CD27– B cells to 
activate them, which was shown to correlate with the proportion of circulating revertant 
memory T cells (Trm) and to a lesser extent effector memory T cells (Tem) in chapter 5.2.  
The proposed model suggests that patients with levels that rise and fall depending on the 
severity of the disease would have T cells that migrate to non-lymphoid tissue, whilst those 
patients that have high anti-dsDNA antibody levels that never return to normal, even during 
remission, would have T cells that migrate to SLOs.  
T cells from patients with SLE have been shown to express a number of different chemokine 
receptors, some which guide migration to the non-lymphoid tissue and others that guide 
migration to SLOs. I therefore decided to compare the expression of chemokine receptors and 
adhesion molecules of CD4+ T cells in patients depending on the levels of their anti-dsDNA 
antibody levels during active disease and remission and their memory T cell subsets.  
It was also hypothesized that there might be differences between patients depending on 
whether their B cells were likely to repopulate early with high percentages of IgD–CD27– B 
cells or late after BCDT, which can be predicted by the percentage of revertant (Trm) or 
effector (Tem) memory T cell subsets as was shown in chapter 5.2. 
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5.6.2 Results 
Patients were divided into three columns according to the levels of their anti-dsDNA antibody 
levels during active and inactive disease; if they rise with disease activity and then fall below 
50 IU/L during remission (1), if they remain <50 IU/L regardless of disease severity (2), or 
remain elevated even during remission (3). Each column was divided into three rows 
according to their percentage of memory T cell as previously described in chapter 2; patients 
with revertant memory T cells >0.8% (A), with effector memory T cells >3% and Trm <0.8% 
(B) or with neither high Trm or Tem cells (C), thus creating 9 groups in total.  
Chemokine receptors 
The expression of chemokine receptors and adhesion molecules of CD4+ T cells by CD4+ T 
cells were compared between the 9 groups (Table 5.6.1). As the precise pathology of group 2 
was unclear it was decided to compare them between columns 1 and 3, who were 
hypothesized to have disease due to plasma cells from ELT and SLOs respectively.   
The chemokine receptors and adhesion molecules that were examined were CXCR3, CCR4, 
CCR5, CCR7 with CD62L, CD49d by CD4+ T because they have all been shown to be 
increased in different subgroups of patients with SLE. Studies show that terminally 
differentiated effector memory T cells have higher percentages of cells that express receptors 
that are specific for chemoattractants to non-lymphoid tissue, such as CXCR3, CCR4 and 
CCR5, and have lower percentages of cells that express receptors for chemoattractants to 
SLOs, such as CCR7 and CD62L. However, it was hypothesized that patients with 
persistently elevated anti-dsDNA antibody levels due to LLPCs from SLOs would have a 
higher percentage of CD4+ T cells expressing CCR7 and CD62L, whilst patients with levels 
of anti-dsDNA antibodies that return to normal after BCDT, and are therefore being produced 
by SLPCs from ELT, would have a higher percentage of CD4+ T cells expressing CXCR3, 
CCR4, CCR5 and CD49d.  
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Comparisons of columns within each row showed that the percentage of CCR7+CD62L+ 
CD4+ T cells was significantly lower in column 1 compared to column 3 in rows A (p = 
0.0001) and B (p = 0.04). The expression of CD49d by CD4+ T cells was significantly higher 
in group 1 compared to group 3 in the rows A (p = 0.0007) and B (p = 0.04). The percentage 
of CXCR3+ and CCR5+ CD4+ T cells was significantly higher in column 1 compared to group 
3 but only in row A (p = 0.007 for CXCR3 and p < 0.0001 for CCR5). The percentage of 
CCR4+ CD4+ T cells did not differ between the columns. 
Comparisons of rows within each column showed that the percentage of CCR7+CD62L+ 
CD4+ T cells was significantly lower in row A compared to C row in columns 1 (p < 0.0001) 
and 2 (p = 0.001) but not in column 3. The expression of CD49d by CD4+ T cells was 
significantly higher in the row A compared to rows B (p < 0.0001) and C (p = 0.0005) but 
only in the column 1. The percentage of CXCR3+ CD4+ T cells was significantly higher in 
row A compared to row C in the columns 1 (p = 0.002) and 2 (p = 0.04) but not in column 3. 
The percentage of CCR5+ CD4+ T cells was significantly higher in row A compared to row C 
in column 1 only (p < 0.0001). The percentage of CCR4+ CD4+ T cells did not differ between 
the rows. 
Comparisons of groups regardless of rows and columns showed that the mean percentage of 
CXCR3+ and CCR5+ CD4+ T cells and the mean level of expression of CD49d by CD4+ T 
cells was highest in the group A1, particularly when compared with group C1 (p = 0.02 for 
CXCR3, p = 0.0001 for CCR5 and p = 0.005 for CD49d), group C3 (p = 0.007 for CXCR3, p 
< 0.0001 for CCR5 and p = 0.005 for CD49d) and group A3 (p = 0.06 for CXCR3, p = 
0.0002 for CCR5 and p = 0.007 for CD49d). However, there was no significant difference in 
the expression of CXCR3, CCR5 and CD49d by CD4+ T cells of patients in the C3 group 
compared to patients in the A3 group. The mean percentage of CD4+ T cells expressing CCR4 
did not differ between any of the group. The mean percentage of CCR7+CD62L+ CD4+ T 
cells was lowest in group A1 when compared with groups C1 (p = 0.001), C3 (p < 0.0001) 
and A3 (p < 0.0001). Similar to the results that were seen with the other chemokine receptors 
 201 
there was no significant difference in the mean percentage of CCR7+CD62L+ CD4+ T cells in 
group A3 compared to group C3. 
One-way ANOVA with post test for linear trend showed that there was a significant negative 
linear trend in the mean percentage of CXCR3+ and CCR5+ CD4+ T cells from the A1 to the 
A3 (p = 0.03 for CXCR3, p = 0.01 for CCR5) and the C3 groups (p = 0.002 for CXCR3, p = 
0.001 for CCR5) and a positive linear trend in the mean percentage of CCR7+CD62L+ CD4+ 
T cells from the A1 to the A3 (p = 0.0006) and the C3 groups (p < 0.0001) supporting the 
hypothesis that column 2 is an intermediate group with patients that share pathology with 
groups in either columns 1 and 3. 
Although CCR4 expression did not differ between the groups, the percentage of CD4+ T cells 
that express CCR4 was higher in all groups compared to healthy controls (p < 0.05, Mann-
Whitney U test) except in the A1, A3 and C1 groups. Also, whilst the percentage of CD4+ 
cells expressing CCR5 did not differ between the groups A3 and C3, there was significant 
difference in the percentage of CD4+CCR5+ T cells in the A3 group compared to healthy 
controls (p = 0.015, Mann Whitney U test) but there was not a significant difference between 
group C3 and healthy controls (p = 0.26, Mann Whitney U test). 
There is therefore statistically significant difference in the expression of chemokine receptors 
between the groups, in particular between rows A and B of columns 1 and 3. The CD4+ T 
cells of patients in column 1 are more likely to express chemokine receptors for non-
lymphoid tissue and high levels of CD49d, whilst the CD4+ T cells of patients in column 3 are 
more likely to express chemokine receptors for SLOs. Statistically significant difference was 
consistently greatest between groups A1 and the C3 suggesting that they had diametrically 
opposite T cell migrating patterns, which might explain the differences in the changes in anti-
dsDNA antibody levels following BCDT between the two groups. Figure 5.6.1 illustrates the 
differences in the expression of the chemokine receptors CCR5, CCR7, CD62L, CXCR3 and 
the adhesion molecule CD49d by CD4+ T cells from patients in the groups A1, A3 and C3. 
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Disease manifestations 
The incidence of clinical manifestations was compared between the groups using Fisher’s 
exact or Chi-squared tests (Table 5.6.2). Glomerulonephritis (WHO Class III to V) occurred 
most frequently in the columns 1 and 3, which had high anti-dsDNA antibodies (p = 0.002 
Chi-square test), consistent with other studies. Vasculitis occurred most frequently in column 
1 (p = 0.03, Chi-square test for trend). Neuropsychiatric disease occurred most frequently in 
row A (p = 0.02, Chi-square test) and was also associated with higher percentages of CCR5 
expressing CD4+ T cells when the one case of CNS vasculitis was excluded (p = 0.03, Mann 
Whitney U test) (data not shown). Lymphadenopathy occurred most frequently in column 3 
(p = 0.003, Chi-square test) and there was significant positive trend as T cells became more 
differentiated (p = 0.02, Chi-square test for trend).  However, it is possible that 
lymphadenopathy was under-recorded. 
There were no statistically significant differences in the incidence of cytopaenia, mouth 
ulcers, serositis, alopecia and rashes between the groups. 
Laboratory parameters 
Complement levels and leukocyte numbers have been shown to be abnormal in some but not 
all patients with active disease. I therefore investigated whether there are significant 
differences in C3 levels, and numbers of lymphocyte and monocytes prior to BCDT between 
the groups (Table 5.6.3).  
Multiple comparisons tests showed that there was a significant difference in the mean C3 
level at baseline between column 3 and column 2 (p = 0.02). The results are consistent with 
studies that have shown an association between hypocomplementaemia and high anti-dsDNA 
antibodies.  However, there were no other significant differences between the groups. In 
particular, patients in column 1, who had high anti-dsDNA antibody levels during active 
disease that fell after BCDT, had mean C3 levels that were not significantly different to 
patients in column 2, who had persistently low anti-dsDNA antibody levels.  
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Comparisons of the mean number of lymphocytes at baseline within each column showed that 
in column 1 row A had the highest number of lymphocytes compared to rows B (p = 0.0002) 
and C (p = 0.01). Similarly comparisons within each row showed that in row A the mean 
lymphocyte number was highest in column 1 compared to columns 2  (p = 0.005) and 3 (p = 
0.009). Comparisons of groups regardless of rows and columns showed that the mean 
lymphocyte number was again highest in group A1 compared to groups B1 (p = 0.002), A2 (p 
< 0.05), B2 (p < 0.05) and C3 (p = 0.02). 
Comparisons of the mean number of monocytes at baseline did not reveal any statistically 
significant differences between the groups. 
Age at diagnosis 
Comparisons of the mean age of diagnosis between the groups regardless of columns and 
rows showed that patients in group A2 were diagnosed at an older age compared to patients in 
the B1 (p = 0.01) and B3 (p < 0.05) groups (Table 5.6.4). Comparisons of rows within each 
column showed that patients in the A2 group had a significantly higher mean age of diagnosis 
compared to patients in the C2 group (p = 0.04). Comparisons of columns within each row 
did not reveal any significant differences between the groups.  
Response to BCDT 
It has already been shown that the median time to relapse following BCDT was lower in 
patients with more differentiated T cells but there was surprisingly no significant difference in 
patients with high anti-dsDNA antibody levels compared to patients with low anti-dsDNA 
antibody levels at the time of treatment. In this study the time to relapse was compared 
between the 9 groups. A significant difference in survival curves was seen between the 
groups (p = 0.02, log-rank (Mantel-Cox) test) (Table 5.6.5). Group A3 had the lowest median 
time to relapse of 8 weeks, whilst groups C1 and C3 had the highest median times to relapse 
of 287 and 295.5 weeks respectively. Thus it shows that the time to clinical relapse is 
associated with several CD4+ T cell factors, including the memory T cell phenotypes, which 
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correlate with the rate of B cell repopulation, and their expression of chemokine receptors and 
adhesion molecules, which are associated with different patterns of changes in the anti-
dsDNA antibody levels. 
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Table 5.6.1 – Expression of chemokine receptors and adhesion molecules by CD4+ T 
cells in SLE patients treated with BCDT 
Expression of chemokine receptors and adhesion molecules by CD4+ T are shown in groups 
of patients that are divided according to their memory T cell phenotypes (rows; High Trm 
(A), High Tem with low Trm (B) or Low Tem (C)) and how anti-dsDNA antibody levels 
change after BCDT (columns; High at baseline (>50 IU/L) and fall after BCDT (1), Low (2) 
or Persistently elevated after BCDT (3)). Data shows the mean with 95% confidence interval 
and numbers in the group in parentheses. Differences between the groups were analysed by 
two-way ANOVA with Tukey’s multiple comparison post-test. Statistical significance is 
shown for comparisons with group A1 (shown in bold). * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001. 
 
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
CXCR3+))
%)
High%Trm%%A) 59.9)
(661.56181.2;%2)%
39.9%
(20.4659.4;%4)%
31.1%
(14.4647.8;%4)%
High%Tem%%B% 31.6*%
(25.9637.3;%14)%
33.4%
(26.8640.0;%8)%
27.7**%
(21.3634.1;%15)%
Low%Tem%%C) 13.7*%
(—;1)%
23.5**%
(14.9632.1;%7)%
22.3**%
(610.4655.1;%3)%
)
CCR7+)
CD62L+))
%)
High%Trm%%A) 14.1)
(61046132;%2)%
40.0%
(28.2649.8;%4)%
58.0**%
(45.0670.9;%4)%
High%Tem%%B% 55.0***%
(46.1663.9;%14)%
53.7**%
(46.4660.9;%8)%
65.3****%
(60.0670.7;%15)%
Low%Tem%%C) 82.7****%
(68.86174;%2)%
65.0****%
(56.4673.6;%7)%
71.8***%
(42.56101;%3)%
)
CD49d))
MFI)
High%Trm%%A) 299.0)
(1976400;%2)%
102.2***%
(54.46150;%4)%
147.4**%
(25.56269;%4)%
High%Tem%%B% 145.0**%
(1116178;%13)%
99.2****%
(69.96128;%5)%
98.9****%
(78.36119;%10)%
Low%Tem%%C) 79.8**%
(—;1)%
106.6****%
(81.46132;%7)%
118.1**%
(61726409;%2)%
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Table 5.6.1 continued 
Expression of chemokine receptors and adhesion molecules by CD4+ T are shown in groups 
of patients that are divided according to their memory T cell phenotypes (rows; High Trm 
(A), High Tem with low Trm (B) or Low Tem (C)) and how anti-dsDNA antibody levels 
change after BCDT (columns; High at baseline (>50 IU/L) and fall after BCDT (1), Low (2) 
or Persistently elevated after BCDT (3)). Data shows the mean with 95% confidence interval 
and numbers in the group in parentheses. Differences between the groups were analysed by 
two-way ANOVA with Tukey’s multiple comparison post-test. Statistical significance is 
shown for comparisons with group A1 (shown in bold). * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001. 
  
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
CCR4+))
%)
High%Trm%%A) 19.6%
(944.6983.7;%2)%
37.1%
(22.8951.4;%4)%
29.1%
(4.9953.3;%4)%
High%Tem%%B% 31.7%
(22.3941.1;%14)%
37.9)
(30.4945.4;%8)%
27.2%
(21.6932.8;%15)%
Low%Tem%%C) 19.4%
(—;1)%
26.1%
(21.1931.1;%7)%
28.7%
(20.4936.9;%3)%
)
CCR5+))
%)
High%Trm%%A) 55.9)
)(91839295;%2)%
19.1****%
(8.0930.3;%4)%
20.9***%
(11.2930.3;%4)%
High%Tem%%B% 16.6****%
(11.3921.9;%14)%
16.3****%
(11.9920.7;%8)%
11.3****%
(8.1914.6;%15)%
Low%Tem%%C) 5.8***%
(—;1)%
9.8****%
(6.0913.6;%7)%
13.7****%
(912.3939.6;%3)%
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Figure 5.6.1 – Expression of chemokine receptors and adhesion molecules by CD4+ T 
cells in SLE patients treated with BCDT 
Representative flow cytometry dot plots showing the expression of CCR7, CD62L, CCR5, 
CXCR3 and CD49d by CD4+ T cells from patients in groups A1, A3 and C3. Values 
represent the percentage of CD4+ T cells expressing CCR7, CD62L, CCR5 and CXCR3 and 
the mean fluorescence intensity of CD49d expression. 
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Table 5.6.2 – Clinical symptomatology in SLE patients treated with BCDT  
Percentage (numbers) of patients with SLE symptoms are shown in groups that are divided 
according to their memory T cell phenotypes (rows; Low Tem (N), High Tem with low Trm 
(E) or High Trm (R)) and how anti-dsDNA antibody levels change after BCDT (columns; 
High at baseline (>50 IU/L) and fall after BCDT (1), Low (2) or Persistently elevated (3)). 
Differences between the groups were analysed by Chi-square test or Chi-square test for trend. 
Rows or columns with significantly higher incidence of symptoms are shown in bold. 
  
p=0.03 
Chi2-test for trend 
  
p=0.002  
Chi2-test 
  
p=0.02  
Chi2-test 
  
p=0.003  
Chi2-test 
  
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
Renal)(Class)
III)to)V))
High%Trm%%A) 33%(1/3)% 0%(0/5)% 50%(2/4)%
High%Tem%%B% 81%(13/16)% 25%(2/8)% 47%(7/15)%
Low%Tem%%C) 0%(0/2)% 14%(1/7)% 100)(4/4)%
)
Vasculi#s)
High%Trm%%A) 0%(0/3)% 0%(0/5)% 0%(0/4)%
High%Tem%%B% 38%(6/16)% 13%(1/8)% 7%(1/15)%
Low%Tem%%C) 50%(1/2)% 14%(1/7)% 25%(1/4)%
)
NPLE)
High%Trm%%A) 33%(1/3)% 40%(2/5)% 25)(1/4)%
High%Tem%%B% 7%(1/16)% 25%(2/8)% 0%(0/15)%
Low%Tem%%C) 0%(0/2)% 0%(0/7)% 0%(0/4)%
)
Lymphadeno
pathy)
High%Trm%%A) 0%(0/3)% 0%(0/5)% 75%(3/4)%
High%Tem%%B% 0%(0/16)% 0%(0/8)% 20%(3/15)%
Low%Tem%%C) 0%(0/2)% 0%(0/7)% 0)(0/4)%
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Table 5.6.2 continued 
Percentage (numbers) of patients with SLE symptoms are shown in groups that are divided 
according to their memory T cell phenotypes (rows; Low Tem (N), High Tem with low Trm 
(E) or High Trm (R)) and how anti-dsDNA antibody levels change after BCDT (columns; 
High at baseline (>50 IU/L) and fall after BCDT (1), Low (2) or Persistently elevated (3)). 
Differences between the groups were analysed by Chi-square test or Chi-square test for trend. 
Rows or columns with significantly higher incidence of symptoms are shown in bold. 
 
 
 
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
Serosi#s)
High%Trm%%A) 33%(1/3)% 20%(1/5)% 25%(1/4)%
High%Tem%%B% 31%(5/16)% 13%(1/8)% 33%(5/15)%
Low%Tem%%C) 100%(2/2)% 29%(2/7)% 25%(1/4)%
)
Cytopaenia)
High%Trm%%A) 0%(0/3)% 20%(1/5)% 0%(0/4)%
High%Tem%%B% 25%(4/16)% 0%(0/8)% 7%(1/15)%
Low%Tem%%C) 0%(0/2)% 14%(1/7)% 0%(0/4)%
)
Mouth)Ulcers)
High%Trm%%A) 0%(0/3)% 20%(1/5)% 25%(1/4)%
High%Tem%%B% 13%(2/16)% 13%(1/8)% 13%(2/15)%
Low%Tem%%C) 0%(0/2)% 0%(0/7)% 0%(0/4)%
)
Alopecia)
High%Trm%%A) 0%(0/3)% 20%(1/5)% 25%(1/4)%
High%Tem%%B% 31%(5/16)% 25%(2/8)% 13%(2/15)%
Low%Tem%%C) 0%(0/2)% 13%(1/7)% 0%(0/4)%
)
Skin)
High%Trm%%A) 33%(1/3)% 60%(3/5)% 50%(2/4)%
High%Tem%%B% 56%(9/16)% 88%(7/8)% 53%(8/15)%
Low%Tem%%C) 50%(1/2)% 43%(3/7)% 0%(0/4)%
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Table 5.6.3 – Baseline complement levels and circulating numbers of lymphocytes and 
monocytes of SLE patients treated with BCDT  
Baseline complement levels and numbers of lymphocytes and monocytes are shown in groups 
of patients that are divided according to their memory T cell phenotypes (rows; Low Tem 
(N), High Tem with low Trm (E) or High Trm (R)) and how anti-dsDNA antibody levels 
change after BCDT (columns; High at baseline (>50 IU/L) and fall after BCDT (1), Low (2) 
or Persistently elevated (3)). Data shows the mean with 95% confidence interval and numbers 
in the group in parentheses. Differences between the groups were analysed by two-way 
ANOVA with Tukey’s multiple comparison post-test. Statistical significance is shown for 
comparisons with group A1 (shown in bold). * p < 0.05, ** p < 0.01. 
  
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
C3)
High%Trm%%A) 1.10)
(60.5062.71;%3)%
1.13%
(0.5461.73;%5)%
0.58%
(60.3261.48;%3)%
High%Tem%%B% 0.73%
(0.5860.87;%16)%
0.88%
(0.4961.26;%7)%
0.72%
(0.5760.87;%15)%
Low%Tem%%C) 0.85%
(64.6866.37;%2)%
0.93%
(0.7061.15;%7)%
0.58%
(0.2960.87;%4)%
)
Lymph)
High%Trm%%A) 2.43)
(61.8166.66;%3)%
0.98*%
(0.4961.47;%5)%
0.91%
(0.8261.01;%3)%
High%Tem%%B% 0.76**%
(0.5061.03;%16)%
1.07*%
(0.6161.53;%7)%
1.27%
(0.8761.66;%13)%
Low%Tem%%C) 0.81%
(60.9762.59;%2)%
1.70%
(1.3962.02,%7)%
0.74*%
(60.1761.66;%4)%
)
Mono)
High%Trm%%A) 0.62)
(0.2960.94;%3)%
0.40%
(0.1460.66;%5)%
0.33%
(60.1460.81;%3)%
High%Tem%%B% 0.40%
(0.2860.52;%16)%
0.42%
(0.2660.57;%7)%
0.47%
(0.3360.62;%11)%
Low%Tem%%C) 0.23%
(60.0960.54;%2)%
0.54%
(0.3260.75;%7)%
0.29%
(60.1860.76;%4)%
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Table 5.6.4 – Age at diagnosis of SLE patients treated with BCDT  
Age shown in groups of patients that are divided according to their memory T cell phenotypes 
(rows; Low Tem (N), High Tem with low Trm (E) or High Trm (R)) and how anti-dsDNA 
antibody levels change after BCDT (columns; High at baseline (>50 IU/L) and fall after 
BCDT (1), Low (2) or Persistently elevated (3)). Data shows the mean with 95% confidence 
interval and numbers in the group in parentheses. Differences between the groups were 
analysed by two-way ANOVA with Tukey’s multiple comparison post-test. Statistical 
significance is shown for comparisons with group A2 (shown in bold). * p < 0.05. 
 
 
Table 5.6.5 – Disease free survival of SLE patients following BCDT  
Disease free survival shown in groups of patients that are divided according to their memory 
T cell phenotypes (rows; Low Tem (N), High Tem with low Trm (E) or High Trm (R)) and 
how anti-dsDNA antibody levels change after BCDT (columns; High at baseline (>50 IU/L) 
and fall after BCDT (1), Low (2) or Persistently elevated (3)). Data shows the median time to 
relapse with numbers in each group in parentheses. Differences between the groups were 
analysed by log-rank (Mantel-Cox) test.  
  
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
Age)at)
diagnosis)
High%Trm%%A) 21%
(61066148;%2)%
38.4)
(25.8651.0;%5)%
27.0%
(14.3639.7;%4)%
High%Tem%%B% 19.4*%
(15.0623.9;%16)%
29.6%
(23.2636.1;%8)%
21.7*%
(14.1629.3;%15)%
Low%Tem%%C) 26.5%
(61326185;%2)%
23.7%
(19.1628.3;%7)%
22.5%
(16.3628.7;%4)%
An#$dsDNA)level)IU/L)
Min:%0%to%50%
Max:%>%50%
1)
Min:%0%to%50%
Max:%0%to%50%
2)
Min:%>100%
Max:%>200%
3)
)
Median)
disease)free)
survival)
following)
BCDT)(weeks))
High%Trm%%A) 48%
(n=3)%
41%
(n=5)%
8%
(n=3)%
High%Tem%%B% 89.5%
(n=16)%
56%
(n=6)%
40%
(n=15)%
Low%Tem%%C) 287%
(n=2)%
150%
(n=7)%
295.5%
(n=4)%
p=0.02 
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5.6.3 Discussion 
In chapter 5.5 it was suggested that SLPCs are formed by ELT, which are initiated by the 
migration and then aggregation of T cells in the non-lymphoid tissue. The results of this study 
support this model by showing that patients with low anti-dsDNA antibody levels at 
remission that then increase during relapse have higher percentages of CD4+ T cells that 
express chemokine receptors for the non-lymphoid tissue and vascular adhesion molecules. 
The markers CXCR3 and CCR5 have been seen on CD4+ T cells in renal tissue and urine 
from patients with nephritis, whilst CD49d has been seen on CD4+ T cells of patients with 
vasculitis but this is the first study to suggest that these markers might be important for the 
development of ELT and the formation of SLPCs.  
This study also shows that patients with anti-dsDNA antibody levels that do not return to 
normal after B cell depletion have high percentages of CD4+CCR7+CD62L+ T cells that 
migrate to SLOs, supporting murine studies that show that LLPCs are generated in the SLOs. 
The results also provide evidence to suggest that LLPCs are formed by T cell help, which has 
not been shown before in human SLE. 
The pathogenesis of SLE therefore appears to be characterized by two distinct processes – the 
first is an effector memory immune response initiated by T cell activation and migration, 
followed by ELT formation leading to SLPCs (Figure 5.6.2). The second is a central memory 
immune response defined by circulating anti-dsDNA antibodies produced by LLPCs 
generated and maintained in SLOs (Figure 5.6.3). Both processes are likely to play a role in 
the disease, although to varying degrees in different patients, and overlap in some patients. As 
a result patients would be expected to have different responses to therapy, in particular 
BCDT, which is supported by the observed differences in the median time to relapse.  
Patients with mainly cellular inflammation will have disease that responds relatively rapidly 
to B cell depletion but relapse as soon as B cells repopulate, whilst patients with mostly 
antibody mediated pathology might take longer to respond, depending on how long immune 
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complexes are cleared from the circulation and tissue and the time it takes for the LLPCs to 
eventually die but they then appear to take longer to relapse. However, some patients (in 
group A3 in particular) appear to have features of both cellular inflammation (with 
moderately high percentages of CD4+CCR5+ T cells and Trm cells) and LLPCs (with 
moderately high percentages of CD4+CCR7+CD62L+ T cells), which is the most likely 
explanation for their poor response to BCDT. On the other hand patients with low 
percentages of CD4+CCR5+ T cells, SLPCs, low anti-dsDNA antibody levels at baseline and 
low percentages of memory T cells (groups C1 and C2) have the best responses to BCDT as 
would be predicted. 
The good response to BCDT by patients in group C3, who have persistently elevated anti-
dsDNA antibody levels is surprising and difficult to explain. All of the patients in this group 
had renal disease, but it is not clear why depleting B cells would lead to an improvement in 
disease, particularly renal disease, if anti-dsDNA antibody levels remain high. It is possible 
that the renal lesions are due to other nephritotoxic antibodies, such as anti-nucleosome 
antibodies, that can decrease after BCDT (435) or that B cells are needed for an additional 
reason that has not yet been elucidated. Anti-dsDNA antibodies cause variable proteinuria in 
SCID mice (194), supporting the possibility that B cells might be an additional requirement 
for glomerular inflammation. Chapter 5.4 showed that the skin histology of patients with high 
anti-dsDNA antibodies and cutaneous disease had small perivascular T cell infiltrates. These 
T cell infiltrates might be important for allowing antibodies to cross the endothelium, as has 
been demonstrated in autoimmune neuropathies (445, 446). It is possible that B cells are also 
important in activating these perivascular T cells, although this mechanism does not appear to 
be associated with HLA-DR expression by CD4+CD49dhi T cells. 
One study has suggested that there are two different types of renal disease in SLE - one that is 
dependent on circulating immune complexes and another that is dependent on lymphocytic 
infiltration (152). This hypothesis is supported by the results from this study. It would be 
interesting to compare the renal lesions between patients in groups A1 and B1 with those in 
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B3 and C3. I would hypothesize that patients in group A1 and B1 would have more interstitial 
infiltrates and vasculitis, whilst patients in B3 and C3 would have more pure glomerular 
lesions with fewer lymphocytic infiltrates. 
The mechanisms that induce T cells to differentiate into either central or effector memory in 
SLE are unknown but is likely to be due to a combination of cytokines, including IFN-α and 
IL-6, secreted by APCs that have been stimulated by nuclear antigen. Each group had slightly 
different patterns of ENA antibodies (data not shown). Group A1 had Ro antibodies only, 
whilst the patients in the C3 group all had Sm and RNP antibodies. It is tempting to speculate 
that these different combinations of autoantibodies might be inducing the secretion of a 
different combination of cytokines, although it is also possible that they reflect the differences 
in the pathogenesis between a more cellular immune process and a humoral immune process.  
This study has so far shown that the four factors that appear to predict the rate of disease flare 
after BCDT are: 1) the rate of B cell repopulation, 2) B cell differentiation to the IgD–CD27– 
memory subset, 3) anti-dsDNA antibody levels at the time of B cell repopulation, which is 
associated with the tendency of CD4+ T cells to migrate to SLOs where LLPCs are likely to 
be produced and 4) the ability of CD4+ T cells to form ELT to produce SLPCs that can make 
more anti-dsDNA antibodies, which is associated with the tendency of CD4+ T cells to 
migrate to the non-lymphoid tissue. A method of stratifying patients into nine groups is 
proposed using markers that are associated with differences in the rates of B cell repopulation 
and differentiation (memory T cell subsets) and chemokine receptors for either non-lymphoid 
tissue and/or SLOs (Table 5.6.6). As expected group A3, that had all four of these factors 
(high percentage of Trm cells that are associated with fast rates of B cell repopulation and 
high percentages of IgD–CD27– memory B cells), and CD4+ T cells that expressed chemokine 
receptors for SLOs and the non-lymphoid tissue and therefore had the poorest response to 
BCDT. This group possibly corresponds to the group that we have previously identified in an 
open-label study that does not respond to BCDT (425). 
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This is a unique method of stratifying patients and comparing clinical parameters and 
outcomes to therapy. It has three important advantages. The first is that it provides an 
opportunity to identify combinations of factors that might contribute towards the pathogenesis 
of the disease symptoms and manifestations, and as a result identify the biomarkers and 
therapeutic targets that might be helpful for that group of patients. For example, vasculitis 
was most common in a group of patients with high levels of CD49d. However, it was not seen 
in group A1 where CD49d was also high, suggesting that an additional factor, possibly 
CD11a, is also required (164). NPLE was more common in patients with high percentages of 
Trm cells suggesting that a combination of factors such as IgD–CD27– B cells, and the 
expression of CCR5 and possibly CXCR3 by CD4+ T cells might be important, supported by 
a study showing high CSF levels for chemokines that are specific for both of these chemokine 
receptors (551). Lymphadenopathy might be due to a combination of CXCR3 and CCR7 
expression by CD4+ T cells and anti-dsDNA antibodies. However, this analytical approach 
might have certain limitations. For example, the lack of a significant difference in symptoms 
such as serositis, alopecia and skin inflammation between the groups might either suggest that 
T cells do not have an important role in the pathogenesis or that a chemokine receptor that is 
expressed in high percentages by CD4+ T cells in all or most groups, such as CCR4, might 
contribute to the disease. Skin lesions from patients with cutaneous LE have been shown to 
have significant numbers of CCR4+ T cells, particularly from scarring lesions (322), but I was 
unable to detect a specific association between CCR4 and skin disease. One possible 
explanation is that the clinical data available to me was modest and did not differentiate 
between the various subtypes of skin disease. 
The second and most important potential benefit of this stratification is that it might help to 
predict the likely outcome from therapeutic interventions or expect different responses to 
therapy. A larger prospective study would be needed to validate this method of stratification 
but if confirmed future clinical trials should achieve more predictable and positive outcomes.  
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The third benefit is that once patients are stratified it becomes possible to then quantify the 
progression of the disease, particularly in the patients with low anti-dsDNA antibody levels at 
remission (explained in discussion 5.5.3). Some of these biomarkers are not useful for 
patients with anti-dsDNA antibody levels that remain high during remission – i.e. IgD–CD27– 
B cells and CD4+CD49dhiHLA-DR+ T cells. However, this group can be identified by the 
high expression of CCR7 and CD62L by CD4+ T cells (Figures 5.6.1 and 5.6.3). In this group 
relapse appears to be associated with the appearance of plasmablasts and possibly a fall in 
circulating lymphocyte numbers in some patients, although the precise sequence of events 
that lead to tissue inflammation and the significance of the lymphopaenia is less clear. A 
better understanding of the disease process in this group with persistently elevated anti-
dsDNA antibody levels might result in better biomarkers. Table 5.4.1 in chapter 5.4 showed 
that the inflamed skin of the patients with high anti-dsDNA antibody levels during active 
disease had immune deposits with small perivascular T cell infiltrates and low circulating 
lymphocyte numbers. In this group it is possible that the perivascular T cells cause disruption 
of the endothelial barrier allowing antibodies and complement to cross into the interstitium. 
The complex inflammatory pathway that is illustrated is a proposal. An in vivo model would 
be needed to prove it conclusively, but this would be impossible to do in humans and animal 
models have obvious limitations, such as being too homogeneous. However, the model 
predicts that the relapse rate of patients after BCDT will be influenced by T cell 
differentiation and their chemokine receptors, which has proven correct, and therefore 
supports the proposed model of disease. 
  
 217 
 
 
 
 
 
 
 
 
Figure 5.6.2 – Development of short-lived plasma cells in ectopic lymphoid tissue 
The development of short-lived plasma cells that produce anti-dsDNA antibodies is 
associated with the expression of CXR3, CCR5 and CD49d (VLA-4) by CD4+ T cells in 
patients with high percentages of CD4+CD45RA+CD27– revertant T cells (TR) suggesting that 
SLPCs are formed in ectopic lymphoid tissue. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.3 – Development of long-lived plasma cells in secondary lymphoid organs 
The development of long-lived plasma cells that produce anti-dsDNA antibodies is associated 
with the expression of CCR7 and CD62L by CD4+ T cells in patients with low percentages of 
CD4+CD45RA+CD27– revertant T cells (TR) suggesting that LLPCs are formed in germinal 
centres in the SLOs, such as the lymph nodes, spleen and bone marrow. Recruitment of 
myeloid dendritic cells into the germinal centres in the SLOs is also likely to be important in 
this process. 
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Table 5.6.6 – Summary of groups according to T cell markers and anti-dsDNA antibody 
levels  
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5.7 The monocyte recruiting chemokines, IP-10 and MCP-1, are elevated 
in SLE patients with high anti-dsDNA antibody levels that do not fall after 
BCDT 
5.7.1 Introduction 
Chemokines recruit leukocytes to SLOs and sites of inflammation. The serum, tissue and 
urinary levels of several chemokines are increased in patients with active SLE (316, 322, 388, 
412, 413, 551-553), but the precise source of the chemokines and their effect on leukocytes in 
the disease is unclear. One study has suggested that DCs are the main source of chemokines 
in inflamed tissue (554). However, lymphocytes are seen in non-lymphoid tissue even when 
DCs are not present (152, 153), suggesting that they might be another important source of the 
chemokines.  
B cells are able to produce several different chemokines (50, 183, 416). Therefore, it was 
hypothesized that they are the source of the high levels of chemokines in the serum of patients 
with SLE and that B cell depletion would lead to a fall in the serum levels of the chemokines 
that attract T cells and APCs either to SLOs, where LLPCs are formed, or to non-lymphoid 
tissue. 
Some of the results in this study were obtained by Andrew Fester for his intercalated BSc 
project, which I co-supervised.  
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5.7.2 Results 
MCP-1 and IP-10 levels positively correlate with anti-dsDNA antibody levels before 
BCDT 
Immune complexes containing anti-dsDNA antibodies have been shown to increase the 
synthesis of chemokines by both DCs and B cells (183). Several of these chemokines have 
been shown to be increased in the serum or urine of patients with active SLE (413) and attract 
T cells (RANTES, MIG, MCP-1 and IP-10), monocytes (MCP-1, IP-10, IL-8) and neutrophils 
(IL-8). I therefore examined whether there was a correlation between anti-dsDNA antibody 
levels and the serum levels of the chemokines MCP-1, IP-10, MIG, RANTES and IL-8 in  
SLE patients not previously treated with rituximab (n = 23). The results showed that there 
was a positive correlation between anti-dsDNA antibody levels and MCP-1 (rp = 0.52, p = 
0.014) and IP-10 levels (rp = 0.54, p = 0.009) but there was no correlation with RANTES (rp = 
0.31, p = 0.15), MIG (rp = –0.05, p = 0.80) or IL-8 levels (rp = 0.10, p = 0.67) (Figure 5.7.1). 
These results are supported by another study, which has also shown a positive correlation 
between IP-10 and anti-dsDNA antibody levels (553). 
MCP-1 and IP-10 levels are not affected by the presence of B cells but might be 
increased by high anti-dsDNA antibody levels 
It was then hypothesized that if anti-dsDNA antibodies induce the synthesis of MCP-1 and 
IP-10 then the serum levels of these chemokines would only fall after BCDT in the group of 
patients whose anti-dsDNA antibody levels also fall. As in the previous study patients were 
divided into 3 groups; 1) low (<50 IU/L; n = 8), 2) fluctuating (>50 IU/L at baseline but fall 
by 50% and below 100 IU/L after BCDT; n = 5) and 3) persistently high anti-dsDNA 
antibody levels (>100 IU/L following BCDT; n = 5). The results showed that MCP-1, IP-10 
and MIG levels pre-BCDT were higher in patients with high anti-dsDNA antibody levels that 
did not fall after BCDT (group 3) compared to patients with low anti-dsDNA antibody levels 
(group 1) (p < 0.0001 for MCP-1, p < 0.001 for IP-10 and p < 0.05 for MIG, 2-way ANOVA 
with Sidak’s multiple comparisons test) and compared to patients with high anti-dsDNA 
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antibody levels that fell after BCDT (group 2) (p < 0.0001 for MCP-1, p < 0.01 for IP-10 and 
p < 0.05 for MIG, 2-way ANOVA with Sidak’s multiple comparisons test) (Figure 5.7.2). 
MCP-1 and IP-10 levels post BCDT were also higher in patients with high anti-dsDNA 
antibody levels that did not fall after BCDT (group 3) compared to patients with low anti-
dsDNA antibody levels (group 1) (p < 0.0001 for MCP-1 and p < 0.01 for IP-10, 2-way 
ANOVA with Sidak’s multiple comparisons test) and compared to patients with high anti-
dsDNA antibody levels that fell after BCDT (group 2) (p < 0.0001 for MCP-1 and p < 0.01 
for IP-10, 2-way ANOVA with Sidak’s multiple comparisons test). IL-8 levels also were 
higher in group 3 compared to group 1 following BCDT (p < 0.05, 2-way ANOVA with 
Sidak’s multiple comparisons test). 
After BCDT none of the chemokine levels changed significantly in the groups of patients 
with low anti-dsDNA antibody levels pre-BCDT (group 1) or in the group of patients with 
high anti-dsDNA antibody levels that did not change after BCDT (group 3). However, in the 
group of patients whose anti-dsDNA antibody levels were high pre-BCDT and fell after 
BCDT (group 2) there was a significant fall in IL-8 levels (p = 0.04 for IL-8, paired t test), 
although the baseline levels were not significantly higher than the levels in patients with low 
anti-dsDNA antibody levels (group 1). There were no significant changes in MCP-1, IP-10, 
MIG and RANTES levels after BCDT. These data therefore support the studies that show that 
anti-dsDNA antibodies induce the synthesis of MCP-1, IP-10 and IL-8. B cells might produce 
IL-8 or induce its production by other cells, but they do not appear to be important for the 
production of MCP-1, IP-10, MIG and RANTES. 
BCR stimulated PBMCs produce higher levels of MCP-1 and IL-8 but purified BCR 
stimulated B cells only produce IL-8 
Studies have shown that B cells can produce MCP-1 (202). To examine whether B cells from 
SLE patients produce higher levels of MCP-1, PBMCs from healthy controls (n = 3) and SLE 
patients (n = 7) were cultured with goat anti-human Ig F(ab’)2, which activates B cells by 
binding to the BCR. The results showed that SLE PBMCs produced higher levels of MCP-1 
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and IL-8 when stimulated (p = 0.031 and 0.046 respectively, Wilcoxon matched-pairs signed 
rank test) (Figure 5.7.3). Healthy PBMCs also appeared to produce higher levels of MCP-1 
and IL-8 but the numbers of samples used was too small to reach significance. There were no 
significant differences in the levels of IP-10, MIG or RANTES when healthy or SLE PBMCs 
were stimulated. 
To determine whether B cells were producing MCP-1 and IL-8, B cells were purified from 
the PBMCs from healthy controls (n = 3) and SLE patients (n = 8) and cultured with goat 
anti-human Ig F(ab’)2. Stimulated B cells from SLE patients produced higher levels of IL-8 (p 
= 0.016, Wilcoxon matched-pairs signed rank test) but did not produce higher levels of MCP-
1, IP-10, MIG or RANTES (Figure 5.7.4). The observation that stimulated B cells from SLE 
patients produce IL-8 is consistent with a study showing B cell production of IL-8 following 
stimulation with immune complexes containing DNA (183). The data therefore suggest that B 
cells synthesize IL-8 and induce the synthesis of MCP-1 via other cells, most likely myeloid 
cells.  
Monocyte levels do not rise after BCDT in patients with persistently elevated anti-
dsDNA antibody levels 
One study has shown that monocyte levels increase after BCDT. It was hypothesized that if 
MCP-1 and IP-10 levels remain elevated after BCDT in patients with persistently elevated 
anti-dsDNA antibody levels then monocyte numbers should also remain low in this group. 
The monocyte counts of patients with low (group 1; n = 11), fluctuating (group 2; n = 11) and 
persistently elevated anti-dsDNA antibody levels (group 3; n = 16) who relapsed when B cells 
repopulated after BCDT were therefore compared (Figure 5.7.5). The results showed that the 
mean monocyte number of patients in group 3 was 0.35 x 109 cells/L at baseline (normal 
range 0.2 to 1.0 x 109 cells/L) compared to 0.49 x 109 cells/L in group 1 and 0.50 x 109 cells/L 
in group 2, although it was not significantly lower than the other groups. However, 5/16 
patients had a monocyte count below the normal range compared to 2/11 patients in group 1 
and 1/11 in group 2 with fluctuating anti-dsDNA antibody levels. There were no significant 
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changes in monocyte numbers between baseline and B cell depletion in any of the groups. 
Surprisingly, monocyte numbers fell as B cells repopulated in group 1 (p < 0.01, Wilcoxon 
matched-pairs signed rank test), but there were no significant changes in monocyte numbers 
after B cells repopulated in groups 2 and 3 with high anti-dsDNA antibody levels, suggesting 
that B cells are influencing monocyte numbers independently of anti-dsDNA antibodies. It is 
possible that IL-8 influences circulating monocyte numbers as it was previously shown that B 
cells can produce IL-8 with just BCR stimulation.  
CD14+ cells were not seen in high numbers in the biopsies of patients with cutaneous 
disease 
To examine whether monocytes might be present in the inflamed tissue, skin biopsies from 
the active lesions of five patients were stained for CD14. The results showed that CD14+ 
myeloid cells were seen in small numbers (5 to 10% of cells) in three of the five biopsies, 
from patients 78, F and G (Table 5.7.1). There was no relationship between circulating 
monocyte numbers and the presence of monocytes in the skin. Thus, the cause of the low 
circulating monocyte numbers in patients with SLE remains unclear. 
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Figure 5.7.1 – Relationship between the serum levels of the chemokines MCP-1, IP-10, 
MIG, RANTES and IL-8 and anti-dsDNA antibody levels in patients with SLE not 
treated with BCDT  
Serum chemokine levels are plotted against the anti-dsDNA antibody levels of patients with 
SLE not treated with BCDT [n = 23]. Data are represented as scatter plots with lines of best 
fit. The Pearson correlation coefficient (rp) is provided for each association. NS = p > 0.05. 
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Figure 5.7.2 – Serum levels of chemokines MCP-1, IP-10, MIG, RANTES and IL-8 in 
SLE patients with active disease treated with BCDT 
Serum levels of chemokines from SLE patients treated with BCDT that have been divided 
into three groups according to how their anti-dsDNA antibody levels change after treatment; 
Group 1 – low anti-dsDNA antibody levels [<50 IU/L; n = 8], Group 2 – high anti-dsDNA 
antibody levels that fall after BCDT [>50 IU/L and fall by 50% and below 100 IU/L; n = 5] 
and Group 3 – high anti-dsDNA antibody levels that do not fall after BCDT [>100 IU/L; n = 
5]. Data are shown as dot plots with lines representing the mean. Differences between groups 
were analysed by 2-way ANOVA and paired t test for paired data. * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001. 
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Figure 5.7.3 – Expression of chemokines MCP-1, IP-10, MIG, RANTES and IL-8 by 
PBMCs following BCR stimulation in vitro 
PBMCs were obtained from healthy individuals [n = 3] and patients with SLE [n = 7]. 2.5 x 
106 cells were cultured in 200 µl of complete medium (RPMI with 10% foetal calf serum) for 
48 hours with either no stimulant (Nil) or 2.5 µg/ml F(ab’)2 anti-Ig (anti-Ig). Chemokines 
were measured by cytometric bead array. Data are shown as dot plots with lines representing 
the mean. Differences between groups were analysed by Mann-Whitney U test for unpaired 
data and Wilcoxon matched-pairs signed rank test for paired data. * p < 0.05. 
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Figure 5.7.4 – Expression of chemokines MCP-1, IP-10, MIG, RANTES and IL-8 by B 
cells following BCR stimulation in vitro 
PBMCs were obtained from healthy individuals [n = 3] and patients with SLE [n = 8]. B cells 
were isolated by incubating the PBMCs with a cocktail of antibodies against CD2, CD14, 
CD16, CD36, CD43, and CD235a attached to MicroBeads and passing the cells through 
magnetic columns. 2.5 x 106 cells were cultured in 200µl of complete medium (RPMI with 
10% foetal calf serum) for 48 hours with either no stimulant (Nil) or 2.5 µg/ml F(ab’)2 anti-Ig 
(anti-Ig). Chemokines were measured by cytometric bead array. Data are shown as dot plots 
with lines representing the mean. Differences between groups were analysed by Mann-
Whitney U test for unpaired data and Wilcoxon matched-pairs signed rank test for paired 
data. * p < 0.05. 
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Figure 5.7.5 – Changes in monocyte numbers following BCDT in relapsing patients 
Monocyte numbers are shown at baseline, during B cell depletion, at B cell repopulation and 
at remission (6 months post repopulation) or at clinical relapse in all patients [n = 38] and in 
three groups that have been divided according to how their anti-dsDNA antibody levels 
change after treatment; Group 1 – low anti-dsDNA antibody levels [<50 IU/L; n = 11], Group 
2 – high anti-dsDNA antibody levels that fall after BCDT [>50 IU/L and fall by 50% and 
below 100 IU/L; n = 11] and Group 3 – high anti-dsDNA antibody levels that do not fall after 
BCDT [>100 IU/L; n = 16]. Columns indicate the means; bars indicate the S.E.M. 
Differences between the groups were analysed by Wilcoxon matched-pairs signed rank test 
for paired data. * p < 0.05, ** p < 0.01. 
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Table 5.7.1 – Comparison between myeloid cell infiltrates in lupus skin lesions and anti-
dsDNA antibody and C3 levels before BCDT 
Immunohistochemical analysis of myeloid (CD14+) cells in tissue biopsies of active skin 
lesions from five patients with SLE who had not been treated with rituximab (ID numbers 54, 
62, 78, F and G). Original magnification: x400. Results from the direct immunofluorescence 
are also given with symptomatology, disease duration, ENA antibody seropositivity, anti-
dsDNA antibody levels, C3 levels and monocyte numbers. 
 
  
!
!!ID! CD14+!cells! IMF! Disease!
duration!
Symptoms! ENA! Anti=
dsDNA!
(IU/L)!
C3!
(g/dL)!
Mono!
(x109/L)!
!!62!
!
!
Granular!deposits!of!IgM!and!C3!at!the!BMZ.!In!addition!there!is!epidermal!ANA!staining.!!
7!months!(2008)! Malar!rash,!fatigue!and!arthralgia! Ro+!La+! 11! 0.83! 0.52!
!!78!
!
Data!not!available! 11!years!(1999)! Malar!rash!only.!No!constitutional!symptoms!!(Digital!vasculitis!and!fever!after!9!months)!
RNP+!Sm(+)!Ro(+)! 62!!!!!(2686!after!9!months)!
1.07!!!!(0.30!after!9!months)!
0.37!!!!(0.20!after!9!months)!
!!54!
!
Speckled!BMZ!staining!with!IgM,!IgA!and!to!a!lesser!extent!with!C3.!
22!years!(1985)! Diffuse!desquamating!rash,!serositis!and!fever!
Negative! 70! 0.60! 0.10!
!!F!
!
Granular!deposits!of!IgM,!IgG,!IgA!and!C3!at!the!BMZ.!!
7!years!(2002)! Diffuse!macular!rash,!alopecia,!mouth!ulcer,!nephritis!(class!II),!arthralgia,!!and!fever!
Ro+! 366! 0.39! 0.24!
!!G!
!
Granular!deposits!of!IgM,!IgG,!IgA!at!the!BMZ!and!colloid!bodies!labelling!with!IgM,!IgG!and!IgA!in!the!papillary!dermis!and!along!the!dermoVepidermal!junction.!
1!month!(2010)! Diffuse!desquamating!rash,!hair!loss,!thrombocytopaenia,!arthralgia,!weight!loss!and!fever!
Negative! 300! 0.38! 0.11!
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5.7.3 Discussion 
Monocytopaenia is a recognized feature of active SLE (337), which, like lymphopaenia, has 
also been attributed to the presence of cytotoxic antibodies (555). In chapters 5.4 to 5.6 it was 
suggested that lymphopaenia is instead due to T cell migration and I think that 
monocytopaenia is also likely to be due to monocyte migration, either to the non-lymphoid 
tissue where it contributes to the formation of ELT and/or to SLOs.  
Myeloid cells were present in three of the five histological specimens that were examined and 
studies of renal biopsies also show the presence of monocytes and macrophages near the 
glomerulus in patients with lupus nephritis showing that monocytes are certainly migrating to 
the tissue, although possibly only in small numbers. Monocyte migration to SLOs is difficult 
to demonstrate in humans, but it has been demonstrated in animal models of autoimmune 
disease (556). 
The mechanism of monocytopenia appears to differ between patients. In patients with 
persistently high anti-dsDNA antibodies the monocytopenia might be related to high serum 
levels of MCP-1 and IP-10, synthesized by non-B cells. In the previous study it was shown 
that CD4+CCR7+CD62L+ T cells, that migrate to SLOs, might be important for the 
development of LLPCs. The preliminary evidence that MCP-1 and IP-10 remain high in 
patients with high anti-dsDNA antibody levels after BCDT suggests that monocyte 
recruitment might also have a role. This is supported by a study using an experimental model 
for myasthenia gravis that showed that MCP-1 is important for the recruitment of monocytes 
to the draining lymph node, where it contributes to the initiation of B cell mediated 
autoimmunity (556). Therefore, recruitment of monocytes to the SLOs, where they become 
MDCs, might be an additional step, along with the recruitment of CD4+CCR7+CD62L+ T 
cells, towards the establishment of niches from which LLPCs can develop. This would create 
a vicious circle, which can only be stopped by depleting the LLPCs or blocking MCP-1 
and/or IP-10.  
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Whilst B cells do not appear to directly recruit monocytes, TLR-9 stimulated B cells have 
been shown to increase IFN-α production by PDCs (557), which in turn activates monocytes 
(241). It is also intriguing that IgDlowCD27– B cells have been shown to regulate the 
maturation of monocytes and a defect in this interaction was seen in patients with SLE (558). 
Figure 5.7.6 shows a proposed model for the recruitment of monocytes and T cells to the 
lymph node and/or spleen by B cells and monocytes stimulated by nuclear antigen and 
immune complexes. Future studies would be needed to confirm this model, but if proven 
MCP-1 would become a novel target for the reduction in the LLPCs that maintain a 
propensity for disease flare by continuously secreting pathogenic autoantibodies even during 
clinical remission. 
The high levels of MCP-1 and IP-10 in patients with high anti-dsDNA antibody levels, who 
have an increased incidence of nephritis, suggests that these chemokines are specifically 
involved in recruiting monocytes and macrophages to the glomerulus. A role for MCP-1 in 
nephritis is supported by several studies, which show a consistent association between high 
levels of urinary MCP-1 with active nephritis (559). However, IP-10 has not been 
consistently associated with renal disease, although interestingly it has been associated with 
mucocutaneous disease, anaemia and lymphopaenia (553). The association with 
lymphopaenia is intriguing because IP-10 can also recruit T cells. 
Whilst monocytopaenia might not be directly due to B cells in patients with high anti-dsDNA 
antibody levels, the repopulation of B cells after BCDT is associated with a fall in monocyte 
levels in patients with low anti-dsDNA antibody levels. This would suggest that they have a 
direct role in monocyte recruitment in this sub-group of patients. The precise mechanism is 
unclear, but IL-8, which B cells can secrete (183), is able to attract monocytes in addition to 
neutrophils and is a candidate for further investigation. It is possible that the fall in monocyte 
levels during relapse in this group of patients with low anti-dsDNA antibody levels reflects 
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the recruitment of myeloid cells and granulocytes to the non-lymphoid tissue by low levels of 
IL-8 secreted by B cells. 
The ligands for IP-10 and MCP-1 are also expressed on CD4+ T cells. IP-10 binds to CXCR3, 
which is primarily expressed by TH1 cells (560), and MCP-1 binds to CCR2, which is 
expressed on TH17 cells (561). The expression of these chemokine receptors on T cells 
supports the hypothesis that these chemokines can induce a fall in circulating lymphocyte 
numbers that have been shown to occur during active disease, but also the recruitment of 
different helper T cell subsets by these chemokines provides another possible mechanism to 
explain the heterogeneous manifestations that are seen in the disease.   
This chapter reiterates the point made previously in this thesis that B cells have multiple 
functions and are therefore capable of contributing in several ways to a heterogeneous 
disease, such as SLE. By selecting the groups of patients according to differences in serology 
it has been possible to identify different factors that might be important for each subgroup and 
that stratifying patients might help clinicians to carefully select the optimal treatment for their 
patients.  
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Figure 5.7.6 – A proposed model for the development of long-lived plasma cells in 
secondary lymphoid organs 
B cells induce the development of long-lived plasma cells by recruiting and activating other 
cells to germinal centres in the SLOs. Myeloid cells are recruited either directly via IL-8, 
which is produced by BCR or DNA immune complex stimulated B cells, or indirectly by 
inducing the production of MCP-1 by other myeloid cells. In the case of CD4+ T cells, the 
mechanism of recruitment might involve inducing CD69 expression. 
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6 Final Conclusion 
 
Although several human and animal studies have shown that B cells have an important role in 
the pathogenesis of SLE, RCTs have failed to confirm that depleting B cells from patients is 
therapeutically beneficial. Most explanations focus on potential problems with the design of 
the trials, for example possible problems with the disease activity assessment tool that was 
used and the use of concomitant corticosteroids (146). However, it is important to note that 
several drugs that target specific molecules or cells have been unsuccessful in RCTs in SLE, 
unlike drugs with non-specific or broad mechanisms of action (149, 150). RCTs are most 
likely to be successful if the drug has a broad mechanism of action, if it is interfering in a 
disease process with either a linear or spiraling causal pattern (i.e. an amplification loop) or if 
its target is part of an early stage in the disease process that has a domino causal pattern (i.e. a 
branching process). Therefore, whilst it is possible to conclude from the unsuccessful RCTs 
that the molecules or cells targeted do not cause SLE it is also possible that the disease 
process is non-linear and need to be defined better in order to determine how best to use the 
drugs available and improve the design of RCTs. 
There has possibly been an assumption that whilst the symptoms are heterogeneous, B cells 
have a singular function as autoantibody producing cells in a linear (98) or spiraling disease 
process (231). In these kind of models, depleting B cells should lead to a very predictable 
outcome. However, as has been discussed in this thesis, B cells are known to have multiple 
functions in addition to antibody production and have been shown to have antibody 
independent roles in an animal model of SLE. It would therefore seem reasonable to suggest 
that in patients with SLE B cells also have multiple roles that are important at different time-
points, and are not part of a simple linear or spiraling process. This thesis has shown that B 
cells can induce HLA-DR expression by T cells via cognate interactions and that this 
interaction is most likely part of a different phase to the phase when B cells differentiate into 
anti-dsDNA antibody producing plasma cells. The B cells that induce HLA-DR expression by 
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T cells might also be a different subset to the B cells that differentiate into antibody producing 
plasma cells, which are also likely to differ according to whether they differentiate into short 
or long-lived plasma cells.   
Models of SLE need to show more than just the multiple cellular interactions. They should 
also show the timeline of the disease by showing the sequence of events from the beginning 
to the end, i.e. the inflammation in the non-lymphoid tissue, with the time it takes between 
each event. However, there is significant variation in the factors that initiate events, in 
particular the genetic factors, termed immune redundancy. There is also variation in the tissue 
that is affected and in the type of inflammation, although the latter can be broadly divided 
into four types; lymphocytic infiltration, immune complex deposition, vasculitis and vascular 
occlusion. Therefore, models also need to show how the immune redundancy can lead to a 
relatively conserved number of inflammatory events. The most likely explanation is that these 
aetiological factors result in specific outcomes depending on how and, importantly, where 
they combine with each other.  
The observation that anti-dsDNA antibodies can be produced by either SLPCs or LLPCs 
shows that there are two pathways that can both produce an apparently similar autoantibody, 
and is an important example of immune redundancy in SLE. This thesis tries to illustrate how 
these two pathways appear to be associated with differences in the chemokine receptor 
expression of CD4+ T cells, suggesting that they are a result of differences in where B and T 
cells interact in the body. One pathway (Type A) is associated with T cells that migrate to the 
non-lymphoid tissue, whilst the other pathway (Type B) is associated with T cells that 
migrate to SLOs (Figure 6.1.1).  
There has been a debate in the literature about whether the cause of tissue damage in SLE is 
due to an Arthus (immune complex mediated) reaction, a Schwartzman (cell mediated 
cytotoxicity) reaction or an alternative process (162, 163). The data shown in this thesis 
suggest that type A disease leads to inflammation consistent with the Schwartzman reaction 
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(vasculitis), whilst type B disease leads to inflammation consistent with the Arthus reaction 
(i.e. glomerulonephritis). Therefore, both models appear to be correct. However, the 
likelihood of developing tissue damage due to the Arthus or Schwartzman reaction depends 
on the expression of chemokine receptors by the T cells and the origin of the autoantibodies 
(i.e. ELT or SLOs). 
T cells have been shown to increase endothelial permeability to antibodies (445-447). In type 
B disease where and how T cells adhere to the vascular endothelium and then influence 
endothelial permeability might also account for which tissue autoantibodies can enter to 
induce damage. The number of T cells required to induce endothelial permeability might vary 
depending on the tissue. For example, the glomerulus, which is probably more permeable to 
proteins, might require less T cells than the cerebral endothelium. 
The two different pathways are likely to combine to varying degrees, resulting in a spectrum 
disorder, suggesting that the disease is also partly due to relational causality. Most 
importantly the differing disease process in each patient, with differing rates of progression, 
will lead to different times to clinical relapse. The different processes might also result in 
different times to clinical response, although this was not examined in this thesis.  
Different symptoms might also occur at different phases of SLE. For example, fatigue and 
joint pain might be a symptom of an early phase due to cytokines that contribute to T cell 
differentiation, such as IFN-α, whilst symptoms due to ELT formation, such as the malar 
rash, which is a manifestion of ILE that predicts SLE (110, 112), are likely to be a feature of 
an intermediate phase (in Type A disease). Vasculitis, neuropsychiatric disease, thromboses 
and disease due to immune complex deposition (e.g glomerulonephritis), which require 
combinations of factors to occur at the same time, are almost certainly late manifestations of 
SLE (in both Type A, B and mixed disease). Importantly, vasculitis, renal and 
neuropsychiatric disease, which are associated with higher incidences of mortality and 
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morbidity, can potentially be predicted before they occur using the T cell markers of the two 
different pathways (Table 6.1.1).  
The potential difference in the timepoints for when certain symptoms appear show the 
problems with the current disease activity assessment tools, such as the BILAG index, which 
do not appear to differentiate between symptoms according to the underlying pathology or 
where the symptoms might occur in the disease process. Giving glomerulonephritis, which is 
caused by immune complex deposits, a similar score to discoid lupus, which is caused by 
lymphocytic infiltrates, regardless of whether symptoms are new or worse is unlikely to 
reflect the disease process accurately. 
The proposed model shows how different combinations of factors could theoretically lead to 
different symptoms. It also provides an explanation for why there are no biomarkers that 
directly correlate with active disease. Biomarkers should instead be interpreted in relation to 
other factors. For example, high levels of anti-dsDNA antibodies might only be significant if 
other factors that anti-dsDNA antibodies combine with to become pathogenic are also 
present. Some of these factors are unknown, but the observation that some patients with high 
anti-dsDNA antibody levels relapsed only when B cells were present suggests that anti-
dsDNA antibodies are dependent on them either directly or indirectly. Some biomarkers 
might only be useful at specific phases of SLE. For example, circulating numbers of 
CD4+CD49dhiHLA-DR+ T cells might be useful at an intermediate phase in patients with 
Type A disease, before ELT has formed and anti-dsDNA antibodies are produced. 
This thesis provides a possible method for stratifying patients by grouping them according to 
differences in their T cell phenotypes. These groups appear to be able to predict whether anti-
dsDNA antibody levels will change after therapy, i.e. according to which inflammatory 
pathway is dominant, when their B cells will repopulate, if and when T cell numbers will fall 
and they might also predict the time to clinical relapse. Further work is needed to confirm 
these findings and also examine whether these different groups show differences in the time 
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to clinical response. If they do show differences in the time to clinical response and/or relapse 
then the time for assessing the primary end-points for each group will need to be adjusted 
accordingly. 
In the introduction it was suggested that the immune response should be considered as distinct 
phases; lymphopoieisis (for the primary response) or formation of the memory pool (for the 
secondary response), then surveillance, antigen recognition, clonal expansion and 
differentiation (activation), antigen elimination and finally contraction. Most studies have 
suggested that SLE is caused by inappropriate antigen recognition (562), excessive activation 
(563) and/or failure of the immune response to contract (564). In this thesis I have described 
T cells that are terminally differentiated with central and effector memory phenotypes, 
suggesting that there is a large memory pool, which is not affected by BCDT. The effector 
memory T cells are primed to survey the peripheral non-lymphoid tissue where they instruct 
B cells to become plasma cells that make large numbers autoantibodies inside the tissue. The 
central memory T cells prime B cells within SLOs to form plasma cells that make circulating 
autoantibodies that survey the blood and tissue when the endothelium allows antibodies to 
cross over from the circulation. I therefore believe that SLE should instead be seen as a 
disease of inappropriate surveillance of non-lymphoid tissue by primed memory T cells (Type 
A) and antibodies (Type B). It is likely that most therapies achieve remission (or disease 
maintenance) by inhibiting one or both of these two processes.   
Most patients relapse at some point after BCDT, which shows that “disease memory” is not 
eliminated by the removal of B cells, confirmed by the fact that memory T cell phenotypes do 
not change. A disease cure might be possible if these memory T cells can either be depleted 
or reverted to naïve. Such a therapy might carry a high risk of infection but anti-IL-6 therapy 
has shown that reverting T cells to a naïve phenotype can be achieved (471) and this should 
possibly be the main focus for future research. 
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This thesis provides a new understanding of the pathogenetic sequences that lead to clinical 
disease, a potentially novel method for stratifying patients and biomarkers to quantify disease 
activity. Future work should attempt to validate this model, both in animal models and in 
prospective human studies, the biomarkers that have been identified for each phase, and 
understand the mechanisms of each phase. In Type A disease there are the following 
questions for each phase; Phase 1 – what are the genetic and environmental factors that 
predispose to disease? Phase 2 – what factors mediate T and B cell differentiation and what is 
the precursor of the IgD–CD27– B cell? Phase 3 & 4 – does HLA-DR effect T cell migration 
and what is the mechanism? Phase 5 – what factors recruit B cells to join T cell aggregates in 
the non-lymphoid tissue and where do they originate? Phase 6 – are FDCs necessary for the 
formation of anti-dsDNA antibody producing plasma cells? Phase 7 – are anti-dsDNA 
antibodies from ELT the same as anti-dsDNA antibodies from SLOs or are there functional 
differences? Phase 8 – what role do anti-dsDNA antibodies have? Do T cells follow anti-
dsDNA antibodies and do they cause endothelial dyregulation? Phase 9 – how does the 
adhesion molecule VLA-4 contribute to vasculitis? Do anti-dsDNA antibodies also have a 
role in vasculitis? Phase 10 – are APL antibodies produced in SLOs by LLPCs or in ELT by 
SLPCs? In Type B disease there are the following questions; Phase 1 – what are the genetic 
and environmental factors that predispose to disease? Phase 2 – what factors mediate T and B 
cell differentiation? Phase 3 – what factors lead to the survival of LLPCs. The sequence of 
events after LLPCs are produced then need establishing. As mentioned previously, one 
particular question is what are the mechanisms that allow antibodies to cross the endothelium 
and how do they then induce damage? In mixed disease, does the combination of the two 
different disease pathways lead to symptoms and pathology that are a mixture of the other 
two types of disease or a different group of symptoms?   
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Summary 
In order to develop effective therapies, we need to be able to develop markers that can predict 
the outcome of the disease (prognostic markers) and quantify the progression of the disease. 
These markers will be found when there is a better understanding of the disease pathogenesis. 
Most studies have focused on the autoantibodies and the regulatory processes that lead to the 
production of these antibodies, but this thesis has instead tried to use B cell depletion to 
examine where pathological anti-dsDNA antibodies are produced and how these antibodies 
might then cross the endothelium to get into the tissue. It has identified different patterns of T 
cell migration and a possible unique mechanism of T cell activation by B cells that induces T 
cell migration to the non-lymphoid tissue. In doing so, this thesis describes two distinct 
processes, which can be predicted and quantified. It will hopefully be possible to use these 
markers for future clinical trials.  
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Figure 6.1.1 – A proposed model of SLE 
This thesis proposes that B and T cells have multiple roles in SLE, which result in different 
symptoms and outcomes from therapy, in particular BCDT. It also proposes that the disease 
can be divided into two broad groups, based on where B and T cells interact. Type A disease 
is characterized by B-T cell interactions in ectopic lymphoid tissue (ELT), which result in 
short-lived plasma cells (SLP). Patients with type A disease can be identified by CD4+ T cells 
that express CCR5, CXCR3 and CD49d. Type A disease manifestations are likely to initially 
be due to interstitial infiltrates (e.g. discoid lupus) followed by autoantibody production (e.g. 
vasculitis). Type B disease is characterized by B-T cell interactions in secondary lymphoid 
organs (SLO), which result in long-lived plasma cells (LLP). Patients with type B disease can 
be identified by CD4+ T cells that express CCR7 and CD62L. Type B disease manifestations 
are likely to be due to immune complex deposition combined with other factors, such as 
neutrophils (e.g. glomerulonephritis). Some symptoms might arise via either one of these two 
proposed pathways (e.g. cytopaenia) or as a result of a combination of these two pathways.  
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 Type A Type B 
Circulating T cells Effector/Revertant 
High CD49d, CCR5 and CXCR3 
Low CCR7 and CD62L 
Naïve/Central 
Low CD49d, CCR5 and CXCR3 
High CCR7 and CD62L 
T cell activation marker HLA-DR 
(on CD49d
hi
 T cells) 
CD69? 
Circulating B cells Double Negative Plasmablasts 
DNA Ab producing Plasma cells Short-lived 
DNA Abs return to normal after 
BCDT 
Long-lived 
DNA Abs remain high after BCDT 
Chemokines - High MCP-1 and IP-10 
Relationship between circulating 
leukocytes and DNA Abs 
Lymphocytes (T cells) fall before 
rise in DNA Abs and clinical 
relapse 
DNA Abs are persistently high. 
Lymphocytes and monocytes fall 
during clinical relapse 
Source of DNA Ab production Ectopic Lymphoid Tissue Secondary Lymphoid Organs 
Role of DNA Abs Endothelial activation? Subendothelial immune complex 
deposition 
Clinical disease Localized disease (ELT formation) 
with cerebral lesions, arthritis or 
focal rash followed by vasculitis. 
Chronic, progressive disease. 
Systemic disease with constitutional 
symptoms, diffuse rash and 
glomerulonephritis 
Acute, intermittent disease. 
Pathology Schwartzman reaction 
(Type 4 Hypersensitivity?) 
Endothelial damage 
Arthus reaction 
(Type 3 Hypersensitivity) 
Epithelial damage? 
Response to BCDT Fast clinical response but relapse 
shortly after B cells return 
Slow clinical response but B cell 
return is not associated with relapse 
Table 6.1.1 – Summary of proposed SLE subtypes. 
Clinical, serological and cellular differences that have been observed and described in this 
thesis are written in bold letters. Possible differences that require further investigation are 
written in normal letters.    
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Appendix 1 
  
   
BILAG (British Isles Lupus Assessment Group index) 
 
Patient_______      Date_________  
 
 
All features must be attributable to SLE and refer the last four weeks compared with the prior visit’s disease activity. 
Indicate and score which features are present: 0 = Not Present, 1 = Improving, 2 = Same, 3 = Worse, 4 = New or Recurrence. 
 
 
 
 
 
 
General – MUST BE SLE RELATED  
 
Neurological - MUST BE SLE RELATED 
 
1.  Pyrexia (documented) 0   1   2   3   4 
24.  Deteriorating level of  
       consciousness 
0   1   2   3   4 
2. Weight Loss – unintentional >5% 0   1   2   3   4 
25.  Acute psychosis, delirium,  
       confusion 
0   1   2   3   4 
3.  Lymphadenopathy/Splenomegaly 0   1   2   3   4 26.  Seizures 0   1   2   3   4 
4.  Fatigue/Malaise/Lethargy 0   1   2   3   4 27.  Stroke or stroke syndrome 0   1   2   3   4 
5.  Anorexia/nausea/vomiting 0   1   2   3   4 28.  Aseptic Meningitis 0   1   2   3   4 
 
Mucocutaneous - MUST BE SLE RELATED 
 
29.  Mononeuritis multiplex 0   1   2   3   4 
6.  Maculopapular eruption – severe,  
     active, (bullous) 
0   1   2   3   4 30.  Ascending or transverse myelitis 0   1   2   3   4 
7.  Maculopapular eruption – mild 0   1   2   3   4 31.  Peripheral or cranial neuropathy 0   1   2   3   4 
8.  Active discoid lesions – generalized      
     / extensive 
0   1   2   3   4 32.  Disc swelling/cytoid bodies 0   1   2   3   4 
9.  Active discoid lesions – localized  
     including lupus profundus 
0   1   2   3   4 33.  Chorea 0   1   2   3   4 
10.  Alopecia (severe, active) 0   1   2   3   4 34.  Cerebellar ataxia 0   1   2   3   4 
11.  Alopecia (mild) 0   1   2   3   4 35.  Headache severe, unremitting 0   1   2   3   4 
12.  Panniculitis (severe) 0   1   2   3   4 36.  Organic depressive illness 0   1   2   3   4 
13.  Angioedema 0   1   2   3   4 37.  Organic brain syndrome including  0   1   2   3   4 
14.  Extensive mucosal ulceration 0   1   2   3   4        Pseudotumor cerebri 0   1   2   3   4 
15.  Small mucosal ulcers 0   1   2   3   4 38.  Episodic migranous headaches 0   1   2   3   4 
16.  Malar erythema 0   1   2   3   4 Musculoskeletal - MUST BE SLE RELATED 
17.  Subcutaneous nodules 0   1   2   3   4 39. Definite myositis (Bohan & Peter) 0   1   2   3   4 
18.  Perniotic Skin Lesions 0   1   2   3   4 
40.  Severe Polyarthritis with loss of  
       function 
0   1   2   3   4 
19.  Periungal erythema 0   1   2   3   4 41.  Arthritis 0   1   2   3   4 
20.  Swollen fingers Yes  No 42.  Tendonitis 0   1   2   3   4 
43.  Mild chronic myositis 
0   1   2   3   4 
 
21.  Sclerodactyly Yes  No 
44.  Athralgia 0   1   2   3   4 
22.  Calcinosis Yes  No 45.  Myalgia 
 
0   1   2   3   4 
23.  Telangiectasia Yes  No 
46.  Tendon contractures and fixed  
       deformity 
Yes  No 
  47.  Aseptic necrosis Yes  No 
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Cardiovascular & Respiratory -  MUST BE SLE RELATED Renal - MUST BE SLE RELATED 
(√) if 
SLE 
Relate
d 
48.  Pleuropericardial pain 0   1   2   3   4 
68. Systolic Blood Pressure   
(Enter value) 
 
__________mm-Hg 
 
49.  Dyspnea 0   1   2   3   4 
69.  Diastolic Blood Pressure   
(Enter value) 
 
__________mm-Hg 
 
50.  Cardiac Failure 0   1   2   3   4 70.  Accelerated Hypertension Yes  No  
51.  Friction Rub 0   1   2   3   4 
71.  Urine dipstick  (Enter value) 
( - =  0) (+ = 1) (++ = 2) (+++ = 3) 
 
 
52.  Effusion (pericardial or   
       pleural) 
0   1   2   3   4 
72. Urinary protein (Record a or b) 
a. 24 hr urinary protein 
b. Urine protein-creatine ratio 
a _________ g 
 
b 
_______mm/mmol 
 
53.  Mild or intermittent chest pain 0   1   2   3   4 
73.  Proteinuria (Record a or b) 
a. Newly documented proteinuria of > 1g/24 
hours 
b. Newly documented protein-creatine ratio of 
>100mg/mmol 
 
a. Yes  No 
 
b. Yes  No 
 
54.  Progressive CXR changes –   
lung fields *If Not Done,√ NO on EDC 
BILAG 
Yes OR 
Circle:    
                      
No /    
             Not 
Done 
74.  Nephrotic Syndrome 
Yes  No  
55.  Progressive CXR changes –          
heart size  *If Not Done,√ NO on EDC 
BILAG 
Yes OR 
Circle  
                       
No /    
             Not 
Done 
75.  Creatinine  (serum)            
      (Enter value) 
___________mg/dl  
56.  ECG evidence of pericarditis or 
Myocarditis *If Not Done,√ NO on EDC 
BILAG 
Yes OR 
Circle    
                 No /    
             Not 
Done 
76.  Creatinine clearance/GFR  
      (Enter value)  
__________ml/min  
57. Cardiac dysrhythmias including  
tachycardia >100 in the absence of fever  *If 
Not Done,√ NO on EDC BILAG 
Yes OR 
Circle   
             No /    
             Not 
Done 
77.  Active urinary sediment Yes  No  
58.  Pulmonary function fall by 20%  *If Not 
Done,√ NO on EDC BILAG 
Yes OR 
Circle     
                 No /    
             Not 
Done 
78. Histological evidence of active  
      Nephritis - within 3 months 
Yes  No  
59. Cytohistological evidence of  
inflammatory lung disease       *If Not 
Done,√ NO on EDC BILAG 
Yes OR 
Circle  
             No /    
             Not 
Done 
86.  Evidence of circulating          
       anticoagulant 
Yes  No  
Vascular - MUST BE SLE RELATED Hematology - MUST BE SLE RELATED  
60.  Major cutaneous vasculitis     
       incl.  ulcers 
0   1   2   3   4 
79.  Hemoglobin  (g/dl)  
       (Enter value) 
 
__________g/dl 
 
61.  Major abdominal crisis due to  
       vasculitis 
0   1   2   3   4 
80.  Total white cell count (x 10
9
/L) 
       (Enter value) 
 
__________x 10
9
/L 
 
62.  Recurrent thromboembolism        
       excluding strokes 
0   1   2   3   4 
81.  Neutrophils    (x 10
9
/L) 
       (Enter value) 
 
__________ x 10
9
/L 
 
63.  Raynaud’s 0   1   2   3   4 
82.  Lymphocytes (x 10
9
/L)  
       (Enter value) 
 
__________ x 10
9
/L 
 
64.  Livido reticularis 0   1   2   3   4 83.  Platelets  (x 10
9
/L) (Enter value) __________ x 10
9
/L  
65.  Superficial phlebitis 0   1   2   3   4 84.  Evidence of active hemolysis Yes  No  
66. Minor cutaneous vasculitis   
      (nailfold vascultitis, digital vasculitis) 
0   1   2   3   4 
85.  Coombs test positive 
Yes  No  
67. Thromboembolism  
      (excl. stroke) (first episode)       
Yes  No 
86.  Evidence of circulating          
       anticoagulant 
Yes  No  
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Figure 7.1.1 – Expression of CD69 and HLA-DR by CD4+ T cells 
(A) Representative flow cytometry dot plots illustrating the expression of CD69 and HLA-DR 
by CD4+ T cells in a healthy individual and patient 29 before and after BCDT. The 
lymphocyte population was gated as described in chapter 3.2.8 (Methods). (B) Samples 
stained with the relative isotype control monoclonal antibody were analyzed concurrently to 
determine the positive gate.   
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Figure 7.1.2 – Expression of CD45RA and CD27 by CD4+ T cells 
(A) Representative flow cytometry dot plots illustrating CD4+ T cell memory subsets defined 
by CD45RA and CD27 expression in a healthy individual and patient 29 before and after 
BCDT. The lymphocyte population was gated as described in chapter 3.2.8 (Methods). (B) 
Samples stained with CD27 and the relative isotype control monoclonal antibody were 
analyzed concurrently to determine the positive gate.  
 
 
 
Healthy Pre-BCDT Post BCDT 
B 
A 
CD27 
C
D
45
R
A 
43.0 
50.0 
0.02 
6.97 
28.0 
36.2 
10.2 
25.6 
33.1 
50.1 
4.23 
12.6 
CD27 
Is
ot
yp
e 
